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ABSTRACT 
 
 
Cholesterol-rich membrane microdomains have a significant role in cancer progression, 
particularly in metastasis, and there is evidence that cholesterol inhibitors, most notably 
statins, can change the behaviour of cancer cells in vitro and in vivo. Cholesterol-rich rafts 
act as loci for signal receptor-ligand binding, providing a stable scaffold for protein 
interaction. The purpose of this research was to test the hypothesis that the abundance of 
these inclusions can be controlled with cholesterol inhibitors and to investigate the effects 
of these treatments on cancer cells using simple in vitro assays. Flask shaped cholesterol-
rich scaffolds in the membrane called caveolae, characterised by the presence of the protein 
Caveolin-1, are generally associated with proliferation suppression during oncogenesis but 
with tumour promotion during metastasis. This dual role may be coordinated by the 
cholesterol content of the raft environment and so be vulnerable to cholesterol inhibitors 
such as the statins. 
 
A variety of techniques were used to assess the proteome, mRNA expression, cholesterol 
and Cav-1 levels in cells treated with a variety of cholesterol synthesis inhibitors in an 
attempt to understand the processes that affect metastatic behaviours in vitro.  A number 
of novel derivatives of one particular inhibitor of cholesterol Δ24 reductase (Proadifen) were 
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included in these in vitro assays. The structure of the molecule was iteratively changed to 
determine the important features of the molecule that give rise to Δ-24 enzyme inhibition. 
 
It was found that inhibition of cholesterol synthesis asymmetrically reduces the prevalence 
of rafts and caveolae and is associated with multiple effects on cancer cell behaviour and, 
perhaps most significantly, with changes to gene expression. Targeted blockade of the 
mevalonate pathway using Δ-24 and Δ-7 reductase inhibitors could prevent the successful 
transduction of extrinsic signals that coordinate some cancer cell behaviour. The toxicity 
profiles of the inhibitors used in this project are poor, but further analogues may be 
developed in the future that could have clinical relevance. 
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1 INTRODUCTION 
 
Cancer is the name given to the uncontrolled replication of cells, commonly 
characterised by invasion of these cells into neighbouring tissue and their spread 
through the body in the blood or lymphatic system. Common causes of cancer can be 
divided into environmental and genetic types. The most common environmental cause 
is the consumption of tobacco products which can produce malignant tumours of the 
lung (Kuper et al., 2002). Other environmental agents that can trigger cancer include 
radiation and exposure to asbestos particles. Genetic or hereditary cancers – or a 
predisposition towards their occurrence – include retinoblastoma and some Downs 
syndrome related cancers that typically afflict young children. However, hereditary 
causes of cancer are responsible for a relatively small percentage (3-10%) of cancer 
related deaths. Some cancers, such as cervical cancer, are caused by a virus. Still others 
have an unknown aetiology. Cancer, in all its forms, kills an estimated 13% of the global 
population(Jemal et al., 2011).  
 
When a cancerous tumour occurs in an organ it is often discovered upon biopsy or X-ray 
to be a discreet entity occupying a defined area or portion of the organ. Complete 
removal of this ‘primary’ tumour by surgery or by radiation for example, can often be 
accomplished. Indeed, the entire organ may be removed for an additional margin of 
safety. However, this does not necessarily remove the risk of morbidity or mortality 
since some cells from the tumour may have migrated to distal areas of the body in a 
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process known as metastasis. These cells may have successfully adapted to their new 
host organ and be developing into a ‘secondary’ or ‘daughter’ cancer growth.  The idea 
that the migrating cell may find the most suitable targets for invasion by cognition of 
extra-cellular signals is called the seed-and-soil theory first posited by Fuchs (Fuchs, 
1882), and then later popularised by Paget (Paget, 1889). It has been estimated that 
only 10-15% of cancer related deaths are attributable to the primary growth (Sleeman 
and Steeg, 2010) which means that the process of metastasis currently accounts for 
some 10-12% of all human deaths. 
 
The processes by which a healthy cell becomes a malignant cell and then later a 
metastatic cell are complex and many different cellular processes are implicated. For 
example, the immune system is involved since the cell must evade the normal immune 
surveillance. Mutations leading to genetic transformation may be triggered by oxidative 
stress and this is exacerbated by inflammatory response, so the immune system has 
multiple involvements.  Likewise, the normal restraints on growth such as contact 
inhibition must first be removed so the cell can multiply freely; as the mutant cells reach 
their natural boundary within an organ they are able to switch off production of the 
adhesive molecules -that normally tether them to their proper locations - and migrate 
to new territories. This is a process that is made more complicated due to the fact that 
it must be a reversible step so that when the cell arrives at a suitable site for invasion, 
cell adhesion must be switched back on again for the cell to attach itself to the new 
substrate. Increased motility is another characteristic of cancer cells. It was first noted 
in 1863 by Virchow (Virchow, 1863) that amoeboid movements of cells were visible in 
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isolates from newly excised tumours. What was originally described by Willis (Willis, 
1952) as the ‘possible elaboration of toxic or lytic substances’ from the cancer cell are 
now understood to be the cells production of attachment factors - such as integrins  - 
and enzymes such as matrix metalloproteinases that degrade and prepare the path for 
the invading cell.  Each step in this long and involved process appears to be one of 
deliberate design but is, in fact, simply a probabilistic function that can be 
mathematically defined. For a cell to successfully negotiate the hurdles of apoptosis, de-
attachment, migration, and invasion a number of consecutive mutations must arise and 
the chances of these occurring in the correct sequence in a particular cell are slim. 
However, the numbers of cells produced by the first genetic aberrations – typically, 
activation of an oncogene and de-activation of a proliferation suppressor gene, 
dramatically shift the odds in the cancer cells favour. For example, a breast tumour with 
a diameter of 2cm is likely to shed over 10 million cells per day (Greaves, 2000) into 
surrounding tissue and blood and by their nature these cells are highly prolific. It thus 
becomes a statistical event, rather than a design event, as to whether the cancer cell 
will eventually become fully metastatic.  It is widely agreed that, depending on cell type, 
a minimum of 5-6 genes must be switched for the cell to achieve successful metastasis. 
Each of these genes codes for a protein that becomes part of the cellular machinery of 
the cell and each in turn acts upon a pathway or multiple pathways that control the new 
phenotype. Some of the most crucial pathways involved in the metastasis of cancer are 
signalling systems that enable the cell to coordinate its behaviour and to monitor its 
environment. These signalling proteins use the cell membrane as a platform, often 
traversing the plasma membrane bilayer or arranged on the external face of the 
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membrane. These mediate signal transduction from the outside of the cell into the 
cytoplasm and ultimately the DNA and effectively report the status of the cell 
microenvironment and, through paracrine signalling, the status of the cell and its 
neighbours.  Membrane bound signal receptors are most commonly found in distinct 
areas of the membrane called rafts, which are more rigid than segments composed 
entirely of phospholipids. These areas are particularly rich in cholesterol and ceramide. 
Raft mediated signalling will clearly be affected if the level of cholesterol is reduced and 
the area available for signalling is diminished.   
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1.1 THE PLASMA MEMBRANE AND THE FORMATION OF RAFTS 
The plasma membrane is not simply a cell structure that separates the living cytoplasm, 
nucleus and organelles from the outside environment. It is the locus of activity for 
primary cell functions as diverse as endocytosis and signal transduction. A plasma 
membrane typically consists of perhaps 1500 lipid species and more than a hundred 
different proteins (Gennis, 1989) – all in rapid flux, making signalling dynamics in this 
system particularly hard to fathom. The ability of the membrane to reinforce itself prior 
to G1 phase separation or to interdigitate and then fuse with similar bilayers is crucial 
for various cell processes. The plasma membrane has the ability to segregate the fluid 
mosaic of phospholipids into local temporal domains that have significant functionalities 
(Jacobson et al., 2007), (Dykstra et al., 2003), (Simons and Toomre, 2000). Many of the 
more subtle activities of the plasma membrane – and increasingly apparent, of 
organelle membranes – are due to membrane inclusions that perform specific roles in 
respect of signal transduction. These domains are most often referred to as membrane 
rafts (Simons and Ikonen, 1997) and typically comprise high levels of sphingosine, 
ceramide, protein and cholesterol and low levels of phospholipids. It is generally 
believed that the structural integrity afforded by this combination of sphingolipid, sterol 
and other minor components affords these membrane regions particular rigidity, 
allowing anchorage, orientation and conformation of signal proteins (Brown and 
London, 2000). The role of these proteins in cell-cell and cell-environment signalling is 
increasingly understood.  Lipid rafts are implicated in signalling cascades as diverse as 
mutagenesis-derived apoptosis (Gajate et al., 2009), endocrine and autocrine loops and 
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numerous lipid-protein related signalling such as angiogenesis and immune signalling 
(Patra, 2008).  
 
For many years the existence, size and prevalence of such lipid inclusions was 
controversial (Munro, 2003), (Hancock, 2006), (Edidin, 2003) but it is now clear from 
immunogold electron microscopy, atomic force microscopy and other techniques that 
stable microdomains of different sizes do indeed exist and can be visualized and 
separated from the rest of the membrane with relative ease. Ultracentrifuge techniques 
have permitted the isolation of these lipid regions due to their innately different 
buoyancy in sucrose-density gradients. It has also become clear that rafts range in size 
from 10-200nm in scale, are temporal in nature, and have distinct compositions that 
correspond to their individual signal associations.  In MDA-MB-231 cells (cells used in 
this study), Flotillin-1 is found primarily in microdomains and this has been verified by 
atomic force microscopy coupled with labelled antibody imaging (Orsini et al., 2012).  
 
Many of the cell membrane functions would not be possible if the larger surface area 
were as rigid as the raft microdomain. Most of the plasma membrane requires the fluid 
mosaic structure as described by Singer and Nicholson (Singer and Nicolson, 1972). Cell 
division, for example would not be possible if the membrane was too rigid and likewise 
cell fusion-like processes such as endocytosis and invagination depend on sufficient 
fluidity of the phospholipid matrix. Phospholipid interdigitation is a process that is 
driven thermodynamically and does not rely on cell ATP. Thus the plasma membrane is 
an ocean of phospholipids, glycolipids and transmembrane proteins that has diffusion 
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properties and other mobility related activities, while containing localized areas that 
provide stability not available in the rest of the bilayer (van Deurs et al., 2003). It is also 
known that rafts of 26±13nm diffuse as single entities for minutes at a time and when 
GPI-anchored proteins are present these proteins have significantly reduced diffusion 
compared to non-raft transmembrane proteins (Pralle et al., 2000). Protein 
conformation for signalling requires stable spatial orientation in respect of co-signalling 
molecules and rafts provide this stable environment. In particular, rafts are the location 
for many different types of signalling in cancers including sarcomas, myelomas, breast, 
lung and prostate cancer. This signalling controls proliferation, apoptotic dysregulation 
and metastasis and so lipid rafts may thus be a suitable target for chemotherapeutic 
intervention. Directing drugs against rafts per se may however have negative 
consequences since many of the processes mediated by raft proteins are entirely 
benign. 
 
Increased membrane fluidity generally correlates with increased metastasis: for 
example, tumour cell adhesion in mice inoculated with MT3 breast cancer cells is 
correlated to fluidity. Here, electron paramagnetic resonance was used to assess the 
fluidity of spin labelled cells in different growth phases. It was found that fluidity 
strongly correlated with the phase of proliferation with confluent cells having the most 
fluid plasma membranes (Zeisig et al., 2007). Lymphocytes isolated from normal mice 
exhibit far greater cell capping than leukemic cells yet the membrane fluidity is greater 
in leukemic cells (Dunlap et al., 1979). The same is true in human cells (Ben-Bassat et al., 
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1977) and points to the Bretcher flow model of capping as an explanation (Bretscher, 
1976). 
 
Studies in model membranes reveal that a membrane can comprise liquid-ordered  (I0) 
phase of lipids together with a liquid disordered (Id) phase. I0 phase lipids show a high 
degree of lateral mobility but are otherwise tightly packed lipid-sterol domains (Veatch 
and Keller, 2005).  Disordered Id domains are less tightly packed and a third phase – the 
gel phase- occurs where lipids are too tightly packed for any mobility (Heberle et al., 
2005).  In practice, these different phases may be extracted through increasing degrees 
of detergent solubilisation, most often with non-ionic surfactants such as Triton-X. 
These phases are captured using a sucrose (or similar) density gradient on 
centrifugation. The more tightly packed the domain, the less entry is afforded the 
detergent and it is these detergent resistant microdomains that have been regarded as 
the same entities as rafts for many years. The question remains: are DRMs actually 
isolated raft domains or just parts of the membrane that share characteristics that both 
model membrane experiments and empirical studies ascribe to rafts? One possibility 
remains that the detergent itself changes the liquid ordering of the domains – actually 
inducing the phase separation they are used to isolate (Brown, 2006). 
 
Two studies shed light on this possibility: Ahmed et al studied model membranes that 
were made from a range of Io and Id domains – verified by fluorescence quenching 
studies – and then solubilised by detergents (Ahmed et al., 1997). These provide 
evidence that Triton X100 selectively solubilised the Id phase domains and this work has 
24 
 
since been reproduced using microscopy based assays. A second study by Heerklotz 
(Heerklotz, 2002) using calorimetry suggests that detergents can induce at least some 
phase separation in uniform model membranes. The DRMs isolated from cells do 
contain a subset of proteins not found in the Id domains and this is in accordance with 
the original idea of raft development. Indeed, some proteins (caveolins, flotillins, some 
tyrosine kinases) are routinely used as raft markers in biochemical studies of the 
membrane. Further removal of cholesterol by sterol sequestering agents (such as 
Methyl-β-cyclodextrin (Zidovetzki and Levitan, 2007)) in living cells reduce the amount 
of these proteins associated with the extracted DRM. Ahmed suggests that since phase 
behaviour is temperature dependant then chilling cells should increase the 
development of rafts – and most membrane detergent extractions are performed on ice 
– further distorting the results (Heerklotz, 2002).  
 
However, the most compelling evidence for the existence and prevalence of rafts in vivo 
is their recently discovered role in infection by both bacteria and viruses that 
presumably evolved to recognise and attach to these regions. A study by Arellano-
Roynoso et al suggests that Brucella bacteria produce the cyclic cholesterol 
sequestering compound β-12 glucan to prevent phagosyme-lysozyme fusion (Arellano-
Reynoso et al., 2005). Another study by Ravid et al proposed that para-influenza virus 
(HPIV1) utilises caveolae to assemble its virion envelope and facilitate budding out of 
the infected cell (Ravid et al., 2010).  Palmitoylation of proteins to make them targeted 
to rafts is a process that can activate a signal protein or prolong its action. 
Palmitoylation of viral glycoproteins has been linked to their ability to attach onto rafts 
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as part of virion-cell docking but in several studies this is not always essential for 
infection (Li et al., 2002), (Campbell et al., 2004) . McDonald and Pike (Macdonald and 
Pike, 2005) have examined the role of surfactants play in the promotion of artefact in 
the extraction of membrane rafts. They report a detergent free method of raft isolation 
using Optiprep™ [instead of sucrose solutions] combined with lysis by shearing in 
isotonic buffer containing Ca2+ and Mg2+. The resultant rafts were enriched with 
cholesterol and key protein markers permitting separation of the caveolin rich domains 
without an immunoaffinity purification step.  
1.2 TYPES OF MEMBRANE RAFTS 
Studies of membrane proteomics have revealed that at least three (Patra, 2008) distinct 
types of raft exist: one that is associated with the tyrosine kinase family of proteins and 
is rich in cholesterol and gangliosides (Type I); the second type is rich in ceramide and is 
associated with the death inducing signalling complex (DISC) and Fas apoptosis 
signalling proteins. These Type II inclusions tend to form when the cell is subjected to 
chemical or radiation stress; as an example of this process γ-irradiation induces acid 
sphingomyelinase (aSMase) activation which hydrolyses sphingomyelin into sphingosine 
and ceramide. The build-up of ceramide in the membrane can then displace cholesterol 
from rafts. The death inducing signals are recruited and the apoptotic cascade initiated. 
Likewise, cholesterol rich domains are associated with various onco-receptors such as 
CD44, EGFR and Ras that drive proliferation. The balance of these two raft types in any 
given membrane would therefore appear to reflect the more fundamental genetic 
health of the cell. Caveolae are a third class of raft inclusions and are 50-100nm flask 
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shaped structures characterized by the presence of the oligomeric loop protein 
caveolin-1 (Cav-1). Caveolins are responsible for recruitment of receptors to 
cholesterol-rich sub-domains and control of the actin cytoskeleton – perhaps regulating 
overall membrane fluidity, reinforcing the plasma membrane against shear forces 
during mitosis and regulating fusion dependant processes. Caveolae, like all rafts, are 
loci for signal transduction taking place between the external environment and the 
cytoplasm. 
 
The process by which Type II rafts are enriched with ceramide through displacement of 
cholesterol implies an overall shift of sterol into surrounding non-raft areas of 
membrane. It has been further suggested that this cholesterol subsequently leaves the 
membrane entirely to form circulating lipoproteins. In addition to this steady-state 
desorption, cancer cells are able to ‘dump’ cholesterol in concentrated fragments of 
membrane, shed from the cell as part of its anti-recognition processes. So the move 
towards ceramide rafts could signify a global reduction in membrane cholesterol. 
Membranes with lower than normal levels of cholesterol are more fluid both empirically 
(Vanderkooi et al., 1974) and in model systems (Cooper, 1978) and this fluidity could be 
a factor in the fusion of tumour cells with osteoclasts, especially macrophages (Pawelek 
and Chakraborty, 2008). In the case of myeloma, nuclei fused with these bone marrow 
derived cells resulted in hybrid cells that are both viable and invasive. Likewise, similar 
results were reported with melanoma and carcinoma cells.  
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The fusion process to produce such cells is fluidity-dependant since opposing cells must 
interdigitate their outer membranes in a key step towards coalescence. This 
interdigitation is thermodynamically favoured when the phospholipid matrix is more 
dynamic. If this is true then logically an inverse correlation should exist between rates of 
metastasis and drug refraction: treatments that promote raft mediated apoptosis 
through depletion of cholesterol have been proposed (Podar and Anderson, 2006) but 
conceivably could increase all ceramide-raft mediated signalling.   
 
1.3 RAFT COMPONENTS AND THEIR ROLES IN CANCER 
1.3.1 CERAMIDES AND SPHINGOSINES 
Classically, ceramide has a structural role in the assembly of galactosyl-sphingolipid cell 
adhesion molecules (Lee et al., 2010), however, ceramide, released from the membrane 
by enzymes, is also known to be involved in a range of signalling activities (Colombaioni 
and Garcia-Gil, 2004) including the mediation of caspase -9 and -3 activation (Park et al., 
2004). Tumour necrosis factor (TNF), interferon and interleukin signalling across the 
membrane is mediated by ceramide, leading to apoptotic responses (Zhu et al., 2006) 
and further, there is evidence to suggest that ceramide itself can regulate the immune 
response (Dasgupta et al., 2007).  
 
Ceramides are sphinogolipids that have a wide range of signalling activities (Futerman 
and Hannun, 2004) as well as structural roles in membrane microdomains. One of its 
transmembrane signalling pathways is the TNF and interferon-stimulated caspase-
mediated apoptosis (Zhu et al., 2006). Other roles of ceramide are in cell migration, 
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senescence and cell growth arrest (Merrill et al., 1997). They can also modulate cell 
adhesion molecules such as CD29 (β1-integrin) and up-regulation of such adhesion 
factors is seen in cancer cells (Han M, 2008). Ceramides (but not sphingolipids) suppress 
cell-cell adhesion and cell-fibronectin adhesion by down-regulating CD98, CD147 (a 
matrix metalloprotein inducer) and CD49d; and ceramides also inhibited the 
phosphorylation of the structural protein CD29 (Lee et al., 2010). Gamma irradiation has 
been shown to induce ceramide driven apoptosis (Alphonse et al., 2002) through the 
activation of SMase catalyzed synthesis of ceramide from sphingomyelin and its release 
from rafts (Haimovitz-Friedman et al., 1994). It may be significant that multi drug 
resistant (MDR) cells have elevated cholesterol, sphingomyelin and in particular 
glucosylceramide. Inhibition of the glucosylation of ceramide naturally leads to 
increased levels of ceramide so findings that tumour promotion is indexed to the 
inhibition of glucosylation are unsurprising (Lavie et al., 1999). 
To initiate apoptosis some research has shown that ceramide must be converted to the 
ganglioside GD3 (Malisan and Testi, 2002). 
 
FIGURE 1: CERAMIDE CAN CAUSE OR INHIBIT APOPTOSIS 
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Other work looking specifically at chemosensitization suggests that glucosylation of 
ceramide effectively quenches the apoptotic response (di Bartolomeo and Spinedi, 
2001). Ceramide is overexpressed by cells exposed to insults like radiation and 
chemotherapy and clearly has a central role in apoptotic and mitogenic pathways. The 
addition of water-soluble ceramides to cells in vitro causes apoptosis. Reduction of 
intracellular ceramide increases MDR (Modrak et al., 2006). Ceramides can be 
generated de novo or from hydrolysis of sphingomyelin by SMases. It is this latter route 
that elevates ceramide in cells exposed to environmental stress. The effects of this 
increase in ceramide concentration are likely to be similar to that of exogenously added 
ceramide: growth inhibition (Pushkareva et al., 1995), cell cycle arrest (Jayadev et al., 
1995), induction of differentiation (Kim et al., 1991), tumour inhibition (Weinberg, 
1990), apoptosis (Obeid et al., 1993) and necrosis (Mengubas et al., 1999). 
 
 Modrak et al compare the biological effects of a number of ceramides and note that 
the C4-C5 double bond is essential for activity, since dihydroceramide does not achieve 
apoptosis (Modrak et al., 2006). There is a question about the acyl group: de-acylated 
ceramide (sphingosine) is also pro-apoptotic but chain length seems to be very 
important - with palmitoylsphingosine (C16) being the most potent in its class.  
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1.3.1.1 CANCER PROTEINS AND RAFTS.   
This is a list of cancer related proteins known to locate in or around rafts and caveolae 
(Foster et al., 2003). 
 
Raft proteins Raft Associated Proteins 
CD55 Caveolin 
Flotillin-1 MEK binding partner 
Alkaline phosphatase 14.3.3-gamma 
Vinculin HSP90β 
Insulin receptor Actin 
Rac Ezrin 
Ras MMP-2, -9 
PI3K EGFR 
 Fas (CD95) 
 Integrin 
TABLE 1: PROTEINS BY KNOWN LOCATION IN MEMBRANE 
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1.3.2 CAVEOLIN-1 
Caveolin is so called because it lines the surface of the flask or cave shaped caveolae 
rafts (Rothberg et al., 1992) and was found to be identical to a 21 KDa vesicular integral 
protein previously known as VIP21. Cav-1 is the most abundant of three caveolins (with 
Cav-2 and Cav-3) that differ in distribution according to tissue types (Williams and 
Lisanti, 2004). It is anchored in the membrane by three palmitoylated points and the 
entire molecule acts as a scaffold for protein receptors. Caveolins actually create 
caveolae in certain tissues after transfection (Sowa et al., 2001), presumably by virtue of 
the folding conformation of the homo-oligers. They can, however, be present in 
caveolae-free membranes or as free cytoplasmic protein, presumably as monomers. 
 
Caveolins are associated with cholesterol homeostasis and cell adhesion, pinocytosis 
and migration and they are found in various organelle membranes including the Golgi 
apparatus, ER and mitochondria. In the plasma membrane they occur in a 
heterogeneous distribution across tissue types – ubiquitous in endothelial and fibroblast 
cells but not found in blood, myeloid or lymphatic cell types. Cav-3 is unique to muscle 
cells.  
 
Sonnino et al (Sonnino and Prinetti, 2009) proposed that glycosphingolipids may 
partition between rafts and caveolae and this would explain some inconsistencies 
regarding the distribution and putative role in signalling of GD3 (and other) 
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gangliosides. Caveolin-1 and (glyco)sphingolipid levels appear to be reciprocally 
regulated. Malfunctioning glycosphingolipids affect cell adhesion, invasiveness and 
modulate integrin and growth factor receptor mediated processes, especially cell 
motility and adhesion. This is a process via Src family kinases and adapter tetraspannin 
molecules (Prinetti et al., 2008).  
 
The tetraspanins are sometimes referred to as the master regulators of membrane 
organization and are ubiquitous in nature (Hemler, 2005). The palmitoylated 
tetraspannin protein CD82 is a metastasis suppressor and when disabled is highly 
correlated to metastatic events in vitro and in vivo in a wide variety of malignancies 
(Tonoli and Barrett, 2005). CD82 normally regulates integrin mediated cell migration 
and cancer lines re-expressing CD82 show inhibited migration and invasion (Miranti, 
2009). One mechanism for this may be the internalization of the surface integrins or 
possibly the inhibition of pre-β1 integrin processing.  CD82 also inhibits EGFR signalling 
by the EGF ligand in caveolae but in normal cells are more commonly associated with 
ganglioside rich domains rather than rafts. It has been proposed that upon 
transformation the tetraspannins become palmitoylated and move into raft domains 
and this is supported by experimental evidence wherein the palmitoylation was blocked 
and this prevents their association with rafts (Yang et al., 2002). 
 
 
Cav-1 binds to GM3 (at least in MDCK cells (Chigorno et al., 2000)) yet GM3 over-
expression causes Cav-1 and insulin receptors (IR) to re-locate to outside raft or 
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caveolae microdomains. GM1 also displaces platelet-derived growth factor receptor 
(PDGFR) from caveolae suggesting that there is competition for binding sites of GM1 
and GM3 with Cav-1 and the receptors. When displaced into non-raft / caveolae areas 
of membrane, IR and PDGFR are de-coupled from downstream signalling cascades 
(Inokuchi, 2007), so it is possible that a drug induced reduction of Cav-1 could nullify the 
pro-oncogenic activity of these signals. 
Caveolin-1 is, however, highly expressed in multiple myeloma cells and is also over-
expressed in multidrug resistant breast adenocarcinomas (Williams and Lisanti, 2005). It 
has been proposed that prevalence of Cav-1 might serve as a prognostic indicator in 
these diseases and also in prostate cancers (Yang et al., 1999). Invasiveness of human 
breast cancer cells is positively correlated to Cav-1 abundance as is post-operative 
recurrence of lung cancer (Yoo et al., 2003). Up-regulation of Cav-1 may be a result of 
growth factor mediated serine-phosphorylation which renders the protein free to 
disassociate from the membrane leaflet and become secreted, possibly as part of an 
autocrine loop (Schlegel et al., 2001).  Cav-1 is up-regulated in multiple myeloma (MM) 
and is implicated in interleukin-6 and vascular endothelial growth factor (VEGF) induced 
signalling, increasing survivability of MM cells and conferring steroid resistance. The 
gp130 signal transducing chain of the IL-6 receptor and Cav-1 are known to be found 
together in rafts. IL-6 induces Src-family kinase dependant tyrosine phosphorylation of 
Cav-1 in a process that can be inhibited by caveolae disruption and which is a factor in 
cell migration. In MM VEGF signalling is known to have a pivotal role in terms of growth 
and angiogenesis. Related outcomes in MM of VEGF signalling in vivo are 
immunodeficiency and bone destruction. There is increasing interest in Cav-1 as a 
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possible therapeutic target, most notably in multiple myeloma (Podar and Anderson, 
2006). 
 
Cav-1 binds cholesterol to form oligomers and cholesterol regulates CAV mRNA levels 
(Bist et al., 1997), (Fielding et al., 1997). Podar and Anderson have proposed reducing 
the level of membrane cholesterol to below the 40 mol% [the % cholesterol as a 
fraction of total molar weight of lipid] necessary for the formation of caveolae, by the 
use of statins to restrict proliferative signalling in MM cells. In contrast to cholesterol, 
overexpression of caveolin-1 increases membrane fluidity possibly (like ceramide) by 
displacing sterol from the bilayer (Cai et al., 2004). 
 
Similarly, Tahir et al found that prostate cancer cells secrete Cav-1 and that the protein 
has anti-apoptotic and pro-angiogenic activity both in vivo and in vitro (Tahir et al., 
2008). They hypothesize that over-expression of Cav-1 by these cancer lines is a 
determinant of metastasis and suggest that Cav-1 as a paracrine factor may be a 
“paradigm applicable to other tumours that secrete Cav-1”. 
 
So it appears that a dual role for Cav-1 exists in cancer cells at least in vitro (Cohen et al., 
2004). Tumour suppressing activity related to Cav-1 scaffolding domain and direct 
inhibition of G-proteins has been shown (Li et al., 1995), and the Cav-1 gene is 
repressed by DNA methylation at the onset of transformation. Later however, just prior 
to metastasis it is de-suppressed. It is logical to suppose that either directly through the 
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functions of caveolae or perhaps discreetly through autocrine signalling Cav-1 plays a 
role in metastasis and the proliferation of neoplasias.  
 
1.3.3 CHOLESTEROL  
Cholesterol has multiple roles in cancers. It can be used as a apoptotic marker during 
chemotherapy of mice given colon cancer xenografts (Kennealey P., 2005); inhibits 
viability of prostate cancer cells (Oh et al., 2010) and is reported to accelerate the 
development of mammary tumours in mice and act as a driver for metastasis (Llaverias 
et al., 2011). Exogenous cholesterol typically induces apoptosis in all cells, not only 
cancer cells, and much of the data relating cholesterol to cancer comes from the use of 
statins that are used to lower cholesterol levels in vivo with some positive outcomes for 
cancer patients before and after diagnosis (although this very much depends upon the 
type of cancer) (Moyad and Merrick, 2005), (Osmak, 2012). This implies a contradictory 
role for the sterol: induction of apoptosis and promotion of tumour development. This 
can be explained if the cholesterol is either free sterol or localised in microdomains that 
may produce a more global effect via cell signalling and gene expression. For example, 
cyclooxygenase-2 is associated with metastasis and resistance to apoptosis and 
cholesterol appears to regulate Cox-2 activity (Zhu W., 2009). This effect is biphasic and 
this too could be explained if low levels of cholesterol are unable to form rafts (and 
induce apoptosis) while higher doses initiate raft formation and so trigger metastasis. 
Polyunsaturated fatty acids (PUFA), especially docosahexaenoic acid (DHA), have a 
propensity to displace cholesterol by means of its lower solubility and adverse packing 
arrangement (Wassall and Stillwell, 2009) wherein the hydroxyl moiety of the sterol is 
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displaced from the aqueous-facing layer to the middle (Harroun et al., 2006) and even 
inverted into the cytoplasm-facing layer of the membrane (Harroun et al., 2008). The 
aversion that cholesterol has for the DHA fatty chains has been proposed as a driver for 
the formation of cholesterol rich domains and highly disordered PUFA rich regions 
(Wassall and Stillwell, 2009). There is also some evidence that DHA can displace 
acylated proteins from lipid rafts and alter caveolae lipid and protein composition (Ma 
et al., 2004a). The steric incompatibility of DHA with sphingolipid and cholesterol can 
change the size and distribution of rafts and this appears to impact raft signalling 
(Chapkin et al., 2008), (Ma et al., 2004b), (Seo et al., 2006).  
 
The amount and type of sterol in any given part of the membrane can also affect the 
functionality of the membrane bound signalling proteins by changing the lateral 
pressure profile – the local forces acting on the protein and so changing its 
conformation (Samuli Ollila et al., 2007).  
An intermediate of sterol biosynthesis, lathosterol, can also cause the formation of rafts 
with dipalmitoylphosphatidylcholine (Wang et al., 2004) while lanosterol and 
desmosterol appear to lower lipid ordering to largely the same extent as cholesterol 
(Martinez et al., 2004). It is interesting that mice with an enzyme blockade preventing 
the final conversion of desmosterol into cholesterol, rendering them completely 
cholesterol-free animals, produced only a ‘mild phenotype’ and were viable (Wechsler 
et al., 2003). That said, there is evidence that altered cholesterol metabolism and in 
particular lipid-raft dysfunction may play a critical role in brain and CNS disorders 
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(Korade and Kenworthy, 2008). It is also known that cholesterol inhibition disrupts the 
formation of rafts and caveolae in 3T3-L1 cells and then affects insulin receptor 
activation (Sanchez-Wandelmer et al., 2009). In these cells cholesterol precursors do 
not maintain the insulin signalling cascade. 
 
Bruno Segui et al in a review of sphingolipid involvement as cancer therapeutics points 
out that there are “several ways [for a cancer cell] to die and many ways to resist cell 
death” (Segui et al., 2006) Apoptosis, necrosis, paratosis, caspase-dependant and –
independent cell death some of the possibilities each with different characteristics and 
biochemical signatures. Sphingolipids have been reported to be involved in at least 
apoptosis, necrosis, autophagic cell death and mitotic catastrophe. 
 
It is clear that some lipids inhibit cancer cell growth while others facilitate growth. The 
gangliosides in particular are associated with apoptotic cascades and with multidrug 
resistance. Gangliosides are highly expressed by cancer cells and of these the most 
highly metastatic express the highest levels of sialic acid residue containing 
sphingolipids. Reduction of these sphingolipids using antisense vectors against 
ganglioside GD3 synthase or glucosylceramide synthase inhibit tumour growth and 
metastasis (Zeng et al., 1999), (Deng W., 2002). This correlation is true for at least 
neuroblastoma, renal carcinoma, breast carcinoma and melanomas. Their role in 
tumour development is multifold: increasing cell adhesion, functioning as ligands in 
transduction, and possibly binding with sialic moieties on blood cells (for example) via 
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sialic acid-binding immunoglobin-like lectins (Siglecs) that may assist a tumour to 
metastasize. 
 
Sphingosine-1-phosphate (S1P) has protumourogenic and angiogenic properties and 
favours cell survival and tumour growth (Taha et al., 2006), (Hait et al., 2006). Cuvillier 
et al propose that S1P prevents ceramide-induced cytochrome C release and caspase-
induced apoptosis (Cuvillier et al., 2001). It also stimulates VEGF and consequently 
sphingosine kinase-1 (English et al., 2002). It has long been a target for drug chemists 
and its’ inhibition is the mode of action of some of the most valuable anti-neoplastic 
pharmaceuticals available to clinicians. This list includes Tamoxifen and Verapamil. 
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Example of a GCS inhibitor 
 
 
 
FIGURE 2:  PDMP ENHANCES DOXORUBICIN-ELEVATED CERAMIDE. 
 
Sphingolipids are able to initiate caspase activated apoptosis (Ogretmen and Hannun, 
2004), caspase independent cell death (Kim et al., 2005) and possibly TNF-induced 
caspase independent death (Thon et al., 2005) – this latter function involves SMase. 
 
FIGURE 3: SPHINGOLIPIDS, CERAMIDE AND APOPTOSIS 
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Glycosphingolipid derivatives are also potential chemotherapeutics; structural 
analogues of glucosylceramide that are GCS inhibitors are able to reverse MDR and it is 
significant that clinical drugs that reverse MDR inhibit GCS (Lavie et al., 1997). 
   
Glycosphingolipids, in particular gangliosides (sialic acid residue containing 
sphingolipids), appear to influence cell migration and adhesion (Bremer et al., 1984). 
GM3 inhibits EGF induced cell growth in A431 carcinoma line (Bremer et al., 1986) 
through inhibition of the receptor autophosphorylation. Sialidase gene transfection into 
these cells increases autophosphorylation.  Meuillet et al describe the use of a ceramide 
analogue D-threo-1-phenyl-2-decannoylamino-3-morpholino-1-propanol (PDMP) which 
inhibits ceramide glucosyltransferase and this results in GM3 depletion and restores 
EGFR autophosphorylation to normal (Meuillet et al., 2000).  By using this ceramide 
analogue and exogenous GM3 the authors were able to assess the impact of GM3 on 
receptor activation. Reduction of GM3 increases EFGR function in A431 and the reverse 
is also true. This suggests that gangliosides have a direct impact on EGFR. However, 
PDMP also increases ceramide levels in A431 cells and is known to modify membrane 
fluidity (Barbour et al., 1992) and moreover, Meuillet suggests that modulation of 
ganglioside levels could disrupt the membrane inclusions – specifically caveolae – where 
the EGFR is most prevalent. Likewise, it has been proposed that caveolae-based SMase 
is responsible for ceramide-induced apoptosis following irradiation (Veldman et al., 
2001). Intracellular ceramide levels rapidly increase as part of the signalling cascade 
initiated by TNF, IL-1α and vitamin D3 (Mathias et al., 1998). This is mediated by 
ceramide-dependant protein kinase and type IIA phosphatase (Joseph et al., 1993).  
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1.4 DRUG INTERVENTIONS IN RAFT SIGNALING NOT RELATED TO CHOLESTEROL SIGNALING 
The anti-tumour drug Edelfosine is an ether lysophospholipid analogue that induces the 
translocation of caspases-8 -9 -10 to rafts containing the Fas-associated death domain in 
leukemic cells. It also inhibits activation of ERK1/2, p38 MAPK and Akt/protein kinase B 
so inducing apoptosis (Na and Surh, 2008). Edelfosine has been found to promote the 
recruitment to rafts of Fas and CD95 death receptors and DISC in multiple myeloma 
cells. This apoptosis is inhibited by the depletion of cholesterol from the membrane 
(Gajate et al., 2009).  It has been suggested that Edelfosine promotes the clustering of 
rafts into supra-molecular moieties that concentrate and act as scaffolds for apoptotic 
signalling (Gajate and Mollinedo, 2005). 
 
Intervention in the composition of rafts and caveolae has produced interesting results. 
n-3 fatty acids were found to deplete rafts of cholesterol and sphingomyelin and 
increase ceramide levels. A decrease in cell proliferation and an increase in apoptosis 
was observed. This was associated with a decrease in raft bound epithelial growth 
factor receptor (EGFR). Likewise EGFR-related apoptosis is seen when cholesterol is 
sequestered by 2-hydroxypropyl-β-cyclodextrin. The drug Cisplatin has been shown to 
induce raft recruitment of the death receptor CD95 [Fas-ligand] in colon cancer cells and 
this is inhibited by the aSMase inhibitor Imipramine and the cholesterol sequestering 
drug Nystatin. Cisplatin activates aSMase and therefore ceramide production. This 
action correlates with a reduction of membrane viscosity and onset of CD95 mediated 
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apoptosis (Lacour et al., 2004). Cisplatin is used clinically to reduce tumour size, 
especially in lung carcinoma. Brusselmans et al propose squalene synthase SQS as a 
potential target for anti-cancer drugs (Brusselmans et al., 2007) and used anti-sense 
SQS oligonucteotides to significantly reduce de novo synthesis of cholesterol with an 
associated decrease in raft cholesterol levels.  The sequences were: 
GAGGUUUGGAGCAGGUAUGdTdT and CAUACCUGCUCCAAACCUCdTdT. An attempt was 
made to use this second sequence in this study but was unsuccessful and is not 
reported.  Lange and Ramos (Lange and Ramos, 1983) had earlier shown that 
membrane cholesterol is not in rapid flux with intra-cellular cholesterol and this could 
be the reason that membranes depleted of cholesterol by statins, siRNA or by 
cholesterol sequestering drugs such as Methyl-β-cyclodextrin (MΒCD) are unable to 
quickly restore their homeostasis but may do so after drug treatment ceases.  Filipin 
and MΒCD have been shown to induce cancer cell death in vitro and in vivo (Zhuang et 
al., 2005). Griffoni et al succeeded in using anti-sense oligonucleotides to achieve a 70% 
reduction in Cav-1 mRNA (Griffoni et al., 2000). The application of these small 
interference mRNA were able to reduce the caveolae in HUVEC cells to undetectable 
levels using electron and confocal microscopy. Further, they reported that the use of 
siRNA sequences dramatically reduced capillary vessel formation in the chorio-allantoic 
chicken assay. They conclude that down-regulation of Cav-1 impairs angiogenesis. They 
deduced that the most active oligonucteotide (from the seven they tested) in supressing 
Cav-1 production was 5’ATGTCCCTCCGAGTCTA3’ which is directed against nucleotides 
20-36 of the mRNA open reading frame.   
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1.5 STATINS 
Statins are structural analogues of HMG-CoA and they compete for binding with HMG-
CoA reductase. They were originally discovered as fungal metabolites.  
Statins (especially Simvastatin, Lovostatin, Atorvastatin, Fluvastatin, Rosuvastatin, 
Cerivastatin and Pravastatin) have been studied to see if their pro-apoptotic and anti-
metastatic behaviour has therapeutic value in prostate and other cancers (Graaf et al., 
2004). Elevated levels of circulating cholesterol promote tumour growth and reduce 
apoptosis in cancer cells (Hager et al., 2006). In vitro experiments point to a suppression 
by statins of growth in breast cancer (Kotamraju et al., 2007), colorectal (Agarwal et al., 
1999), prostate (Sivaprasad et al., 2006), leukaemia (Xia et al., 2001) and lung (Khanzada 
U., 2005)  and other cancer cells.  
Further, the routine taking of statin based anti-hypocholesteraemia  drugs is negatively 
correlated with both cancer related morbidity and mortality (Demierre et al., 2005).  
 
The role of statins in metastasis on a molecular level has been recently reviewed by 
Papadopoulos et al (Papadopoulos et al., 2011). The idea that membrane rafts could be 
disrupted by statins and so used to impact raft-dependant signalling events has been 
suggested by others, notably Simons and Toomre as early as 2000 (Simons and Toomre, 
2000).   
 
Statins, through their truncation of the mevalonate pathway, disable the synthesis of 
isoprenoids. Without isoprenylation many important  proteins such as Rho and Ras are 
unable to locate and anchor to the membrane where they must function. This is 
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another possible explanation of the anti-oncogenic activity of statins (Wang et al., 
2008). The isoprenoid intermediate products resulting from targeted manipulation of 
the mevalonate pathway using statins, 6-fluoromevalonate, bisphosphonates, zaragozic 
acid and others has been reported (Henneman et al., 2011). 
 
Statins are reported to have a biphasic impact on angiogenesis with low does increasing 
angiogenic markers and high doses reducing angiogenic activity (Weis et al., 2002). They 
have been shown to inhibit the in vitro invasion of human breast cancer cells (Denoyelle 
et al., 2001), human pancreatic cells (Kusama et al., 2001), brain glioma cells (Gliemroth 
et al., 2003) and melanoma cells (Collisson et al., 2003).  This effect was reversible in 
breast and pancreatic cells (Farina et al., 2002) by supplementation of geranylgeranyl 
pyrophosphate indicating that inhibition of isoprenylation is of key importance in these 
cell types.  
 
One possible mechanism that has been proposed is that insulin growth factor receptor 
(IGF-1R), known to have a role in the proliferation of prostate cancer cells (Pollak et al., 
1998) is depleted by the exposure of cells to statins. Statins have also been studied for 
their anti-metastatic functionality in prostate cancer via their down regulation of 
insulin-like growth factor 1 (IGF-1) receptor (Sekine et al., 2008). Here, IGF regulates the 
growth of prostate cancer cells and inhibition of IGF-1R (by anti-sense) suppresses 
tumour growth and reduces metastasis (Reinmuth et al., 2002). Cholesterol depletion 
by statins to effect an IGF blockade was proposed by Sekine et al (Sekine et al., 2008) as 
a possible treatment for prostate cancer. 
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De novo production of cholesterol is undertaken by the mevalonate/isoprenoid 
pathway. Squalene synthase (SQS) is the enzyme that triggers the switch to the sterol 
biosynthetic branch of the pathway and as such is a determinant of cell membrane 
concentration.  
 
Pathway assembled from multiple references (Swinney et al., 1994), (Walker et al., 
1993), (Korosec et al., 2008). 
 
 
 
 
 
 
 
 
 
The mevalonate-isoprenoid pathway begins with Acetyl-CoA which is further acetylated 
to become acetoacetyl-CoA. HMG-CoA synthase converts acetoacetyl-CoA into HMG-
CoA which is the feedstock for the mevalonate pathway. It is this molecule that statins 
mimic and thereby bind competitively with HMG-CoA reductase, the rate limiting 
enzyme in the formation of mevalonate. There is evidence that this pathway can be 
directly activated by up-regulation of gene expression of all the subsequent enzymes by 
Acetyl-CoA 
Acetoacetyl-CoA 
HMG-CoA 
HMG-CoA synthase 
Mevalonate 
Farnesyl 
pyrophosphate 
Squalene Lanosterol Cholesterol 
Squalene synthase 
Multiple steps Multiple steps 
HMG-CoA reductase Mevalonate  reductase 
 
Multiple steps 
FIGURE 4: SIMPLIFIED CHOLESTEROL SYNTHESIS PATHWAY 
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a family of transcription factors called sterol regulatory element binding proteins 
(Weber et al., 2004). 
 
Mevalonic acid is metabolised to geranyl pyrophosphate and farnesyl pyrophosphate 
that can then be used for iso-prenylation of proteins – including activation of the 
Ras/Rho pathway – and the synthesis of ubiquitin. These secondary effects are blocked 
by statins and it has been assumed that these (as opposed to the lowering of 
cholesterol per se) have been uniquely responsible for the anti-cancer effects observed 
(Sebti, 2005), (Andela et al., 2003).  Other cholesterol inhibitors, notably Proadifen 
(diethylaminoethyl diphenylpropyl acetate) (Holmes and Bentz, 1960), have a profound 
membrane fluidizing effect (Swenson E.S., 1992) in vitro compared to the statins and 
this property may augment their ability to disrupt raft or caveolae domains.  
1.6 RAFTS AND GENE EXPRESSION 
1.6.1 ONCOGENES 
Dysregulation of transcription factors involved in signal transduction is a likely 
consequence of cholesterol raft de-population since the expression of many genes is 
responsive to external stimuli – such as hormones – mediated across the bilayer. This is 
a consequence of the eukaryotic cells’ devolution of control to external chemical 
semiotics that inform the nucleus of the environmental status. The response of the 
nucleus, in terms of gene expression, can be dysregulated by interference with the 
signal transduction through truncation of the signal pathway at the membrane. One 
possible effect of such dysregulation could be intracellular accumulation of 
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transcriptional regulators. In multiple myeloma for example, the proteasome inhibitor 
drug Bortezomib causes a build-up of NF-κb inhibitor IκB which (indirectly) activates 
apoptotic pathways. Similar effects are conceivable if autocrine/ paracrine loops are 
interrupted by reduced signalling at the membrane-raft transduction sites (specifically 
receptor tyrosine kinases (RTK) and G-coupled proteins that are known to occupy these 
sites). 
 
Most oncogenes contribute to cell transformation because their products are regulatory 
growth factors or transcription factors. These include growth stimulating genes such as 
PDGF. Roughly 30% of oncogenes code for protein kinases which are recruited to the 
inner layer of the cell membrane where they mediate signal protein phosphorylation. 
This is a characteristic shared with several autocrine/paracrine growth factors. The 
metastatic phenotype is independent of the tumourigenic –phenotype and this 
characteristic has been reviewed by Liotta (Liotta, 1988). One of the most studied 
oncogene families is Ras or RasH gene. Transfection of this gene into non-metastatic 
cancer cells leads to an increase in the intrinsic aggressiveness of these cells by means 
of a cascade of gene expression leading to full metastatic conversion (Egan et al., 1987).  
Ras, for example, does not cause Ras-transfected cells to proliferate faster (in vitro or in 
vivo) but there is a difference in the invasiveness of the transfected cells. It enables the 
cells to grow in serum depleted media – i.e. it allows the cells to produce autocrine 
growth factors, and this is a crucial metastatic step. This behaviour of Ras is associated 
with a significant up-regulation of p21 protein and the expression of this protein 
correlates well to the transfected cell’s metastatic potential (DeFeo et al., 1981). High 
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expression of p21 leads to very high in vivo metastasis – intravenous injection of 5 x 104 
normal cells appropriately transfected with oncogene and enhancers can produce over 
200 metastases in the lungs of mice (Nicolson, 1987). Lymphoma cells (such as the BJAB 
line used in these experiments) show no requirement for collagenases or laminin 
receptors for their invasiveness but these proteins are up-regulated after transfection 
with ras and lymphoma cells are then able to attach to and  invade collagen-containing 
tissue. It is clear that the activation of oncogenes is a critical step in the evolution of a 
tumour cell into an invasive metastatic cancer.  
RTK are a group of ligand binding proteins that normally act as receptors for growth 
factors and hormones such as EGFR, VEGFR and PDGFR. Kinase inactivation blocks 
production of all down-stream signalling molecules including c-myc and c-fos. PDGF 
receptor activation would normally be followed by phosphorylation of src family 
proteins and increase of src kinase activity. src proto-oncogene is associated with 
numerous types of cancer. 
 
1.6.2 TUMOUR SUPPRESSOR GENES 
Interestingly, when p53 was first discovered in 1979 it was thought to be an oncogene 
but is actually a tumour suppressor gene. This type of gene is associated with negative 
control of proliferation. Inactivation of p53 (and others) is linked to tumour 
development in many cancers e.g. small cell lung cancer. Thus tumour cell proliferation 
is governed by the competing forces of oncogenes and growth suppressors. An 
accumulation of genetic changes both in oncogenic and suppressor genes are early but 
necessary steps towards metastatic cancer.  
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Lipid metabolism interventions (by gene knock-down) and effects on cancer cells 
Effect of Intervention Cell Type  Consequence 
Decrease of glycosyl 
ceramide 
Murine melanoma; MCF-7 
breast cancer 
Reduction of tumourogenicity (Deng 
W., 2002) and restoration of drug 
induced apoptosis (Liu et al., 2004) 
Increase in GD3 
expression 
Human leukaemia  Increase in apoptosis (De Maria et al., 
1997)  
Increase in GM3 Murine carcinoma Increase in apoptosis (Watanabe et al., 
2002) 
Increase in ganglioside 
sialidase 
Murine melanoma Reduction of metastasis (Tokuyama S., 
1997) 
Reduction of 
sphingomyelin 
Murine lymphoma Resistance to anti-FAS induced 
apoptosis (Miyaji et al., 2005) 
Increase of C-18 ceramide Human squamous cell 
carcinoma 
Induction of apoptosis (Koybasi et al., 
2004) 
Decreased S1P Murine NIH3T3 fibroblasts; 
human HEK293 kidney; human 
PC-3  and LNCaP prostate 
cancer 
Increase in apoptosis (Mandala et al., 
2000), (Le Stunff et al., 2002), 
(Pchejetski et al., 2005) 
Increase in S1P  Human Jurkat leukaemia; 
human PC-3  and LNCaP 
prostate cancer 
Inhibition of ceramide induced 
apoptosis (Olivera et al., 1999), 
(Pchejetski et al., 2005) 
TABLE 2: EFFECTS IN CANCER OF GENETIC CHANGES TO LIPIDS 
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2 MATERIALS AND METHODS 
2.1 CELL LINES 
All experiments were conducted using either one or two cell lines. The main line studied 
was MDA-MB-231. This line is a human breast adenocarcinoma that grows in monolayer. It 
was taken from a Caucasian woman of 51 years by pleural effusion (Cailleau et al., 1974). 
To compare the effect of Proadifen on a non-adherent line, the Burkett’s lymphoma BJAB 
cell line was also used in one analysis of the proteome by microarray. In the final series of 
assays a third cell line, a grade 3 human lung carcinoma called CaLu-1 was included. All cells 
were obtained from Cell Lines Service, Eppenheim, Germany. 
2.2 TEST AGENTS 
Most of the test compounds were sourced from chemical suppliers (see Table 4 Page 53). 
Those that were synthesized by the author and those analogues prepared in contracted 
laboratories were tested for structure and purity by NMR. The primary test agent was N,N-
diethylaminoethyl 2, 2-diphenylethanoate hydrochloride  (Proadifen) known to inhibit the 
final stages of cholesterol biosynthesis, leading to a build-up of the precursor lanosterol. It 
is known to be surface-active in artificial membranes (Anders and Mannering, 1966) and 
has been studied in the context of cholesterol regulation and therapeutic enhancement 
(Fernandez et al., 1978), (Brodie et al., 1958), (Galeotti et al., 1983), (Ravis and Feldman, 
1979), (Fouts and Brodie, 1956).  It was observed that this compound prolonged the 
hypnotic action of hexobarbital in rats and mice without altering the toxicity (Cook et al., 
1954).  It was later found that this effect occurred in combination with secobarbital, 
pentobarbital, butethal, ortal, phenobarbital and chloral hydrate (Anders and Mannering, 
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1966).  By contrast, no synergistic effect was discernible with barbital and thiopental, 
thioethamyl and methylparafygol.  Thus, this enhancement effect is difficult to predict - it 
does inhibit the de-methylation of neperidine but not of N-methylaniline or N-ethyl aniline. 
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TABLE 3: PRIMARY TEST AGENTS USED IN THIS STUDY 
Commercially 
available 
drug 
Experimental use in 
this study 
Biological activity 
Nocodazole  Phagokinetic track 
experiment 
Used as a positive control as it prevents the formation of microtubules. This part of the cytoskeleton is essential for the cells 
motility.  
Proadifen All experiments Possible Δ24 reductase inhibitor. Membrane fluidizer and drug potentiator 
Fluphenazine  All experiments A piperidine phenothiazine used in medicine since the 1970s as an anti-psychotic in the treatment of schizophrenia. 
Currently in clinical trials against some blood cancers. Believed to alter DNA turnover and may affect hormone expression. 
Pravastatin  Cav-1 assay, RNA assay 
and cholesterol assay 
A typical cholesterol lowering statin and is approved for use in humans. Like all statins it is an inhibitor of 3-hydroxy-3-
methyl-glutaryl-CoA reductase and so acts as a blockade of the isoprenoid pathway by preventing the synthesis of 
mevalonate and, in turn, squalene.  
Simvastatin Cav-1 assay and anti-
Tub-1 assay 
Typical HMG-CoA inhibiting treatment for hypercholesteremia. Very similar to Pravastatin. 
AY9944  Cav-1 assay , proteomic 
assay and cholesterol 
assay 
An amphiphilic diamine that blocks cholesterol synthesis by inhibiting 7-dehydrocholesterol reductase and Δ7, Δ8 
isomerase.  It is a teratogen. Used to help locate the blockade point of Proadifen 
BIB515  Cav-1 assay and 
cholesterol assay 
A specific inhibitor of 2,3-Oxidosqualene cyclase preventing the conversion of [3S]-oxidosqualene  to lanosterol. Used to 
help locate the blockade point of Proadifen 
Triparenol 
 
Cav-1 assay  Δ24-dehydrocholesterol reductase. Used to help locate the blockade point of Proadifen 
Ro-48-8071 Cholesterol assay Inhibitor of oxidosqualene cyclase – causes a reduction in cholesterol similar in range to Simvastatin 
BIBX1382 Cholesterol assay Specific  epidermal growth factor inhibitor considered as anti-tumour agent 
Ergoesterol Cholesterol and Cav-1 
assay 
Simulates a Δ-24 reductase inhibitor by competitive inhibition. 
Methyl β-
cyclodextrin 
Proteome assay, Cav-1 
assay, cholesterol 
assay and RNA assay 
Cyclic oligomer of glucose able to entrap cholesterol in its hydrophobic core and specifically sequester the sterol from the 
membrane (Rodal et al., 1999). 
Clotrimazole Anti-Cav-1 assay and 
cholesterol assay 
Anti-fungal  imidazole compound that induces apoptosis in breast cancer cells, disrupts glycolysis and interferes with Ca+ 
ion transport across the plasma membrane 
D-erythro-
MAPP 
Galactin-8 assay Inhibits ceramidase and elevates endogenour ceramide leading to apoptosis (Bielawska et al., 1996) 
BM15766 Cholesterol assays Piperazine derivative that, like AY9944, inhibits Δ7 reductase leading to an accumulation of 7-dehydrocholesterol and 8-
dehydrocholesterol (Lindenthal et al., 2002). 
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Table 4: Solvents and stock concentrations of test agents 
Agent Stock concentration Solvent Notes Source 
Methyl-β-cyclodextrin 0.05% w/v 100% Hanks Balanced Salts 
(Hanks) 
Cholesterol sequestrator Sigma Chemicals Ltd 
Cholesterol 0.1M 20% Dimethylsulfoxide (DMSO); 
40:40 (v/v Hanks: ethanol) 
 Sigma Chemicals Ltd 
AY9944 0.007M 100% Dimethyl sulfoxide (trans-N,N-bis[2-
Chlorophenylmethyl]-1,4-
cyclohexanedimethanamine HCl 
Tocris Bioscience Ltd 
Fluphenazine 0.01M  10% Ethanol in Hanks   Sigma Chemicals Ltd 
Clotrimazole 0.02M 50:50 v/v Ethanol: Hanks  Sigma Chemicals Ltd 
Proadifen 0.015M 100% Hanks  2-(N,N-diethylamino)ethyl 2,2-
diphenylethanoate 
Dynthesized by DG 
Pravastatin 0.01M  100% Hanks   Sigma Chemicals Ltd 
Ergosterol 0.1M Chloroform:DMSO:Dulbeco’s 
saline 50:30:20 v/v/v 
 Sigma Chemicals Ltd 
VL15  0.05M Dichloromethane:DMSO: 
Phosphate buffered saline 
20:30:50 v/v/v 
2-(N-ethylamino)ethyl 2,2-
diphenylpentanoate 
Synthesised by DG 
VL20  0.01M Ethanol:DMSO:Dulbeco’s saline  
20:10:70 v/v/v 
2-(Diethylamino)ethyl 2-
phenylethanoate 
Synthesised by DG 
2,2-Diphenyloctanoic acid amide 0.01M 100% DMSO  Synthesised by Leksing Ltd 
2,2-Diphenylheptanoic acid 
amide 
0.01M 100% DMSO  Synthesised by Leksing Ltd 
2,2-Diphenylhexanoic acid amide 0.01M 100% DMSO  Synthesised by Leksing Ltd 
2,2-Diphenylpentanamide 0.01M 100% DMSO  Synthesised by Leksing Ltd 
2,2-Diphenylpentanoic acid 
morpholino ethyl ester 
 
0.1M Dulbeco’s buffered saline  Synthesised by Leksing Ltd 
2,2-Diphenylpentanoic acid 0.1M Hanks  Synthesised by Leksing Ltd 
 
 
3-(Diethylamino)propyl 2,2-
diphenylpentanoate 
0.1M Hanks  Synthesised by Leksing Ltd 
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2-(Piperidin-1-yl)ethyl 2,2-
diphenylpentanoate 
0.01M Hanks  Synthesised by Leksing Ltd 
BIBB515  DMSO 1-(4-Chlorobenzoyl)-4-[[4-(4,5-
dihydro-2-
oxazolyl)phenyl]methylene]-
piperidine 
Cayman Chemicals 
BIBX1382  DMSO N-(3-Chloro-4-fluorophenyl)-N-
(methyl-4-piperidyl)-pyrimido[5,4-
d]pyrimidine-2,8-diamine .2HCl 
Tocris Bioscience Ltd 
Ro48-8071  Methyl acetate/Dulbeccos 
0.25mg/ml 
(4-Bromophenyl)[2-fluoro-4-[[6-
(methyl-2-propenylamino)hexyl] 
oxy]phenyl]-methanone 
Cayman Chemicals 
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2.2.1 PROADIFEN ANALOGUES TESTED, SYNTHESIZED DE NOVO 
 
 
 
FIGURE 5: PROADIFEN AND ITS ANALOGUES 
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FIGURE 6: ADDITIONAL PROADIFEN ANALOGUES 
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FIGURE 7: ITERATIVE DERIVATIVES BASED ON C5 AND C6 
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2.2.2 DOSES 
The dose is the final concentration in the treatment media. In the case of the statins 
these were chosen to be equivalent to the plasma statin concentration in patients 
receiving the maximum standard dose of statin. For example, in the case of Simvastatin 
this dose is normally no more than 80mg/day (BNF, 2012). In the case of Proadifen the 
original work from the 1950’s indicated the maximum tolerated dose in vivo (rats) and 
this was used in most experiments (Fouts and Brodie, 1956). In one proteomic assay, a 
dose of 10x this level of Proadifen was used without significant toxicity to see if there 
additional response. Proadifen analogues were treated as though they were Proadifen 
in the absence of any clinical or animal data. No significant toxicity was observed but in 
the proteolysis assay the data were scaled by a cell viability test to exclude toxic effects. 
All other compounds were used according to their maximum solubility in media or PBS, 
or according to manufacturer’s application notes.  
 
2.3  ASSAYS 
For many years, the mainstay of experimental work on anti-cancer drugs was a simple 
growth assay performed on cell monolayers (Eccles, 2001). Such a proliferation based 
assay can reveal some effects of research drugs but is best suited to cytotoxic drugs 
such as the alkylating agents. They are very useful in high throughput screens, but they 
do not help elucidate the more subtle and the more complex effects of the test agents, 
and teach little about the metastatic potential of the cells under treatment. Clearly the 
ideal assay to study multiple attributes of a treatment is in vivo and typically involve 
intravenous introduction of  metastatic lung (or breast) cells into mice or rats and then 
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specialised imaging techniques (or dissections) to monitor tumour spread and growth.  
The conditions in an in vitro assay can never fully model the environmental and 
metabolic effects of a whole animal but some in vitro assays have been designed to 
elucidate the effects of drugs on particular metastatic phenomena such as motility, 
protease secretion, cell adhesion, de-adherence, angiogenesis etc. 
 
Typically these involve a highly invasive cancer lines. For example, in a study of organo-
metallic half-sandwich RuII compounds, the chosen cell lines were MDA-MB-231 and 
MCF-7 which proved highly useful (Bergamo et al., 2010). Here, HBL-100 non-
tumourogenic human epithelial cells were used as the control line. This is the reason 
why MDA-MB-231 was used as the main cell type in these experiments. The human lung 
carcinoma CaLu-1 also used in this study is likewise known to be a highly invasive 
cancer.  In theory, however, any aggressive cancer cell should be amenable to these test 
protocols.  
 
 
2.3.1 PHAGOKINETIC TRACK ASSAY 
In these experiments motility of MDA-MB-231 cells was determined by measuring the 
size of a phagokinetic track in a carpet of gold colloid over time. It is a variation of the 
method described by Niinaka et al (Niinaka et al., 2001). Briefly, the gold colloid is 
prepared by boiling 11ml water, 6ml 36.5mM Na2CO3 and 1.8ml 14.5mM AuCl4H. To 
this hot mixture 1.8ml of 0.1% formaldehyde is added. Within a few seconds there is a 
colour change from clear to dark purple and the colloid is ready for immediate use. 
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Extra-large coverslips were dipped into sterile 1% BSA solution and then dipped again 
into 100% ethanol. These are then air-dried. These slides were placed individually in the 
centre of a 90mm Petri dish and the colloid is pored over the slide coverslip until one 
side is completely immersed. These are left for 24 hours at r.t. and then removed using 
forceps and air-dried again at 37oC. When dry they are individually placed in the centre 
of a fresh Petri dish and the cell suspension (+/- treatments prepared as described 
earlier) is pipetted directly onto the coverslip at 1ml per slip. The dishes are covered and 
incubated for 24 hours before being examined with a brightfield microscope by 
removing the coverslip and inverting it onto a clean microscope slide. Individual tracks 
can best be seen at x400 but a field of view at x100 is most suitable for image analysis. 
 
2.3.2  LIGHT MICROSCOPY 
These images are representative samples of photomicrographs taken of treated and 
untreated MDA-MB-231 cells after 24 hours, post passage. 
 
2.3.3 ELECTRON MICROSCOPY 
Cells were grown in 12 well plates each containing a piece of pre-sterilised (with 75% 
alcohol) acetate approximately 2mm x 3mm. Cells were cultured in the normal way and 
after trypsinisation, centrifugation and re-suspension they were pipetted gently onto 
the surface of the acetate. The wells were covered with fresh media containing 10% FBS 
and either of PBS, Proadifen, AY9944 or MβCD and placed in an incubator at 37.5oC for 
24 hours. The acetate strips were removed with forceps and washed in PBS and then for 
1 hour steeped in 1% glutaraldehyde and sodium cacodylate. These were then 
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successively treated at the Keele Electron Microscopy Unit, with ruthenium tetroxide, 
thiocarbohydrazide, osmium tetroxide, thicarbohydrazide and osmium teroxide (RTOTO 
method (Kutz et al., 1985)) prior to scanning in an Hitachi S4500 machine, or for TEM, a 
JEOL1230 at between +1 and +30kV. The treatment doses of these cultures were as 
follows: Proadifen 16µM; MβCD 0.00083%; AY9944 8µM. 
 
2.3.4 PROTEOMIC ANALYSIS METHODS 
These experiments were conducted on MDA-MB-231, an adherent breast cancer line 
known to be highly metastatic and BJAB Burkett’s B-lymphoma cells, a transformed cell 
line that grows in suspension. 
 
The purpose of the experiment was to determine what effect a large dose of the test 
agent would have on signal proteins and other cancer related proteins in these two cell 
lines. 656 proteins were analysed from whole cell lysates including a range of cancer 
markers, proteins associated with metastatic potential, angiogenesis and apoptosis 
markers. A large number of other proteins were also included in the assay. Some 
signalling proteins are known to be located in cholesterol rich rafts and these are listed 
in Table 1 while others have an unknown location in the membrane. Many of the 656 
proteins are cytoplasmic and are therefore outside the scope of this study. However, 
many of these are likely to be directly or indirectly responsive to membrane-bound 
signals. 
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Antibody arrays provide high-throughput screening platforms for accurate protein 
expression profiling and their application lends itself to tissue samples and cell lysates. 
 
2.3.4.1 PRINCIPLE 
 
Antibodies are covalently immobilized on glass slides in duplicates. Multiple positive 
markers (Cy3 fluorophore) and negative controls (BSA) are included on the array and 
provide internal references. Cells from treated and control groups are lysed and the 
protein content extracted and measured. The proteins are then biotinylated and 
conjugated with the antibodies on the array. The slides are washed and then detected 
with Cy3-steptavidin in a classic ‘probe sandwich’ using a microarray  laser scanner at 
480nm.  
 
2.3.4.2 PROCEDURE 
MD-MBA231 cells were cultured in Dulbeco’s MEM + 10% FBS with stabilized antibiotic-
antimycotic. Final concentration contained 100,000 units penicillin G, 100mg 
streptomycin sulphate and 0.25mg amphotericin B per litre of media. All cells were 
subject to a 4 day passage regimen. BJAB cells were cultured in MEM + 10% FBS + 
stabilized antibiotic-antimycotic in Nunc 175cm2 flasks in 5% CO2 at 37oC. 
2.3.4.3 TREATMENTS 
Treatment comprised N,N-diethylaminoethyldiphenylethanoate hydrochloride made up 
in Hank’s Balanced Salt solution to give a final concentration in the media of 10µM and 
100μM. AY9944 and Pravastatin were also tested in this assay with MDA-MB-231 cells 
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but not BJAB. Control flasks contained only the same volume of Hanks solution. Test 
solutions were made up freshly and brought to 37oC immediately prior to treatment.  
 
All chemicals and media were purchased from Sigma Chemicals, UK except where 
specified. The antibody array slides and associated reagents were purchased from Full 
Moon Biosystems Inc, USA.  
Treatment and control solutions each were added directly to three culture flasks at 80% 
of confluence for 24 hrs prior to harvesting. Cells from each triplicate were pooled after 
the trypsinisation step. The tests were performed in accordance with the 
manufacturers’ protocols (Bioscience). Briefly, 1 x 106 MDA-MB-231 cells were 
harvested from the flasks using Trypsin (Bovine pancreas)-EDTA solution made up to 
25g Trypsin in 1 litre of DMEM. BJAB cells were centrifuged without further treatment. 
Cell pallets were then washed in 5ml phosphate buffered saline (PBS) three times with 
aspiration and re-centrifugation steps at room temperature. The cells were then 
washed a final time in PBS at 4oC in 1.3ml Eppendorf tubes. To each tube was added 1 
tube of Full Moon Biosystems lysis beads and 250μl Extraction Buffer. This was vortexed 
for a total of 6 minutes in 1 minute stages over an hour while between vortexing the 
samples were kept on wet ice. The cells were then re-centrifuged at 15000 rpm at 4oC 
for 15 minutes. The clear supernatant was then discarded.  
 
The protein concentration was assayed using a BCA protein assay kit at this stage. 1mg 
of biotin reagent was dissolved in 100μl N,N-Dimethylformamide. The protein solution 
was reduced using a vacuum-orbital evaporator until the protein concentration per 
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100μl is 400μg protein. 25μl of this solution is mixed with 25μl of labelling buffer and 
1.5μl of the biotin-DMF solution. This is incubated with shaking at room temperature 
for 2 hours.  
 
Each tube of protein is added to 6ml of the coupling reagent and vortexed. This is 
poured gently over the array slide in a Petri dish until the slide is submerged. This was 
rocked at room temperature for 1 hour. The slide was then washed with the wash 
solution twice and rinsed with Chromasolv™ grade water. The slide was immediately 
submerged in 30ml of Cy3-streptavidin solution and incubated with rocking for 10 
minutes. It was then extensively washed in the wash solution three times and finally in 
Chromasolv™ grade water.  After drying with N2 the slide was read in the array scanner. 
  
2.3.4.4 STATISTICAL TREATMENT 
Each assay was run once with three technical replicates. The graphs of the mean results 
are plotted for the marker set of proteins with error bars showing ± the standard error 
which is derived from the coefficient of variation.  
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2.3.5 CELL-MATRIX ADHERENCE METHODS 
This assay was found to be amenable to the cells and to the treatments and was used to 
monitor the effects of Proadifen on the re-adherence of newly passaged cells onto the 
culture flask surface over time. The assay was augmented with a simple kit to detect cell 
death and necrosis to examine if those cells that remained attached to the plate were 
indeed living or showing signs of injury or death. 
 
Cells were maintained and treated as previously described. The water soluble nuclear 
stain aniline blue was used to permit the use of the plate reader to measure cell density 
at 500nm. The plate reader was a Biochrom Expert Plus with computer interface.  In 
each of the cell re-attachment / attachment tests all liquid (containing any free floating 
cells) from the well was gently removed using a pipette prior to scanning.  
 
Necrosis and apoptosis were detected using an Enzo Life Science detection kit. 
Apoptosis is detected using an Annexin V-Cy3 conjugate that binds to 
phosphatidylserine on the outside of the cell wall. Necrosis is detected by loss of 
integrity of the plasma membrane and generates a far red emission signal localized to 
the nucleus. This is done using a membrane impermeable DNA intercalating dye 7-AAD. 
Thus, the treated 96 well plates are scanned at two wavelengths: Ex/Em 550/570 for the 
Annexin probe and Ex/Em 546/647 for the 7-AAD. Although these signals are sufficiently 
distant to be multiplexed, in these experiments separate scans were performed in less 
than one minute. 
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2.3.6 RNA EXPRESSION PROFILING METHODS 
The purpose of including this kind of analysis in this study was to try to reveal more 
about the mechanism by which a cholesterol inhibitor actually reduces or enhances the 
level of any given protein. The protein antibody array data provides only the quantity of 
protein available to the antibody but this increase or decrease in protein can arise from 
either increased or decreased feed-stock up-stream in the canonical pathway but it may 
be due to an up-regulation of part or all of the pathway components and substrates. 
Using the same treatments, cells and conditions described in Proteomic Analysis (Page 
66) an expression profile of some 47,000 genes (or gene elements) was obtained to 
determine if instruction signals to the DNA were the origin of the protein shifts 
observed.  
 
2.3.6.1 PROTOCOL FOR THE RNA EXPRESSION PROFILE ASSAY 
Determination of mRNA expression of proteins can now be accomplished using Illumina 
bead-chip assays and this was performed by Gen-Probe Inc, San Diego, USA. 
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2.3.6.2 METHODOLOGY OF CELL TREATMENT FOR MRNA ASSAY 
Cells were treated in 3 x 174ml culture flasks (Nunc) containing 40ml of Dulbeco’s 
DMEM with 10% (v/v) FBS per treatment. Negative control flasks contained only the FBS 
supplemented media.  Primary treatments were Pravastatin, Proadifen and MβCD. 
Opportunistically, two additional treatments were added: lysophosphatidylcholine (LPC) 
known to fluidize cell membranes and the phenothiazine Fluphenazine which is a 
candidate anti-cancer treatment. Treatments were 24 hours and treatment start time 
was 24 hours after sub-culture. Incubation was at 5.0% CO2.  Cells from each treatment 
were harvested with trypsin 10% w/v and immediately spun down to a cell pellet. The 
cells were then re-suspended in PBS containing 0.1% of Sigma Protease inhibitor 
cocktail and then re-centrifuged. The resultant cell pellet was then stored in LN2 prior to 
RNA extraction. 
2.3.6.3 RNA PURIFICATION USING THE QIAGEN RNEASY MAXI KIT 
7.5ml of Buffer RLT was added to each pellet and then the suspension was 
homogenised using a needle and syringe. Each sample was transferred to an RNeasy 
column and placed in a 50ml centrifuge tube. This was spun for 5 minutes at 3000-5000 
x g. The flow through was discarded. 15ml of Buffer RW1 was added to the column and 
it was further centrifuged for 5 minutes. The flow through was discarded. This operation 
was repeated with Buffer RPE for 2 minutes and then again for 10 minutes. The column 
was then placed in a fresh collection tube and the RNA eluted into 150µl of RNA free 
water by further centrifugation under the same conditions. 
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2.3.6.4 PREPARATION OF POLY-A CONTAINING MRNA  USING THE MRNA-SEQ SAMPLE PREP KIT (QIAGEN) 
This protocol uses poly-T oligo-attached magnetic beads. Briefly, the beads are 
prepared in buffer as per the manufacturer’s instructions. The RNA samples are heated 
for 5 minutes at 65oC and then placed on ice. The beads in Bead Binding Buffer are 
added to 50µl of total RNA and the supernatant removed after 5 minutes. 50µl of 
10mM Tris-HCl is added and then the tubes are heated to 80oC for 2 minutes. Then the 
tubes are placed on the magnet leaving the supernatant containing the mRNA. The 
samples are further heated and washed to elute mRNA from the beads yielding 10-20µl 
mRNA.  
 
16µl mRNA is then added to the fragmentation buffer (4µl) and the tubes are incubated 
in a PCR thermal cycler at 94oC for 5 minutes. 2µl of stop buffer is added and the 
samples are placed on wet ice. 3M NaOAC (pH5.2) 2µl, glycogen (2µl) and 200 proof 
ethanol (60µl) is then added to the tubes and these are then centrifuged at 14,000rpm 
for 25 minutes at 4oC. The pellet of RNA is then washed with 70% ethanol and then air 
dried for 10 minutes.  
 
2.3.6.5 RNA QUANTIFICATION 
RNA quantification was performed by absorbance (OD A260nm) on the NanoDrop™ 
1000 (Thermo Fisher). 2 x 1µL aliquots were analysed and the mean concentration 
calculated using a conversion factor of 44.6. The A260/A230nm and A260/A280nm 
purity ratios were also determined. 
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2.3.6.6 RNA NORMALIZATION 
RNA was normalised to 50ng/µL in a 20µL final volume using RNase-free water. Samples 
were formatted into a low volume 96-well plate and passed to Gen-Probe Ltd for 
genotyping. 
 
TABLE 5: RNA CONCENTRATIONS AND DNA YIELDS 
Source Sample /ID Final Stock 
RNA conc. 
(ng/µL)  
A260/A280 Ratio A260/A230 Ratio Total Estimated 
Yield of Stock 
DNA (µg) 
Proadifen A1 413.8 2.110 2.636 413.8 
Proadifen A2 570.6 2.123 2.808 570.6 
Proadifen A3 653.8 2.133 1.365 653.8 
Proadifen A4 448.3 2.103 3.619 448.3 
Pravastatin B1 525.7 2.140 1.874 525.7 
PravastatinB2 761.0 2.129 0.961 761.0 
PravastatinB3 652.8 2.132 2.998 652.8 
PravastatinB4 840.2 2.129 2.833 840.2 
Control C1 897.2 2.124 2.600 897.2 
Control C2 670.4 2.150 1.639 670.4 
Control C3 951.4 2.121 2.654 951.4 
Control C4 1,063.4 2.122 2.544 1063.4 
MβCD D1 557.3 2.154 2.026 557.3 
MβCD D2 762.7 2.139 1.770 762.7 
MβCD D3 707.0 2.119 2.941 707.0 
MβCD D4 698.7 2.135 1.641 698.7 
LPC E1 615.6 2.123 3.011 615.6 
LPC E2 N/A N/A N/A N/A 
LPC E3 685.1 2.106 2.734 685.1 
LPC E4 362.0 2.115 1.963 362.0 
Fluphenazine F1 597.7 2.129 2.846 597.7 
Fluphenazine F2 583.8 2.123 3.226 583.8 
Fluphenazine F3 932.2 2.127 1.845 932.2 
Fluphenazine F4 626.7 2.139 2.877 626.7 
 
First Strand cDNA is prepared using reverse transcriptase and random primers.  LPC E2 
was not done due to cell death/ contamination. E2 space was re-allocated randomly to an extra 
replicate of A4. 
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11.1µl mRNA is added to 1µl random primers. This is then incubated in a PCR thermal 
cycler at 65oC for 5 minutes and placed on ice. A mixture of First Strand Buffer, 100mM 
DTT, 25mM dNTP Mix and RNaseOUT is added to the sample and heated to 25oC for 2 
minutes. 1µ Superscript II is then added the incubated in the cycler : 
25oC for 10 minutes 
42oC for 50 minutes 
70oC for 15 minutes 
Hold at 4oC 
The next step is to remove the mRNA and synthesize double stranded cDNA using 
QIAquick PCR Kit (Qiagen). Briefly, 62.8µl of water is added to the sample along with 
GEX Second strand Buffer and 25mM dNTP Mix. This is incubated at 0-4oC for 5 minutes 
and then RNaseH and DNA Pol 1 are added and then the sample is incubated at 16oC for 
2.5 hours. 
End repair is accomplished using T4 DNA polymerase and Klenow DNA polymerase. In a 
1.5ml Eppendorf tube 50µl of eluted DNA, 27.4µl water, 10µl 10x End Repair Buffer, 
1.6µl of 25mM dNTP Mix, 5µl T4 DNA Polymerase, 1µl Klenow DNA polymerase and 5µl 
T4 PNK are added. This mixture is then incubated at 20oC for 30 minutes. Adapters are 
then ligated to the DNA so they can be hybridised to the flow cell, using a MinElute PCR 
Kit (Qiagen). Here, 23µl of eluted DNA is mixed with 25µl 2x Rapid T4 DNA ligase Buffer, 
1µl PE Adapter Oligo Mix and 1µl of T4 DNA ligase. This is incubated at room 
temperature for 15 minutes. In preparation for the Illumina Assay the ligated cDNA is 
separated on an agarose gel to assess the size of the template needed for PCR 
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enrichment.  Briefly, this is done by mixing 10µl cDNA sample with 6X DNA Loading Dye 
and running the gel lane against 2µl 0f 100bp DNA at 120v for 60 minutes.  
The purified cDNA templates can then be enriched using two primers that anneal to the 
ends of the adapters. This was performed using a Qiagen Qiaquick PCR Purification Kit. 
The PCR mix is made from 10µl 5X Phusion™ Buffer, 1µl PCR Primer PE 1.0, , 1µl PCR 
Primer PE 2.0, 0.5µl 25mM dNTP Mix, 0.5µl Phusion™ DNA polymerase and 7µl water. 
This is added to 30µl of the ligated DNA  and is amplified with the manufacturer’s 
temperature cycle protocol. The samples are then ready for the Illumina 
HumanHT12_V4_0_R2_15002873_B human expression microarray. MDA-MB-2312 and 
CaLu-1 were treated with five different drugs: Proadifen, Pravastatin, MΒCD, LPC or 
Fluphenazine. Six groups, (including an untreated control group), were each comprised 
of 4 biological replicates, except for LPC which had 3 replicates. 
 
The raw array data were assessed for quality, and outliers removed. The remaining 
arrays were normalised and array features annotated. A series of 15 group-wise 
comparisons was undertaken to identify differences (fold changes). Each fold change 
has associated significance statistics, but as the number of significance tests being done 
is equal to the number of array features, significance values are controlled for false 
discovery, yielding a more rigorous adjusted P value. Having chosen a threshold for 
significance (adjusted p<0.01), significant loci in each comparison were assessed for 
functional enrichment of KEGG pathways, and GO terms, based on their annotation 
information. 
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A total of 24 Illumina HumanHT12_V4_0_R2_15002873_B arrays were QC analysed 
using the open-source r-stat arrayQualityMetrics Bioconductor™ package to identify 
sub-standard and/or outlier arrays. No arrays were identified as outliers. 
 
Normalisation of the 47319 features across all arrays was achieved using robust spline 
normalisation after data were subjected to a variance stabilizing transformation. Raw 
data were transformed using a variance stabilizing transformation (VST) method prior to 
normalisation across all arrays using the robust spline normalisation (RSN) method. 
Expression measures (summarised intensities) are in log base 2. 
 
The statistical significance threshold chosen for functional enrichment analyses was 
adjusted p<0.01. Functional enrichment analyses were undertaken for each comparison 
that had loci significant at this threshold. Up- and down-regulated loci were assessed 
separately.  
 
For each comparison, the number of array features significant at various statistical 
thresholds were tallied. These are summarised in the table below. As mentioned 
previously, for statistical robustness, only those with an adjusted p value < 0.05 should 
be considered. The "non-redundant markerset" row details the number of array 
features significant in one or more of the comparisons at the given probability 
threshold.  
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2.3.7 ADDITIONAL ANTIBODY ASSAYS 
Assay for Caveolin-1, Tubulin-1 and Glactin-8.  
These markers were further analysed in discreet experiments that permitted multiple 
treatments and doses. Note: These assays now include some of the newly synthesised 
Proadifen analogues. 
 
2.3.8 TREATMENT OF CELLS FOR INDIVIDUAL ANTIBODY ASSAYS 
MD-MBA231 cells were cultured in Dulbeco’s MEM + 10% FBS with stabilized antibiotic-
antimycotic in Sterilin 75cm2 flasks. Final concentration contained 100,000 units 
penicillin G, 100mg streptomycin sulphate and 0.25mg amphotericin B per litre of 
media. All cells were subject to a 4 day passage regimen. Approximately 2 x 106 cells 
were evenly aliquoted into Corning 96 well plates providing approximately 2 x 104 cells 
per well. Replicates were carried out in entire columns of eight wells except where 
specified. 
 
Treatment comprised the agent made up in Hank’s Balanced Salt solution to give a final 
concentration in the media of 100μM. The positive control was methyl β-cyclodextrin 
and the negative control contained only the same volume of Hanks solution. Cholesterol 
test solutions were made up in Hank’s balanced salt solutions with vortexing. All test 
solutions were made up freshly and brought to 37oC in a water bath immediately prior 
to treatment. All chemicals and media were purchased from Sigma Chemicals, UK 
except where specified. 
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2.3.8.1 PREPARATION OF ANTIBODIES 
Fluorescein isothiocyanate (FITC) has an absorption maximum at 495nm and an 
emission maximum at 525nm. It is commonly used as a fluorescent antibody labelling 
reagent in fluorescent immunobiology and fluorescent immunohistology. This labelling 
is possible due to the formation of a stable thiourea bond with free amino groups on 
the protein.  FITC-anti-Tubulin antibody was prepared using the Sigma Fluorotag kit  and 
monoclonal anti-α-Tubulin (mouse IgG1 isotype derived from the hybridoma AA13 
produced by the fusion of mouse myeloma cells and splenocytes taken from mice 
immunised with rat brain tubulin). It has cross reactivity to human tubulin, according to 
the manufacturer’s instructions. Briefly, 250µl of 0.1M carbonate-bicarbonate buffer 
solution (pH9.0) was added to 200µg of antibody. 1.0mg of FITC was reconstituted in 
2.0ml of the same buffer. 50µl of the FITC solution was added drop-wise to the antibody 
solution and protected from light. The reaction vessel was kept at room temperature 
for 2 hours with occasional shaking.  Following the conjugation the solution was 
pipetted onto the surface of a Sephadex G-25M 10ml column pre-hydrated with 10mM 
phosphate buffer 27mM KCl plus 138mM NaCl pH7.4. This phosphate buffer solution 
was used to elute the column and the first yellow band is collected (approximately 
2.5ml in total). The antibody was stored in amber at 4oC or used immediately.  
 
The second antibody used in the experiment was anti-Caveolin-1 that was purchased 
already linked to the cyanine dye Cy3 that has an absorption maximum at 550nm and 
an emission maximum at 570nm. 1.25ml of phosphate buffer solution was added to 
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1mg of lyophilised protein and the light-protected tube vortexed for 1 minute. It was 
used without further preparation.  
 
2.3.9 A FLUORESCENCE MICROPLATE BASED ASSAY FOR METASTASIS INDICATORS 
A number of methods that measure proteolysis caused by cancer cells have been 
developed. Many of these use quenched fluorescent (DQ) protein substrates wherein 
the fluorescent conjugate becomes more fluorescent when cleaved from the protein. 
For example, FITC-collagen and FITC-gelatin can be used to measure protease activity 
when included in the media since small, highly fluorescent areas underneath individual 
live cells, can be imaged . Indeed, super-saturated fluorescent conjugates are available 
from a number of biochemical suppliers for this purpose. In an adaptation of the 
method described by Sugiyama et al,  a FITC-quenched gelatin soft gel was prepared as 
follows. 
 
0.49g gelatin (bovine, type II, powdered) was dissolved in 10ml distilled water. 20mg 
fluorescein isothiocyanate was added and the tube vortexed briefly then kept at room 
temperature in the dark. After 1 hour 10ml acetone was added which produced a 
flocculation that was dispersed with a magnetic stirrer. The mixture was left in the dark 
for a further 24hrs after which time it was washed thoroughly with cold acetone and 
50mM Tris-HCl buffer. Finally 450mg was washed with 1.0% sodium hydrogen 
carbonate and dried under vacuum. It was then re-dissolved in warm (30oC DMEM) 
media containing 10% FBS and 250mg gelatin. At this point the liquid can be stored at 
4oC for up to 6 hours prior to use. When required the liquid is heated to 45oC and then 
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50µl is aliquoted into each of the 96 wells on the microplate using a sterile microfilter. 
Plates should be used as soon as they have reached 37oC. The gelatin containing media 
is a soft gel at 37oC.  
 
Approximately 50,000 cells in fresh complete media containing the test compounds was 
overlaid gently onto the gel surface. Each column of eight on the plate comprised a 
single treatment with the bottom (G & H) two rows having an additional dosage of 
cytochalisin B. This compound is a powerful anti-motility factor but does not kill the 
cells or prevent expression of proteases. It was hoped that the cytochalisin treatment 
would act as a positive control enabling the discrimination between motility effects and 
proteolysis effects within a single fluorescence plate based assay.  
 
2.3.10 CHOLESTEROL ASSAYS 
 
Cells exposed to different treatments and combinations of enzyme inhibitors were 
harvested. The crude cell pellet was lysed with water and mechanical disruption. These 
samples were then centrifuged to separate the entire cell membrane fraction and then 
both the supernatant (containing the solubilized cytoplasm) and the separated lipid 
fraction were then analysed for cholesterol and cholesterol esters using a highly 
sensitive fluorometric assay. The assay is based on an enzyme coupled reaction that 
detects hydrolysed esters and free cholesterol using cholesterol oxidase to produce 
hydrogen peroxide which is then detected using 10-acetyl-3,7-dihydrophenoxazine 
producing a highly fluorescent product, resorufin (Amundson and Zhou, 1999). 
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2.3.10.1 CELL TREATMENTS 
Cells were grown in 175ml culture flasks in the normal way. Treatments were 
introduced when the cells were seen to be at 70% confluence by sterile injection of a 
stock solution so that the final concentrations were as reported. Cells were left to grow 
at 37oC, 5% CO2 for a further 48hrs before harvesting with trypsin.  Each tube was 
centrifuged at 2500rpm for 3 minutes and the supernatant discarded. The tubes were 
then immediately re-suspended in 500µl distilled water containing 1mg/ml of Sigma 
protease inhibitor cocktail. The tubes were mixed vigorously in a Vortex mixer for 30 
seconds and then disrupted further by repeated aspirating using a small bore 
hypodermic needle. At this stage, the tubes were re-centrifuged to create a small pellet 
and the supernatant removed for later analysis. The material at the bottom of the tubes 
Cholesterol 
Ketone 
Cholesterol 
 
ADHP + 
 
HRP 
Resorufin 
H2O 
 
FIGURE 8:  DIAGRAM OF CHOLESTEROL ASSAY REACTIONS 
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was re-suspended in 500µl of distilled water containing 1.0% (v/v) Triton-X and 
sonicated for 30 seconds at maximum amplitude with the temperature outside the tube 
of 0-4oC. All samples were stored at -20oC except immediately prior to analyses.  
 
All reagent solutions were prepared in a phosphate buffer, pH7.4 containing 50mM 
NaCl and 5mM cholic acid. Cholesterol standard solutions were prepared by serial 
dilutions in ethanol. 50mg of powdered ADHP was prepared with 100µl dimethyl 
sulfoxide and 100µl of HPLC grade water. Both the oxidase and the esterase enzymes 
were prepared with 250µl of HPLC grade water. 50µl of the cholesterol detection 
cocktail was added to each of 96 wells containing 50µl each of the cell extracts (both 
supernatant and solubilized membrane fractions).  
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3 RESULTS AND DISCUSSION 
3.1.1  SYNTHESIS ROUTES TO PROADIFEN AND ITS CLOSE ANALOGUES  
For those molecules made by the author [see Table 4] the following describes the 
general approach and outcomes. 
STRUCTURE OF PROADIFEN 
O
N
O
Tail group
Carbonyl functionality
Head group
 
 
The synthesis of 2-(ethylamino)ethyl 2,2-diphenylvalerate (‘VL15’) and 2-
(diethylamino)ethyl 2,2-diphenylvalerate (Proadifen) were readily achieved from the 
common starting material diphenylacetic acid (1).  Treatment of 1 with two equivalents 
of butyl lithium led to the formation of the di-anionic species (2) which readily reacts 
with allyl bromide to give the alkylated product (3) after completion (Scheme 1). 
OH
O
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H
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O
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Phn-BuLi
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2) H
1 2 3  
SCHEME 1: ALKYLATION OF DIPHENYLACETIC ACID 
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Esterification was accomplished by the reaction of 3 with thionyl chloride to give the 
acid chloride 4, followed by stirring the crude acid chloride with the appropriate 
aminoalcohol for 12 hours (Scheme 2).  The final procedure requires hydrogenation 
over a palladium catalyst to reduce the double bond 5 and in the case of the mono-ethyl 
derivative, to remove the benzyl protecting group. 
 
 
SCHEME 2: ESTERIFICATION OF ALKYL DIPHENYLACETIC ACID 
 
3.1.1.1 PREPARATION OF 2,2-DIPHENYLPENT-4-ENOIC ACID 
A solution of n-butyl lithium in hexane (2.5M, 83ml) was added dropwise to a solution 
of diphenylacetic acid (20g, 94mmol) in tetrahydrofuran (200ml) cooled to -78°C by a 
dry ice-acetone bath.  The resultant solution was stirred for 1 hour before 
3-bromopropene (16.3ml, 188mmol) was added drop-wise.  The solution was stirred at 
-78°C for 1 hour and was then warmed to room temperature and stirred for 12 hours.  
Water (100ml), followed by dilute hydrochloric acid (2M, 100ml) was added to the 
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reaction mixture and the aqueous phase was extracted with diethyl ether (3×100ml).  
The combined ethereal extracts were dried with magnesium sulphate and the solvent 
removed in vacuo to give an off-white solid.  Re-crystallisation of the solid from ethanol 
gave 2,2-diphenylpent-4-enoic acid as colourless crystals (19.0g, 80%). 
 
3.1.1.2 PREPARATION OF N-BENZYL-N-ETHYLETHANOLAMINE 
A mixture of 2-(ethylamino)ethanol (20ml, 0.21mol), benzylbromide (24.4ml, 0.21mol), 
potassium carbonate (29.0g, 0.21mol) and dichloromethane (150ml) was heated to 
reflux for 15 hours.  Water (100ml) was added to the cooled reaction mixture followed 
by extraction with ether (3×100 ml).  The organic extracts were dried with magnesium 
sulphate and the solvent removed under reduced pressure to give the amine as a light 
brown oil.  Purification by distillation gave the compound as a colourless liquid (28.6g, 
76%). 
 
3.1.1.3 PREPARATION OF 2-(ETHYLAMINO)ETHYL 2,2-DIPHENYLVALERATE 
2,2-Diphenylpent-4-enoic acid (9.50g, 37.7mmol) was refluxed with thionyl chloride 
(20ml) for 8 hours after which the excess thionyl chloride was distilled off to give the 
crude acid chloride.  To this was added N-benzyl-N-ethylethanolamine (6.75g, 
37.7mmol) dissolved in pyridine (10ml) and DMF (10ml) and the mixture stirred at room 
temperature for 24 hours.  Water (100 ml) was added and the crude product was 
extracted with ether (3×50ml).  The organic extracts were dried (MgSO4) and the 
solvent removed under vacuum. The resultant product is dissolved in methanol (100ml), 
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10% palladium on carbon added and the mixture hydrogenated at 1 atmosphere of 
hydrogen for 15 hours.  The solution was filtered and the solvent removed under 
reduced pressure to give 2-(ethylamino)ethyl 2,2-diphenylvalerate (7.92g, 65%). 
 
3.1.1.4 PREPARATION OF 2-(DIETHYLAMINO)ETHYL 2,2-DIPHENYLVALERATE 
2,2-Diphenylpent-4-enoic acid (9.50g, 37.7mmol) was refluxed with thionyl chloride 
(20ml) for 8 hours after which the excess thionyl chloride was distilled off to give the 
crude acid chloride.  To this was added 2-(diethylamino)ethanol (4.42g, 37.7mmol) 
dissolved in pyridine (10ml) and DMF (10ml) and the mixture stirred at room 
temperature for 24 hours.  Water (100ml) was added and the crude product was 
extracted with ether (3×50ml).  The organic extracts were washed with water (3×50ml), 
dried with MgSO4 and the solvent removed under vacuum. 
 
The resultant product is dissolved in methanol (100ml), 10% palladium on carbon added 
and the mixture hydrogenated at 1 atmosphere of hydrogen for 15 hours.  The solution 
was filtered and the solvent removed under reduced pressure to give 
2-(diethylamino)ethyl 2,2-diphenylvalerate (9.10 g, 68%). 
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3.1.1.5 PREPARATION OF 2-(N,N-DIETHYLAMINO)ETHYL 2,2-DIPHENYLETHANOATE 
O N
O
OH
O
i)  SOCl2
ii)  HO
N
 
SCHEME 3: PREPARATION OF 2-(N,N-DIETHYLAMINO)ETHYL 2,2-DIPHENYLETHANOATE 
 
A mixture of 2,2-diphenylacetic acid (5.00g, 23.6mmol) and thionyl chloride (10ml) was 
heated to reflux for 1 hour before the excess thionyl chloride was removed by 
distillation.  A solution of 2-diethylaminoethanol (5.53g, 47.2mmol) in dichloromethane 
(10ml) and triethylamine (2ml) was added cautiously and the resultant mixture was 
stirred at room temperature for 2 hours.  The reaction mixture was diluted with 
dichloromethane (50ml) and washed with saturated sodium bicarbonate solution 
(3×20ml) and water (1×20ml).  The organic layer was dried (Na2CO3) and the solvent 
removed under reduced pressure to give the amine as a light brown liquid (6.30g, 86%). 
The hydrochloride salt of the above amine was readily prepared by passing dry HCl gas 
through an ethereal solution of the compound.  The resultant solid was collected by 
filtration and washed well with ether to give an off-white solid. 
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3.1.1.6 PREPARATION OF 2-(N,N-DIETHYLAMINO)ETHYL 2,2-DIPHENYLETHANOATE 
O N
O
OH
O
i)  SOCl2
ii)  HO
N
 
SCHEME 4: PREPARATION OF 2-(N,N-DIETHYLAMINO)ETHYL 2,2-DIPHENYLETHANOATE 
 
 
A mixture of 2,2-diphenylpropionic acid (5.00g, 22.1mmol) and thionyl chloride (10ml) 
was heated to reflux for 1 hour before the excess thionyl chloride was removed by 
distillation.  A solution of 2-diethylaminoethanol (5.17g, 44.2mmol) in dichloromethane 
(10ml) and triethylamine (2ml) was added cautiously and the resultant mixture was 
stirred at room temperature for 2 hours.  The reaction mixture was diluted with 
dichloromethane (50ml) and washed with saturated sodium bicarbonate solution 
(3×20ml) and water (1×20ml).  The organic layer was dried (Na2CO3) and the solvent 
removed under reduced pressure to give the amine as a light brown liquid (5.85g, 86%). 
 
The hydrochloride salts of the above were prepared by passing dry HCl gas through an 
ethereal solution of the compound.  The resultant solids were collected by filtration and 
washed well with diethyl ether to give an off white solid.  
NMR spectra of the key novel analogues are provided in Appendix 5. 
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3.2 LIVE CELL ASSAY RESULTS 
 
• Migration assay – The ability of cells to migrate is measured in Transwell™ cell culture 
chambers. An 8μm pore size filter is coated on one side with fibronectin. Cells are 
exposed to the test compounds and then seeded in serum starved media onto the 
untreated side of the filter.  Cells are left to migrate for 24hrs and cells on the lower 
surface are counted after crystal violet staining.  
 
• Invasion assay – again performed in Transwell™ chambers, this test employs Matrigel™ 
solution instead of the fibronectin.  Cells are treated as described above and left for 
96hrs before counting takes place. 
 
• Re-adhesion assay – Following exposure to the test drug, they are re-suspended in serum 
starved media and seeded in plates or wells coated in Matrigel™. They are left to adhere 
for 60 minutes. The media is removed and the cells washed. Adherent cells are then 
counted. 
 
• Resistance to detachment assay – Petri dishes or similar vials coated with poly-L-Lysine, 
fibronectin and collagen are seeded with the cells. The medium is exchanged after 2 
days for a serum free medium. The cells are exposed to the agent under investigation 
and incubated for a further 1 hour. The plates are then washed twice with a 0.008% 
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trypsin solution and agitated for 30 minutes. The trypsin solution is removed and the 
plates washed again and stained with sulforhodamine. The resistance to detachment is 
the mean absorbance of the treated plates divided by the control plates. 
 
In this study it was found that the above methodologies were unsuitable for use with 
these test agents. Treatment with the cholesterol synthesis inhibitors causes some of 
the cells to spontaneously detach from the substrate surface and float freely in the 
media. They then have the ability to re-attach in the cleared zones measured in the 
above assays. Several attempts were made to use these cleared zone assays but no 
reliable data could be extracted. One assay that performed according to the literature 
was the phagokinetic track assay but this, while an elegant technique, is difficult to 
convert into unequivocal data. It did however reveal a difference between the effects of 
Simvastatin and Proadifen which then led on to further experimental work.  
 
3.2.1 RESULTS OF PHAGOKINETIC ASSAY 
 
PLATE 1  EXAMPLE NEGATIVE CONTROLS  
PLATES 1-4 SHOW BRIGHTFIELD MICROSCOPY AT  X400 MAGNIFICATION OF MDA-MB-231 CELLS MOVING ACROSS A LAYER OF 
GOLD COLLOID. BLOCK ARROWS INDICATE THE TRACK OF DISPLACED PARTICLES AND THE FINE ARROWS INDICATE THE CELL.  
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PLATE 2 FLUPHENAZINE (10µM)  
IN THESE REPRESENTATIVE SLIDES CELLS ARE VISIBLE BUT THERE ARE NO TRACKS TO INDICATE MOVEMENT. 
 
PLATE 3 PROADIFEN  (10µM) E 
IN THESE REPRESENTATIVE SLIDES CELLS ARE CLEARLY VISIBLE BUT NO TRACKS ARE PRESENT. 
 
PLATE 4  SIMVASTATIN (8µM)  
THE FINAL SLIDE SHOWS WHAT MAY BE A TRACK BUT THE CELL IS NOT VISIBLE SUE TO LOSS OF ADHERENCE TO THE SURFACE. THIS 
WAS THE ONLY TRACK SEEN THROUGHOUT THE EXPERIMENT WITH SIMVASTATIN. 
 
THIS ASSAY DOES NOT LEND ITSELF TO EASY STATISTICAL ANALYSIS EVEN IF THE IMAGES ARE DIGITISED. IT IS ILLUSTRATIVE, 
HOWEVER, OF THE ABILITY OF MDA-MB-231 TO MOVE OVER A RELATIVELY SHORT TIME. DISTANCES OF UP TO 1MM IN 24 HOURS 
WERE RECORDED.  
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3.2.2 LIGHT MICROGRAPHS 
 
PLATE 5  CONTROL      PLATE 6 BIBB515 
PLATES 5 SHOWS A BRIGHTFIELD MICROGRAPH OF MDA-MB-231 CELLS GROWING IN DULBECCOS MEDIUM EAGLE MEDIUM (WITH 
NORMAL GROWTH SUPPLEMENTS) AT A MAGNIFICATION OF X400 24 HOURS AFTER SUB-CULTURE. PLATES 6-16 SHOW THE CELLS 
IN IDENTICAL CONDITIONS AFTER 24 HOURS WHERE THE MEDIUM CONTAINS PUTATIVE CHOLESTEROL INHIBITORS. BLOCK ARROWS 
INDICATE NORMAL INVADAPODIA WHILE FINE ARROWS INDICATE A MORE ROUNDED CELL MORPHOLOGY. NOTE THE CELL DENSITY 
IN THE TREATED CULTURES IS LIKELY TO BE A RESULT OF REDUCED PROLIFERATION OR DRUG TOXICITY. PLATE 6 SHOWS HEALTHY 
UNAFFECTED CELLS. 
 
PLATE 7  BIBX1382     PLATE 8  BM15766 
PLATES 7 & 8 SHOW CELLS DISPLAYING AN INTERMEDIATE RESPONSE WITH SOME CELLS APPEARING HEALTHY AND OTHERS 
CHANGING SHAPE. 
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PLATE 9  CLOTRIMAZOLE     PLATE 10 AY9944 (8µM) 
CLOTRIMAZOLE HAS NO VISIBLE EFFECTS ON THESE CELLS WHILE AY9944 TREATED CELLS APPEAR TO BE HEALTHY. 
 
PLATE 11 FUPHENAZINE    PLATE 12   LPC 
FLUPHENAZINE TREATED CELLS PROLIFERATED RAPIDLY EXCEEDING THE DENSITY OF THE CONTROL GROUPS. THE REASON FOR THIS 
IS UNKNOWN. LYSPHOSPHATIDYLCHOLINE, ALTHOUGH BELOW THE CONCENTRATIONS KNOWN TO CAUSE CELL MEMBRANE 
DAMAGE (OR LYSIS) WERE NOT VIGEROUS BUT SHOWED A NORMAL MORPHOLOGY. 
 
PLATE 13   MΒCD     PLATE 14  PRAVASTATIN 
TREATMENT WITH MΒCD CAUSED MANY CELLS TO EXHIBIT THE ROUNDED MORPHOLOGY BUT PROTRUSIONS ARE STILL VISIBLE ON 
SOME CELLS. PRAVASTATIN ALSO CAUSED A MIXED RESPONSE. 
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PLATE 15  PROADIFEN     PLATE 16   RO4871 
CELLS TREATED WITH PROADIFEN WERE VIABLE BUT MANY ROUNDED CELLS WITH AN ABSENCE OF INVADAPODIA ARE VISIBLE. 
RO4871 ABOLISHED ALL VISIBLE CELLULAR PROTRUSIONS. 
 
Optical microscopy of treated cultures revealed some variations in morphology 
dependent on treatment. All slides were taken at the same stage of the experiment. 
BIBX1382 produced lacklustre growth and rounded, poorly formed cell structures. 
BM15766, AY9944 and clotrimazole produced healthy looking cells, if less prolific 
cultures than the negative control. Fluphenazine treatment produced vigorous 
proliferation with healthy cells. No signs of cell lysis were observed in the LPC 
treatment. Proadifen seems to produce rounded cells with fewer cilia, flagella and 
invadapodia and the cultures share similarities to the Pravastatin treated cells. Actually, 
the statin produced a mixture of normal looking cells and cells which were more 
rounded and had fewer protrusions. 
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3.2.3 SCANNING ELECTRON MICROGRAPHS 
 
PLATES 17, 18  CONTROL (UNTREATED) MDA-MB-231 CELLS  
  
PLATES 19, 20  CONTROL (UNTREATED) MDA-MB-231 CELLS 
THESE ELECTRON MICROGRAPHS SHOW MDA-MB-231 CELLS WITH AND WITHOUT TREATMENT WITH CHOLESTEROL INHIBITORS AT 
VARIOUS MAGNIFICATIONS. VOLTAGE AND SCALE ARE PRINTED ON EACH SLIDE.  HEALTHY MDA-MB-231 CELLS DISPLAY MULTIPLE 
LARGE AND SMALL PROTRUSIONS THAT READILY VISIBLE UNDER THE ELECTRON MICROSCOPE. THESE RANGE FROM INVADAPODIA 
(BLOCK ARROWS) TO VERY SMALL CILIA (FINE ARROWS) VISIBLE CLEARLY ONLY UNDER HIGH (≥ X3000) MAGNIFICATION. 
 
92 
 
 
PLATES 21, 22  MDA-MB-231 CELLS TREATED WITH 0.8µM PRAVASTATIN FOR 24 HOURS. 
PRAVASTATIN REDUCES BOTH THE LARGER PROTRUSIONS AND SMALLER CILIA AND FLAGELLA STRUCTURES. SOME CELLS APPEAR 
ROUNDED WHILE OTHERS APPEAR FLATTENED. 
  
PLATES 23, 24   MDA-MB-231 CELLS TREATED WITH PROADIFEN AT 16 MM FOR 24 HOURS. 
PROADIFEN APPEARS TO LEAVE THE OVERALL CELL STRUCTURE INTACT WHILE ALL TRACES OF CILIA ARE ABOLISHED. 
  
PLATES 25, 26  MDA-MB-231 CELLS TREATED WITH METHYL Β-CYCLO DEXTRIN 0.00083% W/V FOR 24 HOURS 
MΒCD APPEARS TO LEAVE CELLS UNAFFECTED IN TERMS OF CELL MORPHOLOGY 
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PLATES 27, 28   MDA-MB-231 CELLS TREATED WITH AY9944 9.0µM FOR 24 HOURS (THESE CELLS ARE DEAD) 
EXPOSURE TO AY9944 FOR 24 HOURS LEFT ONLY CELL DEBRIS WITH A DISTINCTIVE CRENULATED SURFACE. 
 
SEM IMAGES CONFIRM THAT PROADIFEN INDUCES MORPHOLOGICAL CHANGES CHARACTERISED BY A ROUNDING OF THE CELL 
(ALMOST AS THOUGH IT WERE SWOLLEN BY A HYPERTONIC MEDIA: THE MEDIA WAS, HOWEVER, CHECKED FOR OSMOTIC 
BALANCE) AND POORLY DEFINED – IF NOT ABSENT – CILIA AND OTHER MICROTUBULE BASED STRUCTURES.  CILIA AND 
INVADAPODIA NOTICEABLE IN PLATE 17 AND 18, ARE ABSENT IN PLATE 23 AND ARE SCARCE IN PLATE 24. 
MΒCD HAS LITTLE IMPACT ON CELL MORPHOLOGY. AY9944 PRODUCED SOME DAMAGED, DEAD CELLS WITH A CRENULATED 
SURFACE AND SIGNS OF LYSES (PLATES 27 AND 28). MOST CELLS WERE NOT AS BADLY AFFECTED (SEE ALSO PLATE 10) SO THIS 
COULD BE AN ARTEFACT OF THE FIXATION PROCESS OR UNFORTUNATE SAMPLING.  
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3.2.4 TRANSMISSION ELECTRON MICROGRAPHS 
  
PLATES 29, 30  CONTROL (UNTREATED) MDA-MB-231 CELLS  
  
PLATES 31, 32 CONTROL (UNTREATED) MDA-MB-231 CELLS  
  
PLATES 33, 34   MDA-MB-231 CELLS TREATED WITH METHYL Β-CYCLO DEXTRIN 0.00083% W/V FOR 24 HOURS 
95 
 
  
PLATES 35, 36 MDA-MB-231 CELLS TREATED WITH METHYL Β-CYCLO DEXTRIN 0.00083% W/V FOR 24 HOURS 
  
PLATES 37, 38  MDA-MB-231 CELLS TREATED WITH PROADIFEN HCL. AT 16MM FOR 24 HOURS. 
 
TEM IMAGES OF SECTIONS THROUGH THE CELLS CONFIRM THAT MΒCD DOES NOT AFFECT CELL MORPHOLOGY (PLATES 33 AND 34) 
WHILE PROADIFEN TREATMENT COMPLETELY – AT LEAST IN THE SELECTED SAMPLE (PLATES 37 AND 38) – INHIBITS THE 
FORMATION OF ALL TYPES OF CILIA (FINE ARROWS).  THESE FINDINGS ARE ENTIRELY CONSISTENT WITH THE RESULTS OF THE DE-
ATTACHMENT ASSAYS SINCE THE ADHESIVE PROTEINS ARE LOCALISED IN THE PRIMARY IMMOTILE CILIA. CILIA ARE ALSO KNOWN 
TO BE SITES FOR SOME SIGNAL TRANSDUCTION. 
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3.2.5 RESULTS OF VIABILITY, ADHERENCE AND RE-ATTACHMENT ASSAYS 
THE FIGURES 9-10  SHOW MEAN OF TRIPLICATE VALUES FROM MORE THAN ONE EXPERIMENT.  ABSORBANCE (Y-AXIS) INCREASES 
WITH DECREASING ADHERENCE OR VIABILITY. ERROR BARS DENOTE ± STANDARD ERRORS AND * DENOTES STATISTICAL 
SIGNIFICANCE AT P<0.05 (ANNOVA TWO TAILED TEST FOR DIFFERENCE FROM THE CONTROL).  
 
 
FIGURE 9: VIABILITY AND RE-ADHERRANCE MDA-MB-231 CELLS TREATED WITH PROADIFEN TIME 0 HOUR 
 ABSORBANCE IS THE MEASURE OF CELL SURVIVAL OR ADHERENCE. PROGRESSIVELY INCREASING DOSES CAUSED SOME IMMEDIATE 
CHANGE TO ADHERENCE BUT THE DIFFERENCE IS SMALL. 
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FIGURE 10: VIABILITY AND RE-ATTACHMENT OF MDA-MB-231 CELLS FOLLOWING TREATMENT WITH PROADIFEN 1HOUR 
AFTER 1 HOUR THE TREATED CELLS HAVE DETACHED FROM THE PLATE REGARDLESS OF DOSE. THIS EFFECT IS SIGNIFICANT AT 
P<0.05. 
 
FIGURE 11: VIABILITY ASSAY MDA-MB-231 CELLS TREATED WITH PROADIFEN AND CHOLESTEROL 
CO-TREATMENT OF CELLS WITH PROADIFEN AND CHOLESTEROL SUGGEST LITTLE ADDITIVE OR SYNERGISTIC EFFECTS ON OVERALL 
VIABILITY OR ATTACHMENT.  
 
* * * 
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FIGURE 12: APOPTOSIS ASSAY MB231 CELLS TREATED WITH PROADIFEN TIME 0 HOUR 
IN THE FOLLOWING GRAPHS (11-19) THE Y-AXIS SHOWS THE ABSORBANCE OF CHROMOPHORES THAT MEASURE APOPTOSIS AND 
NECROSIS.   APOPTOSIS IS ONLY SIGNIFICANT AT THE HIGHEST DOSE OF PROADIFEN SUGGESTING THAT THE REDUCTION IN CELL 
ADHERENCE SEE IN FIGURE 10 IS REAL. 
 
 
 
FIGURE 13: APOPTOSIS ASSAY MB231 CELLS TREATED WITH PROADIFEN TIME 1 HOUR 
 
* 
 
 
* 
 
* 
 
 
* 
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FIGURE 14: APOPTOSIS ASSAY MB231 CELLS TREATED WITH PROADIFEN TIME 24 HOUR 
FIGURES 12 AND 13. EXPOSURE TIME DOES NOT APPEAR TO SIGNIFICANTLY ALTER THE LEVELS OF APOPTOSIS CAUSED BY 
PROADIFEN 
 
 
FIGURE 15: NECROSIS IN MDA-MB-231 CELLS TREATED WITH PROADIFEN TIME 0 HOURS 
THERE IS LITTLE DIFFERENCE BETWEEN THE TREATED AND CONTROL GROUPS IN TERMS OF NECROSIS. 
* 
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FIGURE 16: NECROSIS IN MDA-MB-231 CELLS TREATED WITH PROADIFEN TIME 1 HOURS 
THERE APPEARS TO BE A DOSE RESPONSE BUT THE DATA IS NOT SIGNIFICANT AT P<0.05. 
 
FIGURE 17: NECROSIS IN MDA-MB-231 CELLS TREATED WITH PROADIFEN TIME 24 HOURS 
FIGURES 15 AND 16. EXPOSURE TIME DOES NOT APPEAR TO SIGNIFICANTLY ALTER THE LEVELS OF NECROSIS CAUSED BY PROADIFEN 
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FIGURE 18: APOPTOSIS ASSAY IN MDA-MB-231 CELLS TREATED WITH PROADIFEN AND CHOLESTEROL 
CHOLESTEROL INDUCES APOPTOSIS WITHIN 1 HOUR OF SUB-CULTURE AND THIS RESULT IS SIGNIFICANT P<0.05. 
 
FIGURE 19: NECROSIS ASSAY IN MDA-MB-231 CELLS TREATED WITH PROADIFEN AND CHOLESTEROL 
NECROSIS WAS DETECTED IN BOTH TREATMENTS SUGGESTING THAT CHOLESTEROL CAUSES APOPTOSIS AND NECROSIS WHILE 
PROADIFEN DOES NOT. 
Proadifen reduces the ability of MDA-MB-231 cells to attach to the flask surface but no 
clear response is visible between 10µl 1mM and 50µl 1mM exposures at time zero. At 
* 
* 
* 
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1hr, the result is profound with only ~20% of the treated cells remaining attached. A 
dose-response profile is now apparent but not statistically (p<0.05) valid (see Figure 9). 
Proadifen appears to cause some limited apoptosis and this is not time dependant (see 
Figure 11). Necrosis was simultaneously measured and increased slightly over time, 
presumably following the trend of apoptosis already recorded (see Figure 15). 
 
Cell viability (along with apoptosis and necrosis) was measured to exclude the de-
attachment of dead cells caused by treatment toxicity. In fact, and in accordance with 
the proteomic analysis (apoptotic marker set), apoptosis was reduced in the treated 
groups in a dose and time dependant manner. Necrosis results were broadly in line with 
apoptosis as might be expected. Overall viability of cells exposed to Proadifen is 
reduced by ~15%. Likewise, 50µl 0.001%w/v cholesterol reduces overall viability by 10% 
and cholesterol appears to induce high rates of apoptosis and necrosis. It is interesting 
to note that both exogenous ceramide and cholesterol are known to induce apoptosis.  
 
Adhesion assays – specifically those involving cleared areas of substrate - were found to 
be very problematic. Several commercially available kits were evaluated and proved to 
be useless with these treatments and these cell lines. Proadifen rapidly induces de-
attachment and free floating cells are able to re-attach on cleared areas and proliferate. 
Anchorage dependence of mammalian cells decreases upon tumourogenicity (Shin et 
al., 1975).  
However, re-attachment of migrating cells is one of the final steps in successful 
metastasis. Oncogenesis overcomes the natural checkpoint of integrin mediated 
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attachment and is correlated to both activation of oncogenes and metastatic potential 
(Schwartz, 1997) Pozo and Schwartz showed that the growth regulatory pathways Rac, 
Erk and Ptdlns-3 kinase mediate anchorage independence (Del Pozo and Schwartz, 
2007). Rac is found in caveolae and is under the control of integrins (del Pozo et al., 
2000). 
 
The proteomic analysis confirmed that Proadifen decreased Rac and Erk so two 
experiments were devised to measure the re-attachment and sustained attachment 
post-passage of MDA-MB-231 and cell-cell aggregation of BJAB cells. It was anticipated 
that Proadifen would decrease attachment to the extracellular matrix (ECM) if caveolae 
based integrin signalling was reduced. The results of this experiment were intriguing: if 
Proadifen is introduced at time zero (that is, simultaneously with the cell suspension 
following trypsinisation and centrifugation) then a modest dose-dependant reduction in 
re-attachment was observed (Figure 9). However, introduction of Proadifen 1hr after 
seeding dramatically reduced the attachment (Figure 10). MDA-MB-231 cells in the 
media and conditions described typically take 4-6 hours to adhere.  
 
Exogenous cholesterol was also tested in the same way and significantly increased 
apoptosis (and necrosis) but did not impact attachment as recorded in the viability 
assay (Figure 17). The combination of Proadifen and cholesterol appears to mitigate the 
apoptosis-inducing effects of exogenous cholesterol. Again, necrosis closely tracked 
apoptosis.  
 
104 
 
 
3.2.6 RESULTS OF 656 PROTEIN ARRAY SEGREGATED BY PROTEIN FUNCTION 
THE FIGURES BELOW SHOW MEAN OF TRIPLICATE VALUES FROM MORE THAN ONE EXPERIMENT. ERROR BARS DENOTE ± 
STANDARD ERRORS AND * DENOTES STATISTICAL SIGNIFICANCE AT P<0.05 (ANNOVA TWO TAILED TEST FOR DIFFERENCE FROM THE 
CONTROL). THE DIRECT OUTPUT OF THE SCANNER (FIGURE 20) REVEALS THE INTENSITY OF THE ANTIBODY-CONJUGATION AND IS A 
VISUAL CHECK THAT THERE WAS SUFFICIENT PROTEIN PRESENT FOR THE EXPERIMENT TO BE VALID. 
BJAB control sample     BJAB treated sample 
 
 
 
 
 
 
 
MDA-MB-231 control sample   MDA-MB-231 treated sample 
 
 
 
 
 
 
 
FIGURE 20: SPOT INTENSITIES 
IT IS CLEAR FROM THESE IMAGES THAT SPOT INTENSITIES WERE GENERALLY LOWER IN THE TREATED GROUPS BUT TO BETTER 
UNDERSTAND THE DATA IS PRESENTED AS SPREAD SHEET OF SPOT INTENSITIES FOR EACH OF THE 656 ANTIBODIES WITH THE 
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COEFFICIENT OF VARIATION FOR THE MEAN OF THE REPLICATES. THESE DATA WERE THEN PLOTTED USING EXCEL SOFTWARE IN 
GROUPS BY PROTEIN FUNCTION.  
3.2.6.1  RESULTS IN MDA-MB-231 
THE FOLLOWING FIGURES SHOW THE CHANGE IN PROTEIN EXPRESSION (Y-AXIS)  AS A PERCENTAGE CHANGE FROM THE CONTROL 
DATA. THE ERROR BARS INDICATE ±SE AND THE STANDARD ERROR IS CALCULATED FROM THE COEFFICIENT OF VARIATION OF THE 
SPOT INTENSITIES. THE DATA HAS BEEN SEGREGATED ON THE BASIS OF PROTEIN FUNCTION DIVIDED INTO ANGIOGENESIS, 
IMMUNE RESPONSE MARKERS, PROLIFERATION MARKERS AND APOPTOTIC MARKERS. THE ASSIGNMENT OF THE PROTEINS INTO 
THESE SUB-GROUPS IS BASED ON COMMERCIAL ARRAYS SUPPLIED BY SIGMA-ALDRICH FOR THESE PARTICULAR MARKER GROUPS.. 
 
 
 
FIGURE 21: EFFECTS OF AY9944 ON APOPTOTIC MARKERS IN PROTEIN ASSAY 
ALL APOPTOTIC MARKERS ARE REDUCED EXCEPT FOR FAS-LIGAND WHICH IS UP-REGULATED. FAS-LIGAND IS A TRANSMEMBRANE 
PROTEIN THAT IS UPSTREAM IN THE DISC CASCADE TO CASPASES 2,3 AND 8. 
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FIGURE 22: EFFECTS OF AY9944 ON ANGIOGENESIS MARKERS IN PROTEIN ASSAY 
THE Δ-7 REDUCTASE INHIBITOR CAUSES A REDUCTION IN ALL THE MARKER PROTEINS FOR ANGIOGENESIS. 
 
FIGURE 23:  EFFECTS OF AY9944 ON IMMUNE RESPONSE MARKERS IN PROTEIN ASSAY  
INTERLEUKIN-3 RESULT HAS A HIGH SE. IL-3 NORMALLY STIMULATES PROLIFERATION OF MYELOID AND MYELOID PROGENITOR 
CELLS. 
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FIGURE 24: EFFECTS OF AY9944 ON PROLIFERATION MARKERS IN PROTEIN ASSAY 
 
FIGURE 25: EFFECTS OF PRAVASTATIN ON APOPTOTIC MARKERS IN PROTEIN ASSAY 
THIS IS A SIMILAR PATTERN OF RESPONSE TO THAT SEEN WITH AY9944 TREATMENT WHERE THERE IS ALSO A SIGNIFICANT 
INCREASE IN EXPRESSION OF FAS-LIGAND 
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FIGURE 26: EFFECTS OF PRAVASTATIN  ON ANGIOGENESIS MARKERS IN PROTEIN ASSAY 
 
FIGURE 27: EFFECTS OF PRAVASTATIN ON IMMUNE RESPONSE MARKERS IN PROTEIN ASSAY 
INTERLEUKIN-3 IS AGAIN EXCEPTIONAL IN THIS RESULT, PERHAPS SIMILAR TO THE AY9944 RESULT. 
109 
 
 
FIGURE 28:  EFFECTS OF PRAVASTATIN ON PROLIFERATION MARKERS IN PROTEIN ASSAY 
A SIGNIFICANT DOWN-REGULATION OF THESE MARKER PROTEINS IS EVIDENT. 
 
FIGURE 29: EFFECTS OF PROADIFEN ON APOPTOTIC MARKERS IN PROTEIN ASSAY 
PROADIFEN RESULTED IN NO UP-REGULATION OF ANY OF THE SELECTED MARKERS. 
110 
 
 
FIGURE 30: EFFECTS OF PROADIFEN ON ANGIOGENESIS MARKERS IN PROTEIN ASSAY 
A SIGNIFICANT DOWN-REGULATION OF THESE MARKER PROTEINS IS EVIDENT. 
 
 
FIGURE 31: EFFECTS OF PROADIFEN ON IMMUNE RESPONSE MARKERS IN PROTEIN ASSAY 
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FIGURE 32: EFFECTS OF PROADIFEN ON PROLIFERATION MARKERS IN PROTEIN ASSAY 
A SIGNIFICANT DOWN-REGULATION OF THESE MARKER PROTEINS IS EVIDENT. 
 
112 
 
Comparative Effect of Proadifen on MDA-MB-231 and BJAB cells 
 
FIGURE 33: COMPARISON OF EFFECTS OF PROADIFEN ON APOPTOSIS MARKERS IN MDA-MB-231 AND BJAB CELLS 
BOTH CELL LINES RESPOND IN A SIMILAR MANNER FOR THIS SUB-SET OF PROTEINS WITH ALL BEING DOWN-REGULATED. 
 
FIGURE 34: COMPARISON OF EFFECTS OF PROADIFEN ON ANGIOGENESIS MARKERS IN MDA-MB-231 AND BJAB CELLS 
GROWTH FACTORS ARE DOWN REGULATED IN BOTH CELL LINES BUT ANG-1 IS UPREGULATED IN BJAB. 
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FIGURE 35: COMPARISON OF EFFECTS OF PROADIFEN ON IMMUNE RESPONSE MARKERS IN MDA-MB-231 AND BJAB CELLS 
MARKER PROTEINS THAT ARE MOST DOWN-REGULATED ARE COMMON TO BOTH CELL LINES. 
 
FIGURE 36: COMPARISON OF EFFECTS OF PROADIFEN ON PROLIFERATION MARKERS IN MDA-MB-231 AND BJAB CELLS 
VIMENTIN EXPRESSION IS DIFFERENTLY AFFECTED BY THE TREATMENT IN BJAB CELLS. VIMENTIN MAY NOT BE A SUITABLE 
INDICATOR FOR PROLIFERATION IN NON-ADHERENT CELLS. 
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FIGURE 37: MDA-MB-231 CELLS SHOW GENERAL DOWN-REGULATION OF PROTEINS AFTER TREATMENT WITH PROADIFEN 
 
BOTH MDA-MB-231 AND CALU-1 CELL LINES RESPONDED TO THE TREATMENT BY DOWN-REGULATING PROTEINS. IN THE CASE OF 
MDA-MB-231 CELLS, 294 PROTEINS WERE DOWN REGULATED COMPARED WITH 350 THAT WERE UP-REGULATED OR UNCHANGED.  
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TABLE 6: SUMMARY OF IMPACTS ON PROTEIN  EXPRESSION IN MDA-MB-231 CELLS TREATED WITH STATIN, PROADIFEN AND AY9944 
This table shows the three treatments of MDA-MB-231 where all the proteins are considered and the 24 proteins most impacted in a positive direction are 
ranked.  Proteins that appear in more than one list are shaded. 
Treatment = AY9944 % Change over control Treatment = Pravastatin % Change over control Treatment = Proadifen High dose % Change over control 
Integrin beta5 313% Integrin beta5 287% Caspase 8 (FLICE)  0% 
Histone H1  58% Histone H1  169% Thomsen-Friedenreich Antigen  -5% 
Fas-ligand 54% Vinculin  95% Heat Shock Protein 90a/hsp86  -7% 
TGF beta 3 43% Fas-ligand 77% Hepatic Nuclear Factor-3B  -9% 
HPV 16-E7  42% TGF beta 3 67% Catenin alpha  -10% 
Vinculin  34% S100A6  63% Cystic Fibrosis Transmembrane Regulator  -11% 
S100A6  19% HPV 16-E7  48% Phosphotyrosine  -14% 
CD57  18% TGF-beta 2 28% PSCA -14% 
Epithelial Membrane Antigen (EMA / CA15-3 / MUC-1)  14% CD57  24% IL-6 -14% 
CD94 12% IL-3 22% CD105  -14% 
Retinoic Acid Receptor (b)  5% Epithelial Membrane Antigen (EMA / CA15-3 / MUC-
1)  
20% Alkaline Phosphatase (AP)  -15% 
Human Sodium Iodide Symporter (hNIS) 1% Superoxide Dismutase 16% B-cell Linker Protein (BLNK)  -15% 
Bovine Serum Albumin  0% Apolipoprotein D 15% Insulin Receptor  -17% 
TGF-beta 2 0% Retinoic Acid Receptor (b)  14% Hepatocyte -17% 
Laminin B2/g1  -1% ER Ca+2 ATPase2 14% Caspase 3  -17% 
ER Ca+2 ATPase2 -2% CD94 12% Synaptophysin  -18% 
Amyloid A -4% Human Sodium Iodide Symporter (hNIS) 10% Negative Control for Mouse IgG2a  -18% 
IL-3 -5% Laminin B2/g1  9% EMA/CA15-3/MUC-1  -19% 
Superoxide Dismutase -9% Heregulin  4% Heat Shock Protein 27/hsp27  -19% 
Surfactant Protein A -9% Glicentin 4% HDAC1 -19% 
CITED1 -9% Surfactant Protein A 1% b-2-Microglobulin  -19% 
Ret Oncoprotein -11% Bovine Serum Albumin  0% Tyrosinase  -20% 
Apolipoprotein D -12% Amyloid A 0% Estradiol  -20% 
Glicentin -13% Ret Oncoprotein -2% DcR2 / TRAIL-R4 / TRUNDD  -20% 
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3.2.7 DISCUSSION OF PROTEIN ASSAYS (ANTIBODY ARRAY) 
To better assess the effects of the treatments, a small number of proteins (33) of the 
656 assayed were isolated from the data according to their role in cancer. According to 
the detailed descriptions provided by a manufacturer of similar protein array (Sigma-
Aldrich Ltd, UK), they were segregated by functional implication - immune response, 
angiogenesis proteins, proteins involved in proliferation and those involved in 
apoptosis. The effects on cancer of their up/down regulation is specific to the proteins 
so that not all down-regulation of proliferation markers is desirable outcome nor is all 
up-regulation of apoptotic markers. They do however provide a manageable data set.  
 
 Table 6: Summary of impacts on protein  expression in MDA-MB-231 cells treated with 
statin, Proadifen and AY9944 reveals that AY9944 and statin treatments share many of 
the most affected proteins while the Proadifen treatment shares none with the other 
treatments. This is quite suggestive and it is tempting to theorize that the effects of 
Proadifen upon the proteome are caused by a different mechanism to those seen in the 
cells treated with other types of cholesterol inhibitor. It is most likely that the statin and 
the Δ-7 reductase inhibitor leave the isoprenoid branch of the mevalonate pathway 
unaffected and that these positive shifts in protein expression are the response to 
interference with this important pathway. 
 
Li et al (Li Y., 2010) compared the proteomics of benign and malignant human 
osteosarcomas using 2-D gel electrophoresis and Western blotting to compare the 
expression levels of proteins. They found 30 alterations in the malignant cells using 
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these techniques of which 18 were identified and of these 12 were up-regulated and 6 
down-regulated. Their results suggested that vimentin and tubulin were of special 
importance to the propensity of the cells to metastasize. These two cytoskeleton 
proteins work together to form and stabilize microtubules that are involved in cell-cell 
interaction and reattachment processes. It is also known that destabilizing actin fibres 
and microtubules with drugs prevents reattachment of circulating colon carcinoma 
(Korb et al., 2004) and so reduce the cancer’s ability to successfully spread. There is also 
evidence that elevated levels of tubulin in patients with breast cancer are positively 
correlated with poor prognosis (Mialhe et al., 2001).  
AY9944 and Pravastatin caused very significant reduction in these proteins – nearly 
100% (Figure 24) – while Proadifen reduced tubulin and vimentin by 21% and 59% 
respectively (Figure 36).  
 
Two partial cancer related signalling pathways can be examined using the 100uM 
Proadifen treatments of -MDA-MB-231 and BJAB cells proteomic data:  
APOPTOTIC PATHWAY AT CHOLESTEROL RICH RAFT, LEADING TO CELL DEATH 
 
Signal pathway  Fas  FASL    Ezrin  FAS-DISC 
Change % post treatment MDA-MB-231 -   -43 -12 -44  
Change % post treatment BJAB - -27 -19 -19 
TABLE 7: EXTRACTION OF PROTEIN DATA TO ONE APOPTOTIC PATHWAY 
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PROLIFERATION PATHWAY BASED AT CHOLESTEROL RICH RAFT: 
 
Signal pathway  EGF  EGFR Grb2  Ras  Raf   MEK    Erk  Elk-1  
Change % post treatment MDA-MB-231 -- -53 -57 -87 -87 -49  -56 - 
Change % post treatment BJAB -  -35 -50 -35 -50  -35 -21 - 
TABLE 8: EXTRACTION OF PROTEIN DATA TO ONE PROLIFERATION PATHWAY 
- Indicates not assayed 
 
The treatment affected these pathways in the two cell lines in the same direction 
(down) but to varying degrees. Ezrin (known to be associated with rafts, Table 12) was 
the only exception and showed a slightly larger decrease in the BJAB assay. 
A high dose of Δ-7 reductase inhibitor (A9944) appears to significantly reduce the 
expression of all but one of the proteins in the marker selection. This exception is Fas-
ligand which promotes apoptosis, although the proteins downstream of this apoptotic 
pathway are, in fact, all down-regulated. A reduction of Δ-7 should theoretically lead to 
the accumulation of 5,7,24-cholesatrien-3β-ol, 4,4-dimethylcholesta-8(9)-1,4-dien-3b-ol 
and 7-dehydrocholesterol. In the presence of a Δ-24 inhibitor the route to 7-
dehydrocholesterol is blocked. 
 
Statin treatment caused a very similar effect in the protein marker set, except that 
there was a 22% rise in interleukin-3 cytokine. IL-3 stimulates the immune response by 
provoking the differentiation of pluripotent stem cells into lymphoid progenitor cells. 
Statin treatment resulted in a generally greater down-regulation of apoptotic markers 
compared with Proadifen or AY9944, but this is not unexpected given that statins 
truncate the cholesterol pathway at a very early stage of the mevalonate-cholesterol 
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pathway, and isoprenylation of the marker proteins is also reduced.  This means that it 
is possible there is little feedstock lanosterol for the ultimate steps of cholesterol 
synthesis and it is known that the enzyme-substrate affinities of the transferases 
involved in prenylation are higher than those involved in sterol synthesis (Goldstein and 
Brown, 1990). Total inhibition of synthesis of cholesterol by statins is unlikely. 
 
There were some marked differences in response to Proadifen in BJAB cells compared 
to MDA-MB-231 cells. Notably, the cytokines Ang-1 and Ang-2, respectively an 
angiogenesis promoter and inhibitor, were affected differently in the two lines by 
Proadifen treatment. Ang-1 expression was increased in BJAB cells but reduced in MDA-
MB-231 cells. Generally, however, BJAB cells followed the same pattern as MDA-MB-
231 cells but with a much reduced response. When the entire data set was ranked by 
impact for the three treatments in MDA-MB-231 cells there was a very clear correlation 
between AY9944 and statin treatments in terms of the proteins most affected. 
Proadifen, however, shared none of the top 24 most affected proteins compared to 
AY9944 (18) and statin (20) (see table 4). 
 
This does suggest that Δ-24 reductase inhibition – as opposed to Δ-7 reductase 
inhibition - causes a very different response in terms of protein profile. It seems possible 
that the extent and nature of the protein regulation is correlated to whatever 
cholesterol intermediate is the ultimate compound in the synthetic pathway. That is to 
say, AY9944 may reduce the overall amount of cholesterol in the membrane through a 
build-up 7-Dehydrocholesterol – a compound very closely related to cholesterol. It is 
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possible that this sterol can form rafts whereas other intermediates cannot. The build-
up of dehydrocholesterol by AY9944 and the reduction of mevalonate feedstock by 
statin, appears to cause 12 of 21 proteins in the marker selection to be up-regulated 
respectively, whereas no proteins were up-regulated in the Proadifen treatments. This 
effect on the marker group by Proadifen is not reflected in the entire data set where for 
Proadifen almost half of the responding proteins are up-regulated. This is a clear 
distinction in the impact of Proadifen compared with the Δ-7 reductase inhibitors. 
Alternatively, one possible hypothesis could be that AY9944 and the statins cause a 
reduction in the number of viable membrane rafts while Proadifen alters the nature of 
those rafts. It is conceivable that cholesterol-rich rafts are reduced in number by both 
sorts of inhibitor but that caveolae are principally affected by the Proadifen.  Perhaps 
rafts can assemble from lanosterol and desmosterol but caveolae cannot. There is 
evidence that desmosterol cannot replace cholesterol to form functional rafts (Vainio et 
al., 2006). It is thus more likely that the organisation of caveolae takes precedence to 
the formation of cholesterol-rich rafts: the affinity of cholesterol with Cav-1 is 
conceivably higher than the affinity of cholesterol with itself or with sphingosines. 
 
In an earlier study, using antisense oligonucleotide DNA probes, Slaton et al (Slaton et 
al., 2001) determined that the expression levels of vascular endothelial growth factor, 
IL-8 and MMP-2 and -9 were significantly higher in metastatic renal cell carcinoma 
(RCC). All three treatments caused IL-8 to be reduced. In particular they identified the 
ratio of the surface glycoprotein E-cadherin to MMP-9 as a significant predictor of 
metastatic potential in RCC. Other reports also indicate a predictive value to the 
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expression levels of E-cadherin (Yasui W., 1991), (Buehler H., 2001) which is known to 
mediate cell-cell adherence and re-attachment (Takeichi, 1991). Integrin-controlled Rac 
activation signalling is another positively correlated factor in metastasis (McLean et al., 
2005) and Rac and Ras binding is known to be localized in cholesterol rafts (Guan, 2004), 
(Del Pozo and Schwartz, 2007) and internalized in caveolae in a process triggered by 
GM1, at least in detached cells. The levels of integrin are dependent on the cells 
anchorage and determine the internalization of receptors or the activation of down-
stream signals involved in cancer promotion and metastasis.  
 
Given that expression levels of vimentin, tubulin, IL-8, MMP-2, E-cadherin, integrin and 
Rac are positively correlated to proliferation it seems reasonable to assume that a 
reduction in these proteins would result in a reduction in proliferation.  
 
In general BJAB and MDA-MB-231 cells responded in a similar manner to Proadifen 
treatment with BJAB cells showing a reduced response (Figure 35). There are, however, 
three clear exceptions: the pro-inflammatory IL-2 and IL-2 and Angiopoietin-1 are each 
up-regulated in BJAB but down-regulated in MDA-MB-231. The reason for this is 
unclear.   
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3.3 RESULTS OF GENE EXPRESSION ASSAYS 
Note: the raw dataset is available at: :   WWW://WWW.NCBI.NLM.NIH.GOV/GEO/ and has the 
accession number GSE47463. 
3.3.1.1 MDA-MB-231 GENE EXPRESSION  
The statistical significance threshold chosen for functional enrichment analyses was 
adjusted to p<0.01. Functional enrichment analyses were undertaken for each 
comparison that had loci significant at this threshold. Up- and down-regulated loci were 
assessed separately.  
 
An overview of the underlying biological changes occurring within each comparison can 
be obtained by functional enrichment analysis. This was performed from two 
perspectives, namely KEGG pathway membership and Gene Ontology (GO) terms. The 
level of statistical significance for functional analysis would normally be chosen to be 
the most stringent level at which 1% of the array features were, on average, significant 
(which would have been adjusted p<0.0001). In this instance, as the number of 
significant genes across the 15 comparisons was quite skewed, the significance 
threshold was manually chosen to be adjusted p<0.01. 
 
3.3.1.2 KEGG PATHWAYS 
Probesets on the array may have been annotated as being a member of a KEGG 
pathway (www.kegg.jp).  Although there is always a degree of overlap between 
functional annotations from different sources, each set has information/applications 
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not available in the others, and thus it is generally beneficial to consider more than one. 
Significant genes (adjusted p<0.01) from each comparison were analysed for 
enrichment of KEGG pathway membership using a hypergeometric test. Enrichment (p < 
0.05) was assessed for up-regulated and down-regulated genes separately. 
 
3.3.1.3 GO TERMS 
As described at www.geneontology.org, the Gene Ontology (GO) project is a 
collaborative effort to address the need for consistent descriptions of gene products in 
different databases. The GO project has developed three structured controlled 
vocabularies (ontologies) that describe gene products in terms of their associated 
biological processes, cellular components and molecular functions in a species-
independent manner. The use of GO terms by collaborating databases facilitates 
uniform queries across them. The controlled vocabularies are structured so that they 
can be queried at different levels: for example, you can use GO to find all the gene 
products in the human genome that are involved in signal transduction, or you can 
zoom in on all the receptor tyrosine kinases. It should be noted that not all GO terms 
assigned to a given gene are manually attached; many are IEA, i.e. inferred from 
electronic annotation. Although rigorous thresholds are typically applied before 
assignment, the caveat remains. Probesets on the array may have been annotated with 
GO terms from any or all of the three ontologies. Within any grouping of genes, chosen 
on any given criterion (e.g. statistical significance), one can assess, using a 
hypergeometric test, whether any of the GO terms attached to the chosen genes are 
over-represented relative to the "universe" of genes, and hence associated terms, that 
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are present on the array. Significant genes (adjusted p<0.01) from each comparison 
were analysed for enrichment of GO terms across all three GO ontologies using a 
hypergeometric test. Enrichment (p < 0.001) was assessed for up-regulated and down-
regulated genes separately. 
 
THE FOLLOWING GRAPHS (FIGURES 38 TO 52) ARE VOLCANO PLOTS WHERE THE LOG2 FOLD CHANGE IN GENE EXPRESSION IS 
PLOTTED AGAINST THE SIGNIFICANCE. THE X-AXIS IS THE LOG2 FOLD CHANGE IN GENE EXPRESSION WHILE THE Y-AXIS SHOWS THE –
LOG10 ADJUSTED P VALUE. IN EACH CASE, THE TREATMENTS ARE FIRST COMPARED WITH THE NEGATIVE CONTROL AND THEN, IN 
TURN, WITH EACH OTHER. THIS ENABLES VERY EASY COMPARISONS BETWEEN TREATMENTS AS TO THEIR OVERALL EFFECTS ON 
GENE EXPRESSION. THE AREAS OF GREATEST INTEREST ARE THE UPPER RIGHT AND LEFT QUADRANTS SINCE THESE ARE THE MOST 
SIGNIFICANT AND MOST AFFECTED GENES THAT HAVE BEEN UP- OR DOWN- REGULATED RESPECTIVELY. CELLS WERE EXPOSED TO 
THE TREATMENTS FOR 24 HOURS PRIOR TO RNA EXTRACTION. 
 
FIGURE 38: VOLCANO PLOT PROADFIEN (10µM) RELATIVE TO CONTROL (MDA-MB-231) 
PROADIFEN CAUSES A MIXTURE OF UP- AND DOWN- GENE REGULATIONS, MANY OF WHICH ARE SIGNIFICANT. 
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FIGURE 39: VOLCANO PLOT PRAVASTATIN (8.0µM) RELATIVE TO CONTROL (MDA-MB-231) 
THE STATIN CAUSES MAINLY DOWN-REGULATIONS. THIS IS REFLECTED IN GENE DATA ISOLATED FOR INVOLVEMENT IN THE 
MEVALONATE PATHWAY (SEE TABLE 10) 
 
FIGURE 40: VOLCANO PLOT MΒCD (0.0008% W/V)  RELATIVE TO CONTROL (MDA-MB-231) 
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FIGURE 41 VOLCANO PLOT LPC (100µM) RELATIVE TO CONTROL (MDA-MB-231) 
LPC CAUSED A WIDESCALE DISRUPTION TO NORMAL GENE EXPRESSION WITH BOTH UP AND DOWN REGULATIONS THAT ARE LARGE 
IN SIZE AND HIGHLY SIGNIFICANT. THIS MAY BE DUE TO THE FLUIDIZING EFFECTS OF THE MOLECULE WHEN IT INTERDIGITATES 
WITH THE MEMBRANE CAUSING SIGNAL PROTEINS TO LOSE THEIR ANCHORAGE IN RAFTS AND OTHER MICRODOMAINS. 
 
FIGURE 42: VOLCANO PLOT FLUPHENAZINE (100µM) RELATIVE TO CONTROL (MDA-MB-231) 
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LIKE LPC, FLUPHENAZINE IS ALSO KNOWN TO BE A MEMBRANE FLUIDIZING AGENT AND THE RESPONSE IN TERMS OF GENE 
EXPRESSION IS PROFOUND.  
 
FIGURE 43: VOLCANO PLOT PROADIFEN (10µM) RELATIVE TO PRAVASTATIN 8.0µM  (MDA-MB-231) 
 
FIGURE 44: VOLCANO PLOT PROADIFEN (10µM) RELATIVE TO MΒCD 0.0008% W/V (MDA-MB-231) 
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FIGURE 45: VOLCANO PLOT PROADIFEN (10µM) RELATIVE TO LPC (100µM)  (MDA-MB-231)  
 
 
FIGURE 46: VOLCANO PLOT PROADIFEN (10µM) RELATIVE TO FLUPHENAZINE  (100µM) (MDA-MB-231) 
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FIGURE 47: VOLCANO PLOT PRAVASTATIN 8.0µM RELATIVE TO MΒCD 0.0008% W/V (MDA-MB-231) 
FIGURE 47 SUGGESTS THAT THERE IS ALMOST NO DIFFERENCE (IN TERMS OF GENE EXPRESSION) BETWEEN THESE TWO 
TREATMENTS AND CONFIRMS THE EQUIVALENCE OF A STATIN AND CHOLESTEROL SEQUESTERING DRUG. IT SUGGESTS ALSO THAT 
THE REMOVAL OF CHOLESTEROL FROM THE CELL MEMBRANE IS WHAT THEN CAUSES CHANGES TO GENE EXPRESSION RATHER 
THAN SOME DIRECT EFFECT OF THE STATIN.  
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FIGURE 48: VOLVANO PLOT PRAVASTATIN 8.0µM RELATIVE TO LPC 100µM (MDA-MB-231) 
THERE IS A CLEAR DIFFERENCE IN EFFECT OF THESE TWO TREATMENTS.  
 
FIGURE 49: VOLCANO PLOT PRAVASTATIN 8.0µM RELATIVE TO FLUPHENAZINE 100µM (MDA-MB-231) 
THERE IS A CLEAR DIFFERENCE IN EFFECT OF THESE TWO TREATMENTS.  
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FIGURE 50: VOLCANO PLOT MΒCD 0.0008% W/V  RELATIVE TO LPC 100µM (MDA-MB-231) 
THERE IS A CLEAR DIFFERENCE IN EFFECT OF THESE TWO TREATMENTS SUGGESTING THAT REMOVAL OF CHOLESTEROL IS NOT 
EQUIVALENT TO INCREASING MEMBRANE FLUIDITY/POROSITY. THIS DESPITE THE FACT THAT CHOLESTEROL IS THOUGHT TO BE A 
REGULATOR OF MEMBRANE RIGIDITY. 
 
132 
 
 
FIGURE 51: VOLCANO PLOT MΒCD (0.0008% W/V)  RELATIVE TO FLUPHENAZINE (100µM) (MDA-MB-231) 
THERE IS A CLEAR DIFFERENCE IN EFFECT OF THESE TWO TREATMENTS.  
 
FIGURE 52: VOLCANO PLOT LPC (100µ) RELATIVE TO FLUPHENAZINE (100µM)  (MDA-MB-231) 
THESE TREATMENTS HAVE MATCHING PATTERNS ENTIRELY WITHIN ±2 LOG2 FC INDICATING VERY SIMILAR EFFECTS ON GENE 
EXPRESSION. 
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It is noteworthy that the response of the cell to LPC and Fluphenazine is very similar  
suggesting a similar mode of action.  
KEGG PATHWAY ENRICHMENT IN MDA-MB-231 CELLS  
Ribosome pathway was strongly up-regulated with Pravastatin and MΒCD versus either 
LPC or Fluphenazine. Spliceosome, cell cycle and pyruvate metabolism were also up-
regulated in these comparisons. Steroid biosynthesis, lysosome, terpenoid backbone 
biosynthesis and metabolic pathways were up-regulated with Proadifen versus control, 
Pravastatin or MΒCD. p53 signalling pathway was down-regulated by Proadifen and 
both Pravastatin or MΒCD. Cytokine-cytokine receptor interaction and NOD-like 
receptor signalling pathways were down-regulated with MΒCD, Proadifen and 
Pravastatin versus control. 
 
 
mTOR signalling, lysine degradation and chronic myeloid leukaemia pathways were 
down-regulated between Pravastatin and either MΒCD or Fluphenazine. Protein 
binding pathway was over-represented in all comparisons except for Proadifen versus 
control, Pravastatin or MΒCD, which had sterol and cholesterol biosynthesis process 
pathways in common. Cytokine activity was down-regulated with Pravastatin, MΒCD 
and Proadifen versus control. 
It is significant that the four loci with the greatest fold change are all associated with 
cancer:  
NUPR1 (Nuclear protein 1) is up-regulated in metastatic cancer and plays a key role in 
malignant breast [and other] cancers, protecting them from apoptosis (Chowdhury et 
al., 2009). Both isoforms are actually enhanced by Pravastatin, MβCD and Proadifen, 
with the latter having the greatest impact.  
 
GDF15 (Growth Differentiation Factor) codes for a cardioprotective protein that 
regulates inflammatory and apoptotic pathways (Ago and Sadoshima, 2006).These are 
all overwhelmingly increased with Proadifen having the greatest impact. CTGF 
(Connective Tissue Growth Factor) up-regulates MMPs and their inhibitors and 
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promotes cell growth, migration and adhesion. It is implicated in angiogenesis 
(Brigstock, 1999). This gene is the most down-regulated by the statin, MβCD and most 
of all Proadifen.  
 
Two additional cancer related loci that are included in the 16-fold change data are 
COL1A1 which is down-regulated by Proadifen. This gene codes for collagen. ATF3 which 
represses MMP-2 (Yan et al., 2002) is up-regulated by Proadifen and to a lesser extent 
by the other treatments. Overall, steroid biosynthesis is up-regulated with Proadifen, 
MβCD and Pravastatin. Furthermore, aminoacyl-tRNA biosynthesis, Biosynthesis of 
unsaturated fatty acids and terpenoid backbone biosynthesis are up-regulated with 
MβCD and Pravastatin.   
 
 
 
The following graphs are volcano plots (as before) but this time the cell type is CaLu-1 
instead of MDA-MB-231, allowing comparison with Figures 38-50. 
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FIGURE 53: VOLCANO PLOT MΒCD 0.0008% W/V RELATIVE TO CONTROL (CALU-1) 
 
 
 
FIGURE 54: HEATMAP PRAVASTATIN 8.0µM RELATIVE TO CONTROL (CALU-1) 
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FIGURE 55: VOLCANO PLOT PROADIFEN (10µM) RELATIVE TO CONTROL (CALU-1) 
 
FIGURE 56: VOLCANO PLOT MΒCD (0.0008%) RELATIVE TO PRAVASTATIN (8.0µM) (CALU-1) 
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FIGURE 57: VOLCANO PLOT MΒCD (0.0008%) RELATIVE TO PROADIFEN  (10µM) (CALU-1) 
 
 
FIGURE 58: VOLCANO PLOT PRAVASTATIN (8.0µM) RELATIVE TO PROADIFEN (10µM) (CALU-1) 
 
FIGURES 54 TO 61 ARE QUALITATIVELY VERY SIMILAR TO THOSE VOLCANO PLOTS FOR THE SAME TREATMENTS IN MDA-MB-231. 
HOWEVER, CALU-1 APPEARS TO BE CONSIDERABLY MORE SENSITIVE TO THESE TREATMENTS . 
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FIGURE 59: SIGNIFICANCE LANDSCAPE (CALU-1) 
A significance landscape for array features significant at adjusted p<0.01 in one or more of the 25 comparisons was 
generated In the plot below, the non-redundant set of 11942 significant genes (X-axis) is broken down by 
comparisons (Y-axis; the number of significant genes in each comparison are shown in parentheses after the 
comparison description); comparisons with no significant genes were removed. This enables one to gain a rapid 
insight into which array features are significant in which comparisons, and if so, were they up-regulated (red) or 
down-regulated (blue). The comparisons are ordered in the plot such that the one with the highest number of 
significant changes is shown at the bottom. Loci that were not significant in a given comparison are shown in grey 
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FIGURE 60: SIGNIFICANCE HISTOGRAM (CALU-1) 
The significance landscape view of the data provides a direct visual representation of which array features were 
significant in which comparison, thus enabling "condition" specific and/or enriched loci to be rapidly identified. 
Groupings of comparison-specific/enriched loci are clearly visible, as are significant loci common to multiple 
comparisons (depicted in the histogram). 
 
 
 
 
FIGURE 61: 2-FOLD CHANGES (CALU-1) 
The figure 61 shows a heatmap of the fold change for all loci exhibiting an up or down 02-fold change in one or more 
of the comparisons. Array features are shown on the X-axis, with the comparisons on the Y axis. A red colour 
indicates up regulation and blue down regulation . Clustering of both array feature and comparison has been 
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performed. This heatmap and Figures 62-64 were used to quality assure the data since they provide a visual check 
on the clustering of replicates which appear in clear bands across the X-axis. 
 
FIGURE 62: 8-FOLD CHANGES (CALU-1) 
The figure above shows a heatmap of the fold change for all loci exhibiting an up or down 8-fold change in one or 
more of the comparisons. Array features are shown on the X-axis, with the treatment comparisons on the Y axis. A 
red colour indicates up regulation and blue down regulation . Clustering of both array feature and comparison has 
been performed. 
 
 
 
 
FIGURE 63: 16-FOLD CHANGES (CALU-1) 
The figure above shows a heatmap of the fold change for all loci exhibiting an up or down 16-fold change in one or 
more of the comparisons. Array features are shown on the X-axis, with the treatment comparisons on the Y axis. A 
red colour indicates up regulation and blue down regulation . Clustering of both array feature and comparison has 
been performed.Details of the genes indicated by the feature numbers 1-18 are provided in Table 9 Part A. 
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FIGURE 64: 32-FOLD CHANGES (CALU-1) 
The figure above shows a heatmap of the fold change for all loci exhibiting an up or down 32-fold change in one or 
more of the comparisons. Array features are shown on the X-axis, with the treatment comparisons on the Y axis. A 
red colour indicates up regulation and blue down regulation . Clustering of both array feature and comparison has 
been performed. Details of the genes indicated by the feature numbers 1-4 are provided in Table 9 Part B 
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Probe ID Symbol Description 
Part A 
    
 
1 QWq7Z1IXOOH7yUCHlE GDF15 
growth differentiation factor 
15 
 
2 HdUm8EQDU6ks46Std4 ATF3 
activating transcription factor 
3 
 
3 um_PC1eV.sRFlbZxxY RN18S1 RNA, 18S ribosomal 1 
 
4 9PSIoIJiqRpniEieiM NUPR1 
nuclear protein, transcriptional 
regulator, 1 
 
5 xJ5IPSIoIJiqRpniEg NUPR1 
nuclear protein, transcriptional 
regulator, 1 
 
6 WhV5j9VA7qAdh5MP7o RNU1-3 RNA, U1 small nuclear 3 
 
7 BueFXmP1UDuoB2Hkw8 RNU1-5 RNA, U1 small nuclear 5 
 
8 l7nlXmP1UDuoB2Hkw8 RNU1-9 RNA, U1 small nuclear 9 
 
9 Z_QKopNLtfpKeP3Kyg CTGF 
connective tissue growth 
factor 
 
10 BS7X6Snj9ysoDusnRk CTGF 
connective tissue growth 
factor 
 
11 lS3DCed5V_50i6O86g THBS1 thrombospondin 1 
 
12 u1dct7Xm13tVq.SIQc COL1A1 collagen, type I, alpha 1 
 
13 uiSdXZ5jc_AtI3URCo 
  
 
14 cTqn3heJFCvioSjyko TRIB3 
tribbles homolog 3 
(Drosophila) 
 
15 0FCogUoBoBIutPVSVo DDIT3 
DNA-damage-inducible 
transcript 3 
 
16 uEGOv.TNPrbr7LW5iA MIR1974 microRNA 1974 
 
17 oon0If5P1yz97_0vdA HSPA1A heat shock 70kDa protein 1A 
 
18 ct43aCcJKtqXryx_ho RN5S9 RNA, 5S ribosomal 9 
     Part B 
    
 
1 BS7X6Snj9ysoDusnRk CTGF 
connective tissue growth 
factor 
 
2 QWq7Z1IXOOH7yUCHlE GDF15 
growth differentiation factor 
15 
 
3 9PSIoIJiqRpniEieiM NUPR1 
nuclear protein, transcriptional 
regulator, 1 
 
4 xJ5IPSIoIJiqRpniEg NUPR1 
nuclear protein, transcriptional 
regulator, 1 
 
TABLE 9 LIST OF GENES AND LOCI ID FOR THE 16-FOLD AND 32-FOLD CHANGES  
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3.3.1.4 KEGG PATHWAY ENRICHMENT IN CALU-1 CELLS  
Spliceosome, DNA replication and Cell cycle, as well as mismatch repair and ubiquitin 
mediated proteolysis, amongst several others are strongly down-regulated by MβCD, 
Pravastatin and Proadifen.  Steroid Biosynthesis is up-regulated with Proadifen, MβCD 
and Pravastatin. Furthermore, Aminoacyl-tRNA biosynthesis, biosynthesis of 
unsaturated fatty acids and terpenoid backbone biosynthesis are up-regulated with 
MβCD and Pravastatin. Proadifen, MβCD and Pravastatin appear to have a narrow 
target range that includes pathways that may be involved in antimicrobial-based 
processes e.g. terpenoid backbone biosynthesis. Comparison of Proadifen, MβCD or 
Pravastatin relative to Control show enrichment of GO terms involved in regulatory 
processing e.g. regulation of macromolecule biosynthetic process. 
 
Kegg pathway analysis revealed that Proadifen treatment up-regulated sterol synthesis. 
It seems likely that the enzymes for sterol synthesis are being manufactured but are 
ineffective in making cholesterol or that cholesterol is shunted from the membrane into 
the cytoplasm (not seen in these experiments). Another, more intriguing possibility is 
that Proadifen prevents the formation of caveolae and this in itself is sufficient for the 
cell to begin up-regulating cholesterol to counter this loss.  These are, in essence, 
homeostatic negative feedback responses from the membrane to the nucleus to restore 
sterol balance.  Why this should be the case for a Δ-24 inhibitor and not the case for a 
statin like Pravastatin is unknown but suggestive. Perhaps the earlier (biochemically 
speaking) intervention of the statins cannot trigger the same response or perhaps the 
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statins do not provoke the abolition of caveolae. Pravastatin and MβCD did not affect 
sterol synthesis pathways in this way but both these treatments caused significant up-
regulation of ribosome and spliceosome pathways.  HMGCS1, the gene associated with 
the production of HMG-CoA (the target for statin intervention) was typical of enzymes 
in this system. 
 
3.3.2 GENE EXPRESSION RESULTS FOR BOTH CELL TYPES 
HMGCS1 is significantly up-regulated by Proadifen but unaffected by all other 
treatments including Pravastatin. Likewise the tumour suppressor p53 was down 
regulated by Proadifen but unaffected by statin or MβCD. Proliferation related signalling 
was reduced by Proadifen as were cytokine and NOD-like receptor signalling. However, 
protein binding per se was not reduced by Proadifen unlike all other treatments. 
 
Interleukins 1 and 6 were down regulated by -1.56 and -1.27 log fold respectively. IL-8 
was down regulated by -1.69 to -2.23 log fold. These data are consistent with the 
reductions of interleukin expression seen in the antibody array experiment. The spread 
of negative and positive impacts on RNA expression was similar to that found in the 
protein assays as shown by the volcano plots and Figure 17 for a global comparison. 
 
LPC and Fluphenazine increased pathway related signalling according to GO analysis 
while MβCD decreased cancer pathways. Exogenous LPC is able, due to the molecule’s 
size and wedge-like shape, to interdigitate into the plasma membrane and typically 
causes an increase in fluidity and permeability of the bilayer. It was used here to check if 
145 
 
the effects of Proadifen were due to a simple fluidizing behaviour in the membrane 
since Proadifen is known to increase absorption of several pharmaceuticals.  Proadifen-
relative-to-LPC at p<0.0001 caused 10 times fewer significant changes to protein 
expression – clearly disturbing the fluidity of the membrane drastically affects RNA 
expression. LPC could be perturbing the rafts and/or caveolae. At the same level of 
confidence, there were no differences in the LPC-relative-to-Fluphenazine analyses, 
suggesting a similar response to these two treatments. Fluphenazine is also a 
membrane fluidiser.  Sequestration of cholesterol by MβCD and HMG-CoA inhibition by 
the statin both caused minimal response at p<0.0001 (25 and 46 events respectively) 
and at p<0.001 both induced only <1000 RNA events. Does LPC make much contribution 
to direct effects on gene expression distinct from those effects on the organisation of 
the phospholipid bilayer? (A separate, but unreported, genome-wide analysis examining 
lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylinositol and 
lysophosphatidic acid revealed that LPE has, by far, the greatest impact on gene 
expression compared to other lysolipids).  Proadifen causes a reduction of cholesterol in 
the membrane and a concurrent up-regulation of cholesterol pathway enzymes. 
However, this up-regulation of sterol pathway does not result in a restoration of the 
membrane cholesterol. Why this pattern is not followed in treatments with statin is 
unknown but it would appear to confirm that the primary feedback originates distal in 
the pathway to squalene. If most of the Δ-24 oxoreductase action is normally on the 
lanosterol, zymosterol and desmosterol then when these routes are shut-down by 
Proadifen the build-up of intermediates is not sufficient to trigger any negative 
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feedback. The effects of Proadifen on cancer related signalling were mainly down-
regulation, including p53 which is a tumour suppressor.  
 
 
FIGURE 65: AN EXAMPLE OF A KEGG PATHWAY 
USING KEGG PATHWAY ANALYSIS METHODS IT IS POSSIBLE TO SEE THE EFFECT ON MULTIPLE POINTS ALONG A BIOCHEMICAL 
PATHWAY. HOWEVER, THE TECHNIQUE IS DESIGNED FOR LARGE AMOUNTS OF GENOMIC DATA AND BECOMES LESS RELIABLE FOR 
SMALL PATHWAYS OF INTEREST OR PATHWAYS THAT BRANCH. 
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3.3.2.1 KEGG PATHWAY DETAILED ANALYSIS OF CANCER RELATED GENES IN MDA-MB-231 
 Treatment  KEGG Pathway 
number  
Pathway name p value Gene(s) 
Fluphenazine-
Control 
Up 5213 Endometrial 
cancer 
0.026379906 AKT1, ARAF, AXIN1, BAD, CCND1, ERBB2, 
FOXO3, GSK3B, HRAS, MAPK3, PIK3CD, 
PIK3R1, PIK3R2 
Fluphenazine-
Control 
Up 5219 Bladder cancer 0.028575455 ARAF, CCND1, DAPK3, E2F2, E2F3, ERBB2, 
FGFR3, HRAS, MAPK3, PGF, TYMP 
Fluphenazine-
Control 
Up 5215 Prostate cancer 0.041136016 AKT1, AR, ARAF, BAD, CCND1, CCNE1, 
CREB1, E2F2, E2F3, ERBB2, GSK3B, GSTP1, 
HRAS, INS, KLK3, MAPK3, PIK3CD, PIK3R1, 
PIK3R2 
Pravastatin-Control Down 5219 Bladder cancer 0.01550555 IL8, MMP1 
MΒCD-Control Down 5219 Bladder cancer 0.001347276 IL8, MMP1, VEGFA 
MΒCD-Control Down 5200 Pathways in 
cancer 
0.006387016 IL6, IL8, LAMC2, MMP1, PTGS2, VEGFA 
LPC-Control Down 5213 Endometrial 
cancer 
0.034873706 BAD, CDH1, CTNNB1, FOXO3, GRB2, ILK, 
LEF1, MAP2K1, MLH1, MYC, PDPK1, SOS1 
LPC-Control Down 5212 Pancreatic 
cancer 
0.036719585 BAD, CDC42, JAK1, MAP2K1, MAPK9, 
RAC1, RAC2, RALA, RALGDS, SMAD4, 
STAT3, TGFA, TGFBR2, VEGFA, VEGFC 
Fluphenazine-Control Down 5211 Renal cell 
carcinoma 
0.000324486 CDC42, CREBBP, CRK, CRKL, CUL2, EGLN1, 
EP300, EPAS1, ETS1, HIF1A, KRAS, 
MAP2K1, MET, NRAS, RAC1, RBX1, SLC2A1, 
SOS1, TCEB1, TGFA, VEGFA, VEGFC, VHL 
Fluphenazine-
Control 
Down 5200 Pathways in 
cancer 
0.008951591 BCL2L1, BID, BIRC2, CASP8, CBL, CCNA1, 
CDC42, CDKN1B, CHUK, CKS1B, CREBBP, 
CRK, CRKL, CTNNB1, CUL2, DVL3, EGFR, 
EGLN1, EP300, EPAS1, ETS1, FADD, FZD6, 
FZD7, HIF1A, HSP90AA1, HSP90B1, IGF1R, 
IL6, IL8, ITGA2, ITGAV, ITGB1, JAK1, KRAS, 
LAMA3, LAMB3, LAMC1, LAMC2, LEF1, 
MAP2K1, MAPK9, MET, MLH1, MMP1, 
MYC, NFKB1, NRAS, PTGS2, RAC1, RAC2, 
RALA, RALB, RARB, RBX1, SLC2A1, SMAD4, 
SOS1, STAT3, STAT5B, TCEB1, TFG, TGFA, 
TGFBR2, VEGFA, VEGFC, VHL, WNT5A 
Fluphenazine-Control Down 5212 Pancreatic 
cancer 
0.011168505 BCL2L1, CDC42, CHUK, EGFR, JAK1, KRAS, 
MAP2K1, MAPK9, NFKB1, RAC1, RAC2, 
RALA, RALB, SMAD4, STAT3, TGFA, 
TGFBR2, VEGFA, VEGFC 
Proadifen-Control Down 5200 Pathways in 
cancer 
0.047516463 CDKN1B, IL6, IL8, JUP, LAMC2, PTGS2, 
VEGFA 
TABLE 10:KEGG PATHWAYS AND CANCER RELATED GENES IN MDA-MB-231 
THIS TABLE PROVIDES THE EXTRACTED DATA FOR THE GENES ASSOCIATED WITH CANCERS.  ONLY SIGNIFICANT (P<0.05) EVENTS ARE 
SHOWN.  
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3.3.2.2 KEGG PATHWAY DETAILED ANALYSIS OF CANCER RELATED GENES IN CALU-1 
 
TABLE 11: KEGG PATHWAY AND CANCER RELATED GENES IN CALU-1 
Treatment  KEGG Pathway 
number  
Pathway 
name 
p value Gene(s) 
LPC-CONTROL Down 5219 Bladder 
cancer 
0.019255247 IL8, MMP2 
LPC-CONTROL Down 5200 Pathways in 
cancer 
0.023254347 CCNE1, IL6, IL8, MMP2, PTGS2 
MβCD-
CONTROL 
Down 5200 Pathways in 
cancer 
0.003765599 ARNT2, AXIN2, BCL2L1, BID, 
BIRC2, BIRC3, BIRC5, BMP4, 
CASP3, CCND1, CCNE1, CDC42, 
CDK2, CDK6, COL4A1, COL4A6, 
CRK, CYCS, DAPK3, E2F2, FADD, 
FGF5, FGFR1, FH, FZD4, HDAC1, 
HDAC2, HSP90AA1, IL8, ITGA6, 
JUN, MECOM, MMP1, MMP2, 
MSH2, MSH6, MTOR, NKX3-1, 
PRKCA, RARA, RASSF1, RBX1, 
RUNX1, RXRA, SKP2, SMAD3, 
TCEB1, TCEB2, TGFA, TGFB2, 
TGFBR2, TRAF2, WNT5B, WNT7B 
Pravastatin-
CONTROL 
Down 5200 Pathways in 
cancer 
0.001593765 ARNT2, BCL2L1, BID, BIRC2, BIRC3, 
BIRC5, BMP4, CASP3, CCND1, 
CCNE1, CDK2, CDK6, CRK, DAPK3, 
E2F2, FGF5, FH, FZD4, HDAC1, 
HDAC2, HSP90AA1, IL6, IL8, ITGA6, 
JUN, MMP1, MSH2, MSH6, NKX3-
1, PRKCA, PTGS2, RARA, RASSF1, 
RBX1, RUNX1, RXRA, SKP2, TCEB1, 
TCEB2, TGFA, WNT5B, WNT7B 
Pravastatin-
CONTROL 
Down 5222 Small cell 
lung cancer 
0.017232385 APAF1, BCL2L1, BIRC2, BIRC3, 
CCND1, CCNE1, CDK2, CDK6, E2F2, 
ITGA6, PTGS2, RXRA, SKP2 
Proadifen-
CONTROL 
Down 5222 Small cell 
lung cancer 
0.00743923 APAF1, BCL2, BCL2L1, BIRC2, 
CCND1, CCNE1, CDK2, CDK6, 
COL4A1, COL4A6, CYCS, E2F2, 
E2F3, ITGA6, ITGAV, ITGB1, 
LAMC1, PIAS2, PIK3CB, PIK3R1, 
PTK2, RXRA, SKP2 
Proadifen-
CONTROL 
Down 5211 Renal cell 
carcinoma 
0.015640768 ARNT2, CDC42, CRK, EGLN1, 
EP300, FH, GRB2, MAP2K1, 
MAPK1, MET, PIK3CB, PIK3R1, 
PTPN11, RBX1, TCEB2, TGFA, 
TGFB2, VEGFC, VHL 
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Proadifen-
CONTROL 
Down 5215 Prostate 
cancer 
0.028467316 BCL2, CCND1, CCNE1, CDK2, 
CREB1, CREB3L2, CREB5, E2F2, 
E2F3, EP300, ERBB2, GRB2, 
HSP90AA1, KLK3, MAP2K1, 
MAPK1, MTOR, NKX3-1, PDPK1, 
PIK3CB, PIK3R1, TGFA 
MβCD-
CONTROL 
Up 5216 Thyroid 
cancer 
0.005342649 CCDC6, CDH1, MAPK3, MYC, 
NRAS, PPARG, RXRB, TFG 
MβCD-
CONTROL 
Up 5219 Bladder 
cancer 
0.006075948 CDH1, CDKN2A, EGFR, MAPK3, 
MYC, NRAS, RPS6KA5, TYMP, 
VEGFA, VEGFB 
MβCD-
CONTROL 
Up 5212 Pancreatic 
cancer 
0.037240109 ARHGEF6, CDKN2A, EGFR, MAPK3, 
PIK3R2, RAC2, RALGDS, SMAD2, 
SMAD4, STAT1, VEGFA, VEGFB 
Pravastatin-
CONTROL 
Up 5219 Bladder 
cancer 
0.004455468 CDH1, CDKN2A, EGFR, MAPK3, 
MYC, RPS6KA5, TYMP, VEGFA, 
VEGFB 
Pravastatin-
CONTROL 
Up 5212 Pancreatic 
cancer 
0.044862777 ARHGEF6, CDKN2A, EGFR, MAPK3, 
PIK3R2, RAC2, RALGDS, STAT1, 
VEGFA, VEGFB 
Proadifen-
CONTROL 
Up 5219 Bladder 
cancer 
0.000339897 ARAF, BRAF, CDH1, CDKN1A, 
CDKN2A, EGFR, FGFR3, IL8, 
MAPK3, MYC, NRAS, RPS6KA5, 
TYMP, VEGFA, VEGFB 
Proadifen-
CONTROL 
Up 5212 Pancreatic 
cancer 
0.002739927 AKT3, ARAF, BAD, BRAF, CASP9, 
CDKN2A, EGFR, MAPK3, PIK3R2, 
PLD1, RAC2, RALA, RALGDS, 
SMAD2, SMAD4, STAT1, STAT3, 
VEGFA, VEGFB 
Proadifen-
CONTROL 
Up 5213 Endometrial 
cancer 
0.003979299 AKT3, ARAF, AXIN1, BAD, BRAF, 
CASP9, CDH1, EGFR, GSK3B, ILK, 
MAPK3, MYC, NRAS, PIK3R2, PTEN 
Proadifen-
CONTROL 
Up 5216 Thyroid 
cancer 
0.014507544 BRAF, CCDC6, CDH1, MAPK3, MYC, 
NRAS, PAX8, PPARG, TFG 
Proadifen-
CONTROL 
Up 5211 Renal cell 
carcinoma 
0.029969488 AKT3, ARAF, BRAF, EGLN2, EPAS1, 
ETS1, FLCN, HIF1A, MAPK3, NRAS, 
PAK1, PIK3R2, SLC2A1, VEGFA, 
VEGFB, VHL 
Proadifen-
CONTROL 
Up 5210 Colorectal 
cancer 
0.044639572 AKT3, ARAF, AXIN1, BAD, BRAF, 
CASP9, GSK3B, MAPK3, MYC, 
PIK3R2, RAC2, RALGDS, SMAD2, 
SMAD4 
 
THIS TABLE PROVIDES THE EXTRACTED DATA FOR THE GENES ASSOCIATED WITH CANCERS.  ONLY SIGNIFICANT (P<0.05) EVENTS ARE 
SHOWN.  WHEN COMPARED TO THE DATA SET FOR MDA-MB-231 IS CAN BE CLEARLY SEEN THAT CALU-1 IS MORE SENSITIVE TO THE 
TREATMENTS WITH MANY MORE CANCER RELATED GENES AFFECTED.  
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3.3.2.3 KEGG PATHWAY DETAILED ANALYSIS OF GENES INVOLVED IN STEROID SYNTHESIS 
 
TABLE 12  KEGG PATHWAYS AND STEROID SYNTHESIS  
Treatment KEGG Pathway 
number 
Pathway 
name 
p value Gene(s) 
CaLu-1      
MβCD-
CONTROL 
Up 100 Steroid 
biosynthesis 
9.11E-06 CYP51A1, DHCR7, FDFT1, 
LSS, NSDHL, SC4MOL, 
SC5DL, SQLE, TM7SF2 
Pravastatin-
CONTROL 
Up 100 Steroid 
biosynthesis 
9.36E-08 CYP51A1, DHCR7, FDFT1, 
LIPA, LSS, NSDHL, SC4MOL, 
SC5DL, SQLE, TM7SF2 
Proadifen-
CONTROL 
Up 100 Steroid 
biosynthesis 
0.005590
514 
CYP51A1, DHCR7, FDFT1, 
NSDHL, SC4MOL, SC5DL, 
TM7SF2 
 
MDA-MB-
231 
     
Proadifen-
Control 
Up 100 Steroid 
biosynthesis 
1.11E-17 CYP51A1, DHCR24, DHCR7, 
EBP, FDFT1, LSS, NSDHL, 
SC4MOL, SC5DL, SQLE, 
TM7SF2 
LPC-Control Up 100 Steroid 
biosynthesis 
0.011254
582 
CEL, DHCR24, DHCR7, LSS, 
NSDHL, TM7SF2 
      
IT IS INTERESTING THAT IN CONTRAST TO THE SPECIFIC GENES (TABLE 10) THE KEGG PATHWAYS FOR CHOLESTEROL SYNTHESIS ARE 
EXCLUSIVELY UP-REGULATED.  WHY THIS IS THE CASE IS UNKNOWN.  
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3.3.3 GENE EXPRESSION OF THE MARKER PROTEINS USED IN PROTEIN ARRAY ASSAY 
 
FIGURE 66: GENE EXPRESSION OF APOPTOTIC MARKERS IN MDA-MB-231 TREATED WITH PROADIFEN 
 FOR COMPARISON TO ACTUAL PROTEIN EXPRESSED SEE FIGURE 29 
 
 
FIGURE 67: GENE EXPRESSION OF ANGIOGENESIS MARKERS IN MDA-MB-231 TREATED WITH PROADIFEN  
 FOR COMPARISON TO ACTUAL PROTEIN EXPRESSED SEE FIGURE 30 
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FIGURE 68: GENE EXPRESSION OF IMMUNE RESPONSE MARKERS IN MDA-MB-231 TREATED WITH PROADIFEN 
   FOR COMPARISON TO ACTUAL PROTEIN EXPRESSED SEE FIGURE 31 
 
 
FIGURE 69: GENE EXPRESSION OF PROLIFERATION MARKERS IN MDA-MB-231 TREATED WITH PROADIFEN   
FOR COMPARISON TO ACTUAL PROTEIN EXPRESSED SEE FIGURE 32 
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ISOLATION OF THE GENES INVOLVED IN THE MEVALONATE PATHWAY REVEALS THAT MOST OF THE TREATMENTS CAUSED DOWN-
REGULATIONS OF THESE GENES (SHOWN IN RED). A NOTABLE EXCEPTION IS PROADIFEN WHICH ONLY CAUSED UP-REGULATIONS.  
 
 
 
 
 
 
 
 
 
 
 
TABLE 13 CHANGES TO REGULATION OF GENES ASSOCIATED WITH CHOLESTEROL SYNTHESIS (NOT FILTERED BY SIGNIFICANCE) 
 
% Change in Mean Averages of mRNA spot intensity by cholesterol pathway genes 
 
Target  Proadifen Pravastatin MβCD LPC Fluphenazine  
HMGCS1 224.8056 -12.46216842 -27.8767 -7.09948 -19.6962   
HMGCR 200.6086 -5.818088499 -10.804 -24.8451 -33.9883   
MVK 144.1146 4.290899663 -0.32409 -6.54222 -17.9803   
FDPS 200.1963 -15.10127375 -7.75527 0.485836 -12.9881   
FDFT1 178.1766 2.398725153 -12.2486 -51.4775 -58.5775   
SQLE 149.0991 3.303303303 -12.4249 -55.7057 -59.9944   
LSS 164.4272 2.641767251 -6.35391 -17.2702 -24.9146   
TM7SF2 159.9011 -6.973245944 -17.5352 -10.1751 -20.1676   
CYP51A1 155.8444 -14.2267498 -8.09695 -22.555 -34.5394   
SC4MOL 244.8134 -10.25277915 -17.5954 -39.1347 -52.064   
DHCR24 159.5037 -21.05399976 -4.65556 6.591043 -19.3596   
EBP 138.3187 -2.112855866 -0.1149 -43.4699 -46.4381   
DHCR7 217.3947 -18.31700865 -18.1847 -3.89648 -27.9796   
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FIGURE 70: CAV1 RNA EXPRESSION IN MDA-MB-231  
 
 
FIGURE 71:  HMGCS1 CODES FOR THE ENZYME THAT CALALYSES ACETOACETYL-COA INTO HMG-COA. 
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3.3.4 RESULTS OF ANTIBODY ASSAYS 
 
 
FIGURE 72: CAV-1 ASSAY WITH MULTIPLE PROADIFEN ANALOGUES 
THE FIGURES 72-88 SHOW MEAN OF TRIPLICATE VALUES FROM MORE THAN ONE EXPERIMENT. ERROR BARS DENOTE ± STANDARD 
ERRORS AND * DENOTES STATISTICAL SIGNIFICANCE AT P<0.05 (ANNOVA TWO TAILED TEST FOR DIFFERENCE FROM THE CONTROL). 
Y-AXIS SHOWS THE BINDING OF ANTI-CAV-1 ANTIBODY TO MEMBRANE CAV-1 AND IS MEASURED ON A SCALE RELATIVE TO THE 
NEGATIVE CONTROL. INCREASING ACYL CHAIN LENGTH OF THE MODEL DIPHENYLVALERATE COMPOUNDS CAUSES MODEST 
DECREASE IN CAV-1 EXPRESSION.  
 
  *            *              *           
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FIGURE 73: CAV-1 ASSAY FLUPHENAZINE 
ALL FLUPHENAZINE TREATMENTS CAUSED A STATISTICALLY SIGNIFICANT REDUCTION IN CAV-1 EXPRESSION BUT THIS RESPONSE 
WAS NON-LINEAR. 
 
FIGURE 74: CAV-1 ASSAY PROADIFEN 
 THIS FIGURE SHOWS A CLEAR DOSE-RESPONSE REDUCTION OF CAV-1 EXPRESSION. 
* * 
* 
* 
157 
 
 
FIGURE 75 CAV-1 ASSAY AY9944 
 PROADIFEN AND AY9944 SHOWED NO INCREASE IN CAV-1 REDUCTION WHEN COMBINED (ALSO SEE FIGURE 81 AND FIGURE 82) 
 
FIGURE 76: CAV-1 ASSAY ERGOSTEROL 
 ERGOSTEROL IS USED TO SIMULATE A Δ24 DESATURASE BLOCKADE AND DOES APPEAR TO REDUCE CAV-1 AT HIGH DOSES (SEE 
ALSO FIGURE 78) 
* * 
* 
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FIGURE 77: CAV-1 ASSAY CHOLESTEROL 
THE RESULTS OF CHOLESTEROL TREATMENTS ON CAV-1 EXPRESSION WERE NOT STATISTICALLY SIGNIFICANT. 
 
FIGURE 78: CAV-1 ASSAY ERGOSTEROL AND AY9944 COMBINED TREATMENTS 
 COMBINED TREATMENTS OF AY9944 AND ERGOSTEROL DO NOT APPEAR TO BE SYNERGISTIC IN TERMS OF CAV-1 EXPRESSION. 
ERGOSTEROL IS USED HERE FOR COMPETITIVE INHIBITION OF THE Δ-24 DESATURASE TO SEE IF THE RESPONSE TO COMBINED 
TREATMENT WITH Δ-7 INHIBITOR IS SIMILAR TO THAT WITH PROADIFEN. SEE FIGURE 87. 
* 
* * * 
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FIGURE 79: CAV-1 ASSAY MΒCD TREATMENT 
SEQUESTRATION BY MΒCD OF MEMBRANE CHOLESTEROL HAS A MODEST IMPACT ON CAV-1 EXPRESSION. 
 
FIGURE 80: CAV-1 ASSAY “VL20” ANALOGUE 
NO ADDITIONAL REDUCTION OF CAV-1 WAS SEEN FOLLOWING THE INSERTION OF AN EXTRA METHYL GROUP BETWEEN THE 
PHENYL MOIETIES. 
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FIGURE 81: CAV-1 ASSAY PROADIFEN 
 
FIGURE 82: CAV-1 ASSAY AY9944 TREATMENT 
AY9944 DOES NOT APPEAR TO REDUCE CAV-1 EXPRESSION BUT DOES REDUCE OVERALL RAFT PREVALENCE (SEE ALSO FIGURE 91) 
* * 
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FIGURE 83: CAV-1 ASSAY “VL15” ANALOGUE 
REMOVAL OF THE TERMINAL ETHYL GROUPS FROM THE PROADIFEN STRUCTURE REDUCES THE EFFECT ON CAV-1 EXPRESSION. 
 
FIGURE 84:  CAV-1 ASSAY MULTIPLE ANALOGUES TESTED ON CALU-1 CELLS 
THERE IS LITTLE DIFFERENCE BETWEEN PROADIFEN AND ITS ANALOGUES ON CAV-1 EXPRESSION. 
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FIGURE 85: CAV-1 ASSAY ADDITIONALPROADIFEN ANALOGUES TESTED ON MDA-MB-231 CELLS 
THERE IS LITTLE DIFFERENCE BETWEEN PROADIFEN AND ITS ANALOGUES ON CAV-1 EXPRESSION. 
 
FIGURE 86: CAV-1 ASSAY COMBINED TREATMENT VL20 AND AY9944 
 A COMBINED TREATMENT OF VL20 AND AY9944 AT HIGH DOSES APPEARS TO SIGNIFICANTLY REDUCE CAV-1 EXPRESSION (SEE 
ALSO FIGURE 80 AND FIGURE 82 FOR COMPARISON. 
 
* 
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FIGURE 87: CAV-1 ASSAY CLOTRIMAZOLE  
CLOTRIMAZOLE DOES NOT APPEAR TO REDUCE CAV-1 EXPRESSION 
 
FIGURE 88: COMPARISON OF SEVERAL TREATMENTS IN CAV-1 ASSAY 
PRAVASTATIN, SIMVASTATIN, PROADIFEN, MΒCD AND TRIPARENOL ALL REDUCE CAV-1 
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FIGURE 89: COMPARISON OF SEVERAL TREATMENTS IN  GAL-8 ASSAY  
FIGURES 89-91 SHOW THE BINDING OF A FLUORESCENT TAGGED ANTIBODY TO MEMBRANE GLECTIN-8, TUBULIN-1 AND FLOTILIN-1 
RESPECTIVELY. Y-AXIS SHOWS ANTIBODY BINDING. GALACTINS ARE SECRETED CARBOHYDRATE-BINDING PROTEINS THAT 
MODULATE CELL-MATRIX ADHESION. GAL-8 FORMS COMPLEXES WITH INTEGRINS TO INHIBIT CELL ADHESION AND INDUCE 
APOPTOSIS (HADARI ET AL., 2000). 
 
FIGURE 90: COMPARISON OF SEVERAL TREATMENTS IN  TUB-1 ASSAY 
TUBULIN IS A MARKER OF CYTOSKELETON REARRANGEMENT. A DECREASE IN TUB-1 IS CORRELATED TO REDUCED MOTILITY. 
* 
* 
* 
* 
* 
* 
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FIGURE 91: COMPARISON OF SEVERAL TREATMENTS IN  ANTI-FLOTILLIN ASSAY 
 
These assays were conducted to examine in more detail the effects of Proadifen and its 
analogues on these key metastatic markers and to compare them with other inhibitors 
of the mevalonate pathway. Introduction of cholesterol resulted in elevated Cav-1 in 
contrast to the reduction of Cav-1 caused by Proadifen or the cholesterol sequestering 
agent MβCD. Tubulin (Tub-1) was also assayed to permit a comparison with the protein 
microarray data as caveolins were not screened in that assay. Proadifen appeared to 
reduce the expression of tubulin in MDA-MB-231 (↓18% at 50μl 1mM) and this 
reduction is predicted by the microarray assay (↓56% at 100μl 1mM). Interestingly, 
both cholesterol and MβCD  also reduced tubulin expression. 
 
Proadifen, Pravastatin, ergosterol and MβCD all significantly reduced Cav-1 expression 
in these assays. Pravastatin, Proadifen and ergosterol display a dose-response profile. 
Combining AY9944 with Proadifen made no difference to the results for Proadifen as a 
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discreet treatment. It may be that Δ-7 inhibition alone produces an accumulation of a 
cholesterol intermediate suitable for complexing with Cav-1 (dehydrocholesterol) while 
the products of the Δ-24 inhibitor (lanosterol and desmosterol) are unsuitable for 
caveolae formation. If this is true then Proadifen could be used to target only caveolae 
mediated signal transduction.  Various close analogues of Proadifen were tested in this 
assay with unremarkable results. A slight reduction in Cav-1 was seen with increasing 
acyl chain length but the insertion of an extra methyl group or removal of both ethyl 
groups has no observable effect on activity as measured in this assay. Of the other 
compounds tested, clotrimazole made no significant impact on Cav-1 expression but 
Pravastatin, Simvastatin, Fluphenazine and MβCD all reduced the amount of caveolin-1 
visible to the labelled antibody in the assay.  
 
Gal-8 expression was measured in a similar experiment and here, Pravastatin, Proadifen 
and MβCD reduced Gal-8 expression but interestingly Fluphenazine and D-erythro-
MAPP did not. Tub-1 was also assayed and here again, Proadifen and the Pravastatin 
caused significant reduction in Tub-1 expression. Flotillin, the general marker for the 
presence of rafts was statistically significant reduced in treatments with Proadifen, LPC, 
MβCD, AY9944 and BM15766.  
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3.3.5 RESULTS FROM COMBINED PROTEOLYSIS AND MOTILITY EXPERIMENT 
 
FIGURE 92: PROTEOLYSIS AND MOTILITY DATA MDA-MB-231 
 
FIGURES 92. THIS EXPERIMENT SOUGHT TO MEASURE THE EFFECT OF THE COMPLETE RANGE OF DRUG TREATMENTS, INCLUDING 
ALL OF THE NEWLY SYNTHESIZED PROADIFEN ANALOGUES, ON THE PROTEOLYSIS CAPACITY OF MDA-MB-231 AND CALU-1 CELLS. A 
SIMPLE TEST OF ENZYME DIGESTION OF FLUORESCENT-QUENCHED GELATIN WAS USED. TO SEE THE EFFECT OF RESTRICTING THE 
CELLS MOVEMENT ON THE DEGREE OF PROTEOLYSIS THE MOTILITY INHIBITOR CYTOCHALISIN B WAS USED IN REPEATED 
EXPERIMENTS. THE EXPERIMENT WAS RUN OVER 29 HOURS BUT THE REPEATED EXPOSURE OF THE PLATES TO LIGHT DURING THE 
INTERVALS TO TAKE READINGS IN THE PLATE READER AND VARIOUS MICROSCOPE EXAMINATIONS OF THE CELLS SEEMS TO HAVE 
CAUSED THE GELATIN CONJUGATE TO BE LOSE ITS FLUORESCENCE AFTER JUST 3 HOURS. DATA AFTER 3 HOURS CAN BE IGNORED 
AND IS PRESENTED HERE ONLY FOR THE SAKE OF COMPLETENESS. FIGURES 92-97 SHOW RESULTS THAT ARE SCALED BY TRYPAN 
BLUE VIABILITY DATA AND HAVE AN ARBITRARY Y-AXIS SCALE. 
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FIGURE 93: PROTEOLYSIS DATA MDA-MB-231 
 
 
FIGURE 94: MOTILITY DATA MDA-MB-231 
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FIGURE 95: PROTEOLYSIS AND MOTILITY DATA CALU-1 
 
FIGURE 96: PROTEOLYSIS DATA CALU-1 
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FIGURE 97: MOTILITY DATA CALU-1 
 
 
Treatment with cytochalsin B reduced the proteolysis by 25-30% presumably because 
the cell exhausts the local media of conjugated protein. The data indicates that all 
treatments (except the 2,2-diphenylpentanamide “amide”) caused a reduction of 
fluorescence. 2-(Diethylamino)ethyl-2,2-diphenylhexanoate appears to the slightly more 
potent than Proadifen itself suggesting a minor increase in efficacy is related to the 
addition of the C6 moiety. Pravastatin and methyl-β-cyclodextrin had very similar 
effects on proteolysis and the statin treatment appeared to be slightly less affected by 
the cytochalisin. In general, CaLu-1 appears to very rapidly exhaust all available gelatin-
conjugate and none of the treatments proved very effective in reducing proteolysis in 
this cell line. The motility data when isolated from the total proteolysis data suggests 
that in MDA-MB-231 particularly, Proadifen and its analogues all have a measurable 
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impact on motility but AY9944 does not. The other cholesterol inhibitors tested also had 
little effect on motility. 
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3.3.6 RESULTS OF CHOLESTEROL ASSAYS CONDUCTED IN MDA-MB-231  CELLS. 
 
FIGURE 98: PROTEIN STANDARD CURVE 
 TO ESTABLISH TEST LINEARITY OF PROTEIN DETECTION BEFORE START OF EXPERIMENT 
 
FIGURE 99: CHOLESTEROL STANDARD CURVE 
 TO VERIFY LINEARITY OF CHOLESTEROL DETECTION BEFORE START OF EXPERIMENT 
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FIGURE 100: CHOLESTEROL IN CYTOPLASM 
 
FIGURE 101: CHOLESTEROL IN MEMBRANE 
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FIGURE 102: TOTAL PROTEIN IN CYTOPLASM PER WELL 
 
FIGURE 103: TOTAL PROTEIN IN MEMBRANE PER WELL 
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FIGURE 104: TOTAL CELL PROTEIN 
 
FIGURE 105: CHOLESTEROL IN CYTOPLASM 
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FIGURE 106:  MEMBRANE CHOLESTEROL 
 
FIGURES 100-106 SHOW THE LEVELS OF CHOLESTEROL AS  ACTUAL WEIGHT % OF CHOLESTEROL PER MG PROTEIN OR 100,000CELLS 
FOR WHOLE CELLS, CYTOPLASM AND THE CELL MEMBRANE FRACTION. THE CHOLESTEROL TEST WAS DEVISED USING A 
COMMERCIALLY AVAILABLE CHOLESTEROL DETECTION KIT IN A 96 WELL PLATE FORMAT. USING THIS TEST AND CENTRIFUGE-
SEPARATED CELLS, MEMBRANES AND THE CELL CONTENTS WERE SEPARATELY ANALYSED FOLLOWING VARIOUS TREATMENTS 
TOGETHER WITH TOTAL CELL PROTEIN. THERE WERE SOME INTERESTING FINDINGS WHEN CHOLESTEROL WAS EXPRESSED IN 
µG/MG PROTEIN. THESE CHOLESTEROL INHIBITORS (WITH THE MARKED EXCEPTIONS OF BIBX1382 AND RO48871 AND THE 
SEQUESTERING AGENT MΒCD) DID NOT APPEAR TO HAVE DRAMATIC IMPACT ON MEMBRANE CHOLESTEROL BUT DID REDUCE 
TOTAL CELL PROTEIN. MΒCD DID REDUCE MEMBRANE CHOLESTEROL AS EXPECTED BUT RESULTED IN AN UNEXPECTED UPLIFT IN 
CYTOPLASMIC CHOLESTEROL.  IF TOTAL PROTEIN CONTENT IS AN INDICATOR OF CELL HEALTH, THEN PROADIFEN AND 
PRAVASTATIN, BM15766 AND BIB515 WERE THE LEAST DETRIMENTAL TREATMENTS, WHILE PROVIDING SIGNIFICANT REDUCTION 
IN CHOLESTEROL. MΒCD AND RO48871 CAUSED THE MOST SERIOUS REDUCTION OF TOTAL PROTEIN.  
177 
 
 
4 CONCLUSIONS 
Proadifen blocks the cholesterol pathway at multiple points (see Figure 107) but the 
RNA expression assay reveals that at each position on the pathway Proadifen also up-
regulates the enzyme involved. Proadifen reduces both cytoplasmic and membrane 
cholesterol. Treatment of cells with Proadifen reduces the amount of Cav-1 (and, 
presumably, caveolae per se) but this is not a direct result of lowered cholesterol since, 
unlike statins and MβCD, Proadifen also directly down-regulates mRNA CAV1 gene 
expression. Two processes appear to be at work in this system: statins reduce 
cholesterol by inhibition of the HMG-CoA enzyme and MβCD sequestrates cholesterol 
into its hydrophobic core and effectively removes the sterol from the membrane as a 
clathrate-type species. Neither of these treatments caused CAV1 mRNA production to 
be down- regulated but both achieved a reduction in Cav-1 expression at the 
membrane. However, Proadifen did down-regulate CAV1 mRNA and caused a 
commensurate reduction in Cav-1 expression in the membrane.   
 
MβCD and LPC both up-regulated cancer pathways while Proadifen and statin down 
regulated cancer pathways. MβCD did not reduce Cav-1 in the membrane but did 
reduce the generic raft marker protein, Flotillin (as did LPC treatment). It is tempting to 
hypothesize that MβCD and LPC cause a similar perturbation in the membrane through 
physico-chemical effects. These have consequences for the health of the cell but do not 
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impact the formation of caveolae. The reduction of Cav-1 in the membrane caused by 
statin must therefore be due solely to the reduction of cholesterol – that is to say, a 
reduction in the recruitment of Cav-1 to raft inclusions. Proadifen, like Fluphenazine, 
must act to induce or repress mRNA expression irrespective of their effects on 
cholesterol and raft/caveolae formation. 
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FIGURE 107: CHOLESTEROL BIOSYNTHESIS PATHWAY 
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Cancer signalling is likely to be affected by a reduction of signal-bearing rafts; for 
example, Fluphenazine caused an increase in the actual amount of Cav-1 and is also 
associated with up-regulation of cancer pathways. Fluphenazine does not increase the 
amount of flotillin detected, suggesting that these cancer-related pathway proteins are 
indeed caveolae –as opposed to raft – based signals. 
 
It is known that statins can induce apoptosis by down-regulating the expression of Bcl-2 
and activation of ErbB2 and this effect is independent of cholesterol inhibition (Herrero-
Martin and Lopez-Rivas, 2008).  Likewise, an RNA-based theory to explain anti-
artherogenic activity of statins through up-regulation of low-density lipoprotein-
receptor related protein 1 has been proposed (Moon et al., 2011). The mechanism 
requires isoprenylation of the relevant proteins, despite a reduced supply of the 
necessary farnesyl pyrophosphate.  However, it is possible that these effects on gene 
expression may be secondary effects originating from the cells inability to assemble 
rafts and perform raft-mediated signalling.  
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Diagram showing the cholesterol synthesis pathway with gene involvement, adapted from Polymeropoulos et al 
(Polymeropoulos et al., 2009) 
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Figure 108:  Cholesterol pathway with genes coding for enzymes 
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4.1.1 MOLECULAR STRUCTURES AND ACTIVITY 
 
A group of membrane-active phenylvalerate derivatives of the research tool Proadifen 
were synthesized in this study and, like Proadifen, are likely to impact membrane 
fluidity (Garnett, 2001). Structurally, they resemble the sphingosine-1-phosphate (S1P) 
agonists currently being investigated for multiple drug activities, notably multiple 
sclerosis. Pro-drugs from the S1P agonists family of compounds are believed to control 
membrane integrity (permeability) by modulating G-protein coupled receptors located 
on lipid rafts. S1P can rescue endothelial cell membranes from thrombin induced lysis 
and yet some members of this drug family also demonstrate viral cognate docking 
inhibition, possibly by raft disruption. 
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FIGURE 109: STRUCTURES OF MODEL PROADIFEN TYPE Δ-24 INHIBITOR AND EDELFOSINE 
 
These disparate actions could be related to either their membrane effects on raft 
formation and stability or perhaps as direct ligands that are involved upstream in raft 
formation. There is evidence that both may be true and this indicates that molecules 
possessing short C4-C8 acyl chains can have both membrane stabilizing effects through 
(for example) S1P receptor activation and subsequent recruitment to lipid rafts; or 
membrane permeabilizing effects that can lead to cell injury. These actions can have 
alternate outcomes dependant on the pathological status of the cells for example, S1P 
can increase permeability and expression of adhesion molecules that stimulate the 
innate immune response leading to inflammation and or cell death. These findings 
further suggest that control of raft mediated receptor-ligand binding may have 
therapeutic relevance.  
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4.1.2 TRIPARENOL AND OTHER REDUCTASE INHIBITORS 
Triparenol, for example, also blocks 24-dehydrocholesterol reductase. It appears to 
down-regulate the Hegehog (Hh) pathway activation associated with certain cancers 
and has been shown to reduce tumour cell proliferation both in vitro  and in vivo 
models. It has been proposed as a new therapeutic (Bi X., 2012) . Pokjak et al performed 
some interesting experiments with Triparenol in rat hepatoma cells using radiolabelled 
mevalonate to study the conversion process to cholesterol (Popjak et al., 1989). They 
found that Triparenol completely blocks the synthesis of cholesterol and inhibits the 
growth of H4 cells even at very low (4.5µM) concentrations. Triparenol acted as an 
effective Δ-24 reductase inhibitor and also partially prevented the isomerization of the 
8(9)-double bond giving rise to an accumulation of the normally trace sterol, 
zymosterol. They propose that cell growth reduction is due to the presence of 
zymosterol which may adversely affect membrane integrity.  
 
 
A decrease in membrane fluidity by the non-steroidal anti-inflammatory (NSAID) drug 
Licofelone has been shown to both inhibit EGFR signalling and to cause apoptosis in 
colon cancer cells. The pro-apoptotic effects of Licofelone are independent of the drugs 
cyclooxygenase and 5-lipoxygenase activity but are associated with changes to the 
levels of mono and poly-unsaturated lipids in the cell membrane that significantly lower 
membrane fluidity. It is claimed that the membrane rigidity prevents phosphorylation of 
EGFR and consequently MAPK and AKT cascades that stimulate oncogenesis and that 
disruption of these pathways induces apoptosis (Tavolari et al., 2012).  
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Donatello et al have described how methyl β- cyclodextrin  can be used to disrupt the 
association of the raft localised protein CD44 and cause it to co-precipitate with ezrin to 
induce cell migration. They also report that knock-down of Cav-1 did not increase cell 
migration (Donatello et al., 2012). No such effects on cell migration were observed in 
these studies by any of the agents used to disrupt or inhibit rafts, including MβCD. 
 
It is known that in MDA-MB-231 cells Simvastatin is able to prevent phosphorylation of 
Akt kinase and so reduce cancer cell growth (Ghosh-Choudhury et al., 2010). 
4.1.3 STATINS 
One study by Brown et al demonstrated that Atorvastatin, Mevastatin, Simvastatin and 
Rosuvastatin all reduced the invasive potential of PC-3  prostate cells. They reported 
that the drugs treated cell colonies all displayed altered morphology, describing the 
cells as “more compact” and  “containing cells of more epithelial phenotype”. This is in 
agreement with the observations in this study where cells became rounded with fewer 
cilia and invasapodia.  However, they report that Pravastatin had no effect up to 100µM 
on the ability of the cells to invade bone marrow stroma (Brown M., 2011).  Lovostatin 
has also been shown to reduce the invasiveness of pleural mesothelioma cells 
(Yamauchi et al., 2011). 
 
4.1.4 FATTY ACIDS AND THE ISOPRENOID PATHWAY 
Fatty acid synthase (FASN) over-expression is a common indicator of malignancy. It is 
thought that this is because rapidly dividing cells have an increased requirement for 
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fatty acids for the generation of new membranes (Swinnen et al., 2002). It is also true 
that fatty acids have a generally fluidising effect on the membranes when they are 
applied to a membrane exogenously so it is tempting to speculate that FASN activation 
is an early event in the coordination of raft formation: as the preponderance of lipids 
and phospholipids increases there is a recruitment to local microdomains of cholesterol 
and sphingolipids, made possible by increasingly fluid conditions.  Di Vizio et al have 
concluded that FASN up-regulation is dependent upon the presence of Cav-1 during 
cancer progression (Di Vizio et al., 2007) – strongly implicating caveolae for such 
signalling. This could be a valuable model system for the control of caveolae 
(independently of other rafts) to manipulate mRNA transcription in cancer.  
 
Inhibition by the bisphosphonates of farnesyl pyrophosphate synthase has not attracted 
much research interest despite the fact that zoledronic acid is a widely prescribed drug 
(in the treatment of bone conditions). The use of bisphosphonates to inhibit synthesis 
of farnesyl pyrophosphate and gerenylgeranyl pyrophosphate and so prevent 
isoprenylation of the GTP-ases such as Ras and prevent it from correctly binding to its 
site of action may be another clinical possibility to impede metastasis through the 
mevalonate pathway. It also illustrates the attractiveness of targeting steps in the distal 
end of the pathway – the bisphosphonates specifically inhibit farnesylpyrophosphate 
synthase some five (and also six) steps further forwards, when compared to the statins, 
and they are known to be well tolerated drugs, while 5% of patients using statins suffer 
from toxic muscle damage (Hamilton-Craig, 2001).  
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All four of the Ras isoforms are modified by farnesyl isoprenylation to become 
oncogenically active forms of the protein but this process can be prevented using 
geranylgeranyl protein transferase inhibitors (GGPTIs) that are able to inhibit tumour 
growth in mice. However, this treatment also killed the mice (Lobell et al., 2001). 
However, if Ras isoprenylation can be prevented using cholesterol inhibitors there 
would be wider scope for doses and reduced mortality. Certainly, farnesyl transferase 
inhibitors and GGPTIs are currently an exciting group of new drug candidates (Buhaescu 
and Izzedine, 2007).  
 
Campbell et al examined the effects of statins on the growth of breast cancer cells. They 
found that only the lipophilic statins caused a reduction in the proliferation of the MB-
231 cells whereas Pravastatin had little effect on growth (Campbell et al., 2006). This 
response is supported by the data presented here – at the concentrations used there 
was no observable reduction in proliferation by Pravastatin but effects on motility were 
apparent and consistent. It could be that for anti-proliferative action to manifest the 
drug concentration in the cells must be higher than required to produce more subtle 
effects on metastatic behaviours. The reported mode of actions for anti-cancer effects 
of statins in vitro are multifold (Sassano and Platanias, 2008). Statins are often 
described as pleiotropic in nature (Zhou and Liao, 2010) [see also Appendix 1]. Their 
cancer related effects include prevention of geranylgeranylation (Ras, Rac, Rab and 
RhoA GTP-ases are all subject to post translational prenylation); inhibition of EGFR; 
activation of Map kinase pathways; induced nitric oxide synthase (eNOS) and arginase 
dependent pathways; caspase-9 activation and inhibition of MMP synthesis. However, 
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Dulak and Jozkowicz point out that some of these studies on the effects of statins on 
cancer cell growth have used very high concentrations (10µM - 100µM) to observe an 
effect (Dulak and Jozkowicz, 2005). What is rarely proposed in these studies are 
mechanistic hypotheses for the effects on a molecular level. Some mevalonate-pathway 
based interactions are readily understood, not least because raised cholesterol is known 
to be associated with gastric (Caruso et al., 2002), breast (Kucharska-Newton et al., 
2008) and leukaemia (Tatidis et al., 2001) cancers, and cholesterol can increase the 
aggressiveness of cancers in vivo (Goldstein and Brown, 1990). Many others are 
obscure. However, it is plausible that some are a result of up- and down- regulation of 
protein expression resulting from the effects of statins on raft-based signal 
transduction.   
 
4.1.5 THE MEVALONATE PATHWAY 
Cholesterol is produced in the cell by the mevalonate pathway but also enters the cell 
from plasma in the form of low-density lipoprotein. In order to maintain the optimal 
level of cholesterol production, the cell must balance these two sources and it performs 
this function through a number of negative feedback systems including down-regulation 
of transcription of HMG-CoA reductase and squalene synthase (Goldstein and Brown, 
1990). This is achieved by the sterol regulatory element (SRE-1) but even when the cell 
is saturated with sterol, attenuation of the mRNA transcription of the HMG-CoA 
reductase is incomplete. In this case approximately 12% of the transcription continues 
the supply of HMG-CoA reductase enzyme. This is because the mevalonate pathway 
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also feeds pyrophosphate intermediates into the farnesylation pathways regardless of 
the cells requirement for cholesterol [see also Appendix 2]. 
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4.1.6 RESEARCH OVERVIEW 
 
This research looked at a number of cholesterol inhibitors – including some novel 
compounds – to see the effects they have on cholesterol synthesis and indirectly on raft 
related signalling. The involvement of cholesterol in cancer pathogenesis is not 
straightforward: for example, it has long been known that (in vitro) macrophages 
(Devries-Seimon et al., 2005) and other cells (Lu et al., 2011) become apoptotic when 
challenged with exogenous cholesterol and yet, recent meta-studies in the USA have 
revealed a negative correlation between the consumption of cholesterol-lowering drugs 
(statins) and the incidence of cancer related morbidity and mortality (Dale et al., 2006). 
These two behaviours of cholesterol appear to be at odds, since most clinical 
treatments of cancer seek to promote apoptosis. One explanation may be that 
cholesterol has different attributes dependent upon its location in the cell (or indeed in 
the body) or even that cholesterol can have multiple roles in cancer dependent on the 
type of cancer cell, staging of the cancer and environmental co-factors. This 
notwithstanding, statins themselves have been implicated in advancing apoptosis in 
breast cancer and other cells by mechanisms independent of cholesterol inhibition 
(Herrero-Martin and Lopez-Rivas, 2008).  
 
As part of this research, the effects of cholesterol inhibitors on the expression of one 
particular membrane inclusion protein, caveolin-1, are investigated. An examination is 
made of the effects of blockades at three different points: HMG-CoA, Δ-7 and Δ-24. 
These points of inhibition cause HMG-CoA, 7-dehydrocholesterol (and 5,7,24-
cholestatrienol) and desmosterol to accumulate respectively.  This study shows that 
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Proadifen is most effective at preventing the formation of caveolae while the statin and 
AY9944 share with Proadifen an ability to reduce the prevalence of rafts in general. This 
implies that Cav-1 is not able to intercalate with desmosterol but can coordinate to 
form caveolae with 7-dehydrocholesterol. In the case of the statin, there is simply 
reduced feedstock entering the mevalonate pathway and this reduction in membrane 
cholesterol probably explains the reduction in raft formation seen in this study.  
 
An array of signalling proteins are quantified under different treatments, as is the 
composition of the membrane. The downstream consequences of perturbation of the 
signals cannot be fully assessed but an effort is made to correlate signalling inhibition 
with metastatic potential in vitro. The upstream effects on the proteome – that is to say, 
the way that the signalling protein levels are attributable to the canonical pathways or 
possibly induction/suppression of protein expression, is tested using mRNA profiling. 
The global effects on cellular morphology are also recorded by optical and electron 
microscopy. 
 
The project began with a series of assays to determine the metastatic behaviours of the 
human breast cancer cell line MDA-MB-231 treated with a variety of agents believed to 
impact cholesterol, but early experiments based on colonization of cleared areas in the 
tissue culture plates were unsuccessful. One of the effects of Proadifen is pronounced 
de-attachment of the cells leading to growth from within the cleared patch rather than 
into it from the margins. A number of similar assays were examined but all were 
vulnerable to this phenomenon. Cell adherence was also measured.  One assay, the 
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phagokinetic track assay wherein the cells are visualised clearing a track through a gold 
colloid was effective but did not produce unequivocal data with the equipment 
available. It did however indicate that Proadifen does affect motility. Total cholesterol 
and membrane cholesterol was measured in the treated cells to check the effects of the 
agent on the amount and location of cholesterol being produced. 
 
A separate strand of research involved the assay of the cells for Cav-1 protein and this 
assay was used to test all of the analogues synthesised. There was clearly a need to 
correlate the expression of this protein to metastatic potential and ultimately this was 
achieved using a fluorescence based gel-invasion test that combined motility and 
expression of digestive enzymes by the cancer cells.  From these experiments it was 
clear that Cav-1 expression is correlated to motility and proteolysis. Using a 
combination of the Cav-1 assay and the gel invasion assay the analogues could be 
ranked in terms of efficacy.   
 
It was hypothesized that a reduction of cholesterol leads to a reduction of caveolae, and 
to a lesser extent, a reduction of rafts per se. This appears to be true but the 
experiments indicate an inhibition of Δ-24 reductase is a specific route to this reduction. 
To better understand the implications of lowered levels of caveolae on the cell and to 
examine how caveolae are implicated in metastasis, gene expression was measured 
using whole genome mRNA profiling. This data, coupled with protein array data, 
provides a comprehensive picture of wide scale changes caused by the cholesterol 
inhibitors.  As an interesting comparison, the lymphoma line BJAB was used in the 
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protein array experiment as this line is non-adherent and does not spread through the 
body using the normal metastasis tools of de-attachment, intravasation and re-
attachment. BJAB appears to be less sensitive to the inhibitors although any 
morphological changes caused by the drugs could not be imaged by e.m. because BJAB 
cell line lives in suspension. 
 
Morphological changes in MDA-MB-231 are evident during exposure to Proadifen and 
these were imaged using scanning and transmission microscopy. Light microscopy also 
reveals some differences in the shape of the cells. A number of additional assays were 
performed to measure changes to the raft marker Flotilin and to several other cancer 
markers. The data indicates 1.875mM of Proadifen can reduce by half the Flotilin 
available to the antibody but was not the most potent inhibitor of rafts: AY9944 at a 
dose of 10µM reduced Flotilin by 30%. AY9944 does not however impact Cav-1 
availability and has a membrane cholesterol lowering approximating that of Pravastatin 
at 1.25mM. It is, however, quite toxic. 
 
Cholesterol measurements from both whole cells and cell membrane fractions were 
taken with a number of treatments. The membrane cholesterol lowering potentials of 
the statin and Proadifen are similar in magnitude. To check that the effects of Proadifen 
were not unique to MDA-MB-231 cells, a second cell line (lung cancer, CaLu-1) was used 
in identical mRNA and gel invasion experiments. The results showed that there were 
differences in the magnitude of effects but the response between treatments was very 
similar.  
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Throughout the experiments, Pravastatin was used as a model hydrophilic type HMG-
CoA reductase inhibitor and provides a baseline for the anti-cholesterol effects of other 
types of cholesterol inhibitor. Statins are reported to be anti-metastatic although their 
mode of action remains uncertain [see Appendix 2].  Proadifen and its analogues 
blockade the cholesterol synthetic pathway at the penultimate sterol Desmosterol 
although they can also inhibit other synthetic steps in the pathway that are reliant on Δ-
24 reductases. This is in contrast to the statins that have their effects at the proximal 
end of the pathway. If the effects on cancer metastasis are to be enhanced without 
deleterious effects on other cell systems, the specificity of the molecule to the distal 
(but upstream of the isoprenoid branch) part of the pathway may be a useful 
development. It is well known that statins cause moderate side effects in vivo and the 
mRNA data indicates profound changes to gene expression resulting from their use. 
Subsequent alterations to the proteome may contribute to this pathology. 
4.1.7 PROADIFEN VERSUS PRAVASTATIN 
This research has revealed that unlike statins, Proadifen inhibits cholesterol synthesis 
through Δ-24 reductase activity and yet increases mRNA expression of Δ-24 reductase 
as well as all other enzymes involved in the synthesis of cholesterol. The consequent net 
reduction in membrane cholesterol is concurrent with a decrease in Cav-1 protein but 
whether this is due to the reduction of sterol in the membrane or to the direct down-
regulation of CAV1 is unknown. Cholesterol synthesis and caveolae formation are linked 
because Cav-1 requires cholesterol to form its oligomer which determines the shape of 
the membrane inclusion. Previous research in this field has focussed on the recruitment 
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of Cav-1 into cholesterol-rich domains that become caveolae. This work has shown that 
there is a RNA involvement either caused by depletion of cholesterol or cholesterol 
intermediates or caused by reduction of caveolae with their associated signalling.  
Inhibition of the HMG-CoA reductase, the Δ-7 reductase and the Δ-24 reductase all 
caused wholesale shifts in gene expression but while the statin and the Δ-7 reductase 
had many overlaps the Proadifen caused a very different set of responses. Generally 
however, the result of Proadifen treatment is lower cholesterol, fewer rafts, lower Cav-
1, reduced expression of CAV1, and so presumably fewer caveolae.   
 
Proadifen – like the statins – appears to impact the behaviours of cancer cells. In 
particular, cell-ECM adhesion is dramatically reduced and it is hypothesized that this is 
due to a reduction in adhesion factors found on membrane structures such as cilia and 
flagella. The cells studied are normally quite motile but as adhesion is lost, so too is 
motility. Microscope images of the treated cells confirm that Proadifen causes the cell 
to lose almost all its peri-membrane structures outside of the bilayer. It seems likely 
that this is caused by the reduction of cholesterol. Indeed, electron microscopy reveals 
drastic changes to the surface of the cells and these changes to the external structures 
could explain the loss of adhesion seen in the adherence assays. Interestingly, R.A 
Cooper noticed that the contours of erythrocytes grown in cholesterol enriched media 
became “redundant and folded”41 whereas the corollary is also true: in this study 
reduction of cholesterol appears to have a generally smoothing effect on the 
membranes.  Another significant effect of Proadifen treatment is the change to the 
proteome. Many proteins – including those associated with proliferation, angiogenesis 
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and apoptosis are simultaneously reduced -and this is also seen at the mRNA level. 
Other proteins are found in elevated concentrations. It is conceivable that the reduction 
in cholesterol is the driver for these protein changes since signal transduction may be 
mediated by cholesterol-rich rafts. It is possible that a homeostatic mechanism involving 
sequestration of additional signals to the membrane is a response to cholesterol 
depletion. 
 
The differences observed between the Proadifen and the statin treatments may be due 
to a specific reduction in caveolae upon exposure to Proadifen. If this is the case then 
Proadifen may be used to target caveolae signal transduction. Certainly, the mRNA 
expression profiling data supports the hypothesis that statins are able to reduce rafts 
per se but that an additional action is involved with Proadifen that (also) reduces the 
prevalence of caveolae. The mechanisms may well be different despite an apparent 
overlap of activity against cholesterol synthesis. Interestingly, Proadifen was not the 
only treatment found to down-regulate the expression of CAV1: Fluphenazine and LPC 
also caused a lower expression of this gene. It is unclear if this is due to the sterol 
intermediates that accumulate as a result of treatment, producing unfavourable 
environments for raft or caveolae formation. Perhaps cholesterol or its intermediates 
are involved in a feedback system to CAV1. That a reduction of specific types of rafts 
then causes gene expression to alter is speculative but would account for the 
differences seen in the data. Generally, the levels of proteins detected tracked the gene 
expression profile.  
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Certainly, cancer cells treated with Proadifen behave differently in vitro, have a very 
different signal protein composition and are morphologically distinct. Proadifen and its 
analogues effectively reduce cholesterol in vitro and have measurable impacts on in 
vitro cancer cell behaviour, similar in magnitude to the statins. The site of action of 
Proadifen is very different to the HMG-CoA reductase inhibitors and this may present 
both opportunities and problems. Further work in a mouse or rat model would be 
invaluable to assess if the in vitro responses translate to an in vivo situation and would 
also quickly reveal if toxicity is an issue.  
 
4.1.8 FUTURE RESEARCH 
The control of cancer metastasis by suppression of caveolae-mediated signalling in vivo 
may be possible but the consequences of using Proadifen or similar enzyme inhibitors 
to achieve this end may entail significant negative effects on ‘innocent’ cell systems. 
Historical work with Proadifen in the 1970’s revealed problematic p450 activity and this 
contributed to the decision (by Smith, Kline & French Ltd.) to abandon further work with 
the compound. However, Triparenol – currently a putative drug - suffers from the same 
issues. Some of the new Proadifen analogues synthesised for this study may offer 
improved toxicological profiles - by greater specificity in binding to the Δ-24 reductase 
enzyme - but they do not offer greatly improved anti-cancer characteristics.  
 
Cav-1 knockdown cells (or rodent model) offer a good opportunity to examine the 
effects of caveolae separate to other signalling platforms and would be a valuable next 
step for this research. Also, the gene expression profiling in this study produced a very 
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large data set and this project concentrated on a tiny minority of genes: the data 
suggests that many metabolic and other systems are impacted by statins and further 
data mining may yield useful information on the pleiotropic effects of statins. The 
microplate assay developed to examine proteolysis and motility is crude but has the 
potential to be a useful experimental protocol if refined since it is applicable to the 
testing of agents that cause almost immediate de-attachment of cells from the plate 
and gives unequivocal data on motility that otherwise tends to be subjective. It may be 
improved by using a better fluorophore ligand or by a single reading at 6 or 12 hours to 
prevent photobleaching of the gelatin-conjugate substrate. 
 
Many signal transduction systems are found on raft entities and the ability to 
specifically target caveolae formation may be useful to combat pathologies where 
caveolae-mediated protein interactions are essential to disease progression. Some 
non-statin cholesterol inhibitors appear to offer this tantalising prospect. Perhaps the 
most immediate application could be against cancers where elevated Cav-1 is 
implicated in pathology and already used as a prognostic marker. 
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Abstract 
There is increasing evidence that statin treatment can be beneficial in certain cancer 
patients. To determine if these benefits are a direct result of the cholesterol lowering effects 
of statins or a result of secondary, protein transcription effects, the impacts of Pravastatin 
and a cholesterol sequestrating agent methyl–β-cyclodextrin (MβCD) on mRNA expression 
in the breast cancer cell MDA-MB-231 and the lung carcinoma cell Calu-1 have been 
compared by microarray techniques. The effects of these agents on cholesterol-rich rafts 
and caveolae, which have significance in cancer signalling, have also been examined. Both 
treatments caused a general down-regulation of not only signal transduction including 
cancer pathway proteins, but also apoptosis and chemokine pathways, with statins 
impacting 35 genes by 2-fold or greater in MDA-MB-231 and >300 genes in Calu-1. These 
manifold dysregulations could also explain the various side-effects reportedly caused by 
statins. MβCD produced far fewer statistical events than Pravastatin in the breast cancer 
line but many more in the lung cell line. Pravastatin increased expression of CAV1 but 
caveolae density decreased and overall raft density was unaffected. MβCD also caused an 
increase in CAV1 expression and reduced the prevalence of both rafts and caveolae. It is 
proposed that sequestration of cholesterol from the membrane by MβCD is not equivalent 
to blockade of the cholesterol pathway and causes different effects on microdomain 
mediated signal transduction dependant on the cell line. The profound effects of statins on 
mRNA expression can be explained by the failure of caveolin-1 to properly complex with 
cholesterol in an altered sterol environment, with caveolae acting as the main loci for 
signalling directed towards those transcription processes unaffected by MβCD. Targeted 
inhibition of the post-mevalonate pathway could offer an opportunity to specifically reduce 
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caveolae-based signalling in cancer cells. The observed impact of Pravastatin on gene 
expression may explain the pleiotropic effects of statins when they are used as adjuvants in 
chemotherapy and suggests impact on gene expression as a possible cause of side-effects 
from statin use. 
 Keywords: cancer, gene expression, pravastatin, rafts, caveolae 
 
Introduction 
Statins inhibit the in vivo expression of inflammatory cytokines1, C-reactive protein (CRP)2,3 
interleukins, tumour necrosis factor (TNF) and matrix metalloproteins (MMP)4. These 
inflammatory mediators are involved in many different diseases5 including coronary 
disease6, type-2 diabetes7,8 and Alzheimer’s9. The possible clinical benefits of statin use 
outside the normal lipid lowering applications have been reported and these pleiotropic 
effects have attracted considerable interest10.  The use of statins to control cancer has also 
been explored11,12 with some studies showing beneficial use in prostate cancer recurrence 
after surgery13  and radiation therapy14; colorectal cancer15,16 and ovarian cancer17. Others, 
notably cancers in the lung and bladder18, do not respond19. Some researchers have 
postulated that statin use could even promote tumour growth20,21 through up-regulation of 
proteins involved in angiogenesis22, although the evidence is by no means conclusive.  
Several putative models have been proposed for the pro-apoptotic and anti-metastatic 
effects of statins including the direct down-regulation of specific genes such as survivin in 
prostate cancer cells23 and in breast cancer cells, and transcription factor activation of c-Jun, 
part of the mitogen activated protein kinase group that induce apoptosis and inhibit 
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growth24. In contrast, two mechanisms that are closely linked to the mevalonate pathway 
inhibited by statins are i) reduction in geranylgeranylpyrophosphate and 
farnesylpyrophosphate  that cause isoprenylation and activation of RhoA,  Ras and other 
pro-oncogenic proteins25,26 and ii) reduction of caveolin-1 and cholesterol dependent 
endocytosis leading to non-canonical signalling and tumour development in colon cells27, 
presumably through reduction of the complexing of Cav-1 with cholesterol to form caveolae 
in a reduced cholesterol environment  Direct down-regulation of CAV1 expression is another 
route to fewer caveolae and generally reduced signal transduction.  It is possible that more 
than one mechanism is involved in the manifold effects of statins on cancer progression. 
Statins are known to affect gene expression in calcium regulatory (eg SERCA3) and 
membrane repair systems and this has been postulated as a cause of statin associated 
peripheral myopathy28. These ‘extensive’ changes in protein turnover have also been found 
in non-myopathic patients receiving statins29.  Although the in vivo effects of statins on gene 
expression have been studied in aortic cells30 and carotid explants31 there have been few, if 
any, attempts to measure genome-wide mRNA changes following exposure to statins in 
human cancer cells despite the plethora of data suggesting involvement by statins in cancer 
pathways. It is difficult to discriminate between the cholesterol related effects of the statin 
and other effects the molecule may have on the proteome.  
The objective of this study was to investigate the impact on gene expression by microarray 
based techniques using the ER-negative and p53-mutant human cell line MDA-MB-231 as a 
model invasive breast cancer and the human lung carcinoma line Calu-1 as an example of an 
aggressive lung cancer. Much of the epidemiological work linking statin use with reduced 
morbidity and mortality has alluded to possible anti-metastatic effects. For this reason these 
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two highly invasive cell lines were tested to examine if genes associated with metastasis 
were affected.  Pravastatin was chosen as a model HMG-CoA reductase inhibitor. To 
examine if the observed effects on gene expression were caused by a reduction of 
cholesterol per se, methyl-β-cyclodextrin, a cyclic oligomer of glucose that is able to entrap 
cholesterol in its hydrophobic core and specifically sequester the sterol from the 
membrane32, was used for comparison since it mimics only the ultimate cholesterol 
lowering effects of the statin.  
Rafts and caveolae are morphologically and chemically distinct platforms that rely on high 
concentrations of cholesterol and, once assembled, serve as platforms for multiple 
signalling systems. To determine if these cholesterol-rich domains were disrupted by the 
treatments, flotillin was used as a general indicator of overall raft density and caveolin-1 as 
a specific marker of caveolae.  Both were assayed using immuno-fluorescence techniques.  
 
Experimental. 
Materials and Methods 
Sources: MDA-MB-231 and Calu-1 cells were obtained from Cell Lines Service, Eppenheim, 
Germany. Explorer protein microarrays were purchased from Full Moon Biosciences Inc, 
California. Illumina HumanHT12_V4_0_R2_15002873_B human expression microarray was 
purchased from Gen-Probe Ltd, UK. RNeasy Maxi Kit was purchased from Qiagen Ltd. All 
other reagents were sourced from Sigma Aldrich Ltd, UK except where noted.  
Treatments: The final concentrations of Pravastatin and MβCD in culture flasks were 8.0µM 
and 0.00085% (w/v) respectively, dissolved in DMEM plus 10% v/v serum. The dose of 
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Pravastatin was chosen because low millimolar serum levels are attainable in vivo at high 
doses of other statins (Lovastatin)33.  Treatment exposure was for 24 hours beginning after 
cells reached 80% confluence. The same treatment regime was used in the antibody assays 
at a range of doses were used 
All treatments and controls were conducted in quadruplicate and the microarray was 
performed using these four biological replicates. There were no technical replicates.  Cells 
were treated in 174ml culture flasks (Nunc) containing 40ml of Dulbeco’s DMEM with 10% 
(v/v) FBS per treatment. Negative control flasks contained only the FBS supplemented 
media.  Treatments were 24 hours and treatment start time was 24 hours after sub-culture. 
Incubation was at 37oC with 5.0% CO2.  Cells from each treatment were harvested with 
0.5g/L porcine trypsin w/v and 0.2g/L w/v EDTA in Dulbecco phosphate buffer and 
immediately spun down to a cell pellet. The cells were then re-suspended in PBS containing 
0.1% of Sigma Protease inhibitor cocktail and then re-centrifuged. The resultant cell pellet 
was then stored in LN2 prior to RNA or protein extraction.  
mRNA expression profiling. Array analysis was performed in accordance with the 
manufacturer’s guidance. Each treatment was conducted in quadruplicate and there were 
no technical replicates in this study.  
Protein assay. Treatments and controls were prepared as above. Each Explorer array slide 
has 656 protein probes in duplicate. Mean spot intensities and coefficient of variations were 
recorded to provide standard errors. 
Immuno-fluorescence Assays. A conjugate of fluorescein isothiocyanate (Ex495 and Em525) 
and anti-Flotillin antibody was prepared using the Sigma Fluorotag kit and affinity isolated 
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anti-Flotillin-1 produced in rabbit. The second antibody used in the experiment was anti-
Caveolin-1 that was purchased pre-conjugated to the cyanine dye Cy3 (Ex550nm and 
Em570nm). 1.25ml of phosphate buffer solution was added to 1mg of lyophilised protein 
and the light-protected tube vortexed for 1 minute. It was used without further preparation. 
Both antibodies were used at 1µg/ml in 96 x 100µl plates (Sterilin).  Readings were taken 
using a Biochrom 480 fluorescence plate reader after 1 hour exposure post treatment 
followed by three gentle washes with phosphate buffer pH 7.4. 
Statistical Treatment 
 
Raw array data were assessed for quality, and outliers removed. The remaining arrays were 
normalised and array features annotated. A threshold for significance was adjusted to 
p<0.01 and significant loci in each comparison were assessed for functional enrichment of 
KEGG pathways, and GO terms, based on their annotation information. p values were 
adjusted using Benjamini & Hochberg method for multiple testing, to 0.001 for the 
comparison of significant array features.  
 
Normalisation of the 47,319 features across all arrays was achieved using robust spline 
normalisation after data were subjected to a variance stabilizing transformation. Raw data 
were transformed using a variance stabilizing transformation (VST) method prior to 
normalisation across all arrays using the robust spline normalisation (RSN) method. 
Expression measures (summarised intensities) are in log base 2. 
Probesets on the array may have been annotated as being a member of a KEGG pathway 
(www.kegg.jp).  Significant genes (adjusted p<0.01) from each comparison were analysed 
for enrichment of KEGG pathway membership using a hypergeometric test. Enrichment (p < 
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0.05) was assessed for up-regulated and down-regulated genes separately. Significant genes 
(adjusted p<0.01) from each comparison were analysed for enrichment of GO terms across 
all three GO ontologies using a hypergeometric test. Enrichment (p < 0.001) was assessed 
for up-regulated and down-regulated genes separately. 
 
Pravastatin treatment relative to negative control 
101 array features were statistically significant at p<0.01; (27 up-regulated, 74 down-
regulated). Within the significant features, ANGPTL2, COL5A1, COPS2, DST, FOS, GAS2L1, 
GPR56, GPRC5C, ID1 and ID2 were up-regulated. Within the significant features, ABCA1, 
ADM, ANGPTL4, C10orf10, C13orf15, C15orf48, C7orf68, CCL20, CCL26 and CDCP1 were 
down-regulated.  
The predominant (number of p<0.01 features are in parenthesis) up-regulated pathways 
include those associated with TGF-beta signalling (3), focal adhesion (2) and ECM-receptor 
interactions (2).  
The predominant down-regulated pathways include those associated with cytokine-cytokine 
receptor interactions (9), chemokine signalling (5), NOD-like receptor signalling (5), cancer 
(4) and MAPK signalling (3). In terms of observed fold change (independent of statistical 
threshold), no features exhibited >2-fold up-regulation, while 24 features exhibited >2-fold 
down-regulation. Fold changes ranged from 2-fold up to 10.4-fold down  
20 KEGG pathways were statistically enriched. Members of ECM-receptor interaction 
pathways were amongst those enriched in up-regulated loci. Members of cytokine-cytokine 
receptor interaction and NOD-like receptor signalling pathways were amongst those 
enriched in down-regulated loci. CAV1 was up-regulated by 10%, FLOT1 by 1% and overall 
gene expression was down-regulated by 0.55% compared to the control group.  In Calu-1 
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cells, 5107 array features were statistically significant (2535 up-regulated, 2572 down-
regulated). The predominant up-regulated pathways include metabolic pathways (154), 
pathways in cancer (37), endocytosis (35), insulin signalling pathway (29), MAPK signalling 
pathway (28), lysosome (26), cytokine-cytokine receptor interaction (22) The predominant 
down-regulated pathways include metabolic pathways (126), pathways in cancer (57),  
 
In terms of observed fold change (independent of statistical threshold), 219 features 
exhibited >2-fold up-regulation, while 174 features exhibited >2-fold down-regulation. Fold 
changes ranged from 11.1-fold up to 5.1-fold down. Within the biggest change loci, NUPR1, 
GDF15, TRIB3, RNF165, DDIT3, ASNS, DDIT4, PDE5A, CTH and PCK2 were up-regulated. 
Within the biggest change loci, TXNIP, MMP3, STC1, CTGF, GLIPR1, NPPB, BMPER, EDN1, 
MAP2K3 and CYP24A1 were down-regulated. FLOT1 was up-regulated with a log2 fold 
change of 0.51 (p=0.0024). CAV1 was also up-regulated but this was not statistically 
significant.  
 
59 KEGG pathways and 408 GO terms were statistically enriched. Members of steroid 
biosynthesis were enriched in up-regulated loci. Members of spliceosome, cell cycle and 
DNA replication pathways were amongst those enriched in down-regulated loci.  
 
MβCD treatment relative to negative control 
There were 79 statistically significant (3 up-regulated, 76 down-regulated) array features. 
Within the significant features, MARCH4, NQO1 and SNX6 were up-regulated and ABCA1, 
ADAM8, ADM, AGR2, ANGPTL4, C10orf10, C13orf15, C15orf48, C7orf68 and CCL20 were 
down-regulated. The predominant down-regulated pathways include those associated with 
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cytokine-cytokine receptor interactions (9), cancer (6), chemokine signalling (5), NOD-like 
receptor signalling (5), MAPK signalling (3), Toll-like receptor signalling (3), Type I diabetes 
mellitus (3), bladder cancer (3), metabolism(2), Apoptosis (2) and VEGF signalling (2).  
In terms of observed fold change (independent of statistical threshold), no features 
exhibited >2-fold up-regulation, while 13 features exhibited >2-fold down-regulation. Fold 
changes ranged from 1.6-fold up to 3.2-fold down. Within the biggest change loci, THBS1, 
AMY1C, FTLP2, NQO1, ID3, FLNC, CAV1, RPL35, SLC7A5 and PSMC1 were up-regulated. 
Cytokine-cytokine receptor interaction and NOD-like receptor signalling pathways were 
down-regulated loci. CAV1 was up-regulated by 25% and the entire treatment caused a 
global increase in gene expression of 8.64% compared to the control group. FLOT1 was not 
significantly affected (increasing by 1.9%). 
In Calu-1 cells, 6868 array features were statistically significant (3417 up-regulated, 3451 
down-regulated). The predominant up-regulated pathways include metabolic pathways 
(173), pathways in cancer (50), endocytosis (39), MAPK signalling pathway (37), insulin 
signalling pathway (34), lysosome (30), cytokine-cytokine receptor interaction (29). The 
predominant down-regulated pathways include metabolic pathways (174), pathways in 
cancer (73), spliceosome (61) and cell cycle (53).  In terms of observed fold change 
(independent of statistical threshold), 393 features exhibited >2-fold up-regulation, while 
349 features exhibited >2-fold down-regulation. Fold changes ranged from 16.4-fold up to 
8.1-fold down. Within the biggest change loci, GDF15, NUPR1, TRIB3, DDIT3, RNF165, ASNS, 
PDE5A, CTH, DDIT4 and FBXO32 were up-regulated. Within the biggest change loci, CTGF, 
STC1, NPPB, BMPER, CYP24A1, GLIPR1, TXNIP, MMP3, EDN1 and MARCH4 were down-
regulated. FLOT1 was up-regulated by log2 fold change of 0.56 (p=0.00069) but CAV1 was 
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not affected. 66 KEGG pathways were statistically enriched. Members of steroid 
biosynthesis were amongst those enriched in up-regulated loci. Members of spliceosome, 
cell cycle and DNA replication pathways were amongst those enriched in down-regulated 
loci.  
500 GO terms were statistically enriched with members annotated with intracellular, 
intracellular part and membrane-bounded organelle GO terms amongst those up-regulated 
loci. Members annotated with organelle part, intracellular organelle part and organelle GO 
terms were amongst those enriched in down-regulated loci.   
 
Pravastatin relative to MΒCD: There were 27 statistically significant array features (16 up-
regulated, 11 down-regulated). Within the significant features, ANGPTL2, GAS2L1, GPR56, 
GPRC5C, ID1, ID2, IGFBP6, ITGB4, MALL and MXD4 were up-regulated while ABCA1, CRY1, 
FST, IGFBP3, IL11, LOX, MMP1, PTGER4 and PTGS2 were down-regulated. The predominant 
up-regulated pathways include TGF-beta signalling (2). The predominant down-regulated 
pathways include pathways in cancer (2). In terms of observed fold change (independent of 
statistical threshold), no features exhibited >2-fold up-regulation, while 3 features exhibited 
>2-fold down-regulation. Fold changes ranged from 1.8-fold up to 3.3-fold down. Six KEGG 
pathways and 21 gene ontology terms were statistically enriched. Genes annotated with 
regulation of localization, negative regulation of transport and negative regulation of 
hormone secretion gene ontology terms were amongst those enriched in down-regulated 
loci.   
In Calu-1, 382 array features were statistically significant (210 up-regulated, 172 down-
regulated). The predominant up-regulated pathways include metabolic pathways (8), 
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cytokine-cytokine receptor interaction (7) and protein processing in endoplasmic reticulum 
(6). The predominant down-regulated pathways include metabolic pathways (17), cell cycle 
(8), pathways in cancer (7), DNA replication (6). 
23 KEGG pathways were statistically enriched with members of prion diseases, protein 
processing in endoplasmic reticulum and NA pathways among those up-regulated loci. 
Members of DNA replication, cell cycle and pancreatic cancer pathways were amongst those 
enriched in down-regulated loci.  
 
113 GO terms were statistically enriched. Members annotated with cellular response to 
stress, response to stress and cellular response to stimulus GO terms were amongst those 
enriched in up-regulated loci. Members annotated with cell division, DNA replication and 
organelle fission GO terms were amongst those enriched in down-regulated loci.  
 
Discussion. 
The response in mRNA expression caused by the two agents suggests some, but not total, 
commonality in mechanism. The volcano plots of mRNA events in MB231 cells reveal that in 
the statin treatment the there is a bias towards down-regulation [Figures 1-2]. MβCD versus 
statin [Figure 3] shows that both treatments cause similar responses, with some additional 
down-regulations caused by the statin. In Calu-1 cells the response is very different with a 
symmetrical distribution of statistical events in both treatments [Figures 4-6] and some 
additional up-regulations caused by the statin. In these two cell lines both the statin and 
MβCD showed considerable crossover in impact on ABCA1, ADM, ANGPTL4, C10orf10, 
C13orf15, C15orf48, C7orf68, CCL20 and this suggests a similar mode of action. Significantly, 
ABCA1 is a cholesterol efflux regulator34, while C13orf15 and ANGPTL4 control the cell 
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cycle35,36,37 and increase tumour growth respectively. A direct DNA suppression of these 
latter genes by both agents seems unlikely so an indirect cholesterol raft-mediated 
mechanism is an intriguing possibility. The results suggest that removal of cholesterol by 
either statin or MβCD causes changes in gene expression unfavourable to cancer 
development, with both treatments causing cancer pathways specifically to be down-
regulated. However, apoptotic pathways are also down-regulated. In MDA-MB-231 cells 
MβCD produced fewer events at p<0.001 (regardless of impact) than pravastatin, with many 
fewer genes up-regulated. At the doses used in this research MβCD invoked down-
regulation of the proteins involved in cholesterol synthesis to a greater extent than 
pravastatin suggesting that normal lipid homeostasis is secondary to cholesterol-raft based 
signal transduction directed at the genome. In Calu-1 MβCD had a drastic effect on gene 
regulation with 742 features exhibiting a fold change of >2. This suggests that Calu-1 is more 
than 20 times as susceptible to the effects of MβCD as the breast cancer cell line but the 
genes most affected are up-regulated and are not related to cancer pathways. The global 
gene events caused by the treatments are given in Table 1. Further analysis of the data set 
reveals that many of these features are highly significant but have a low fold change value 
and are therefore unlikely to affect cell health. In MDA-MB231 cells Pravastatin down-
regulated 4 cancer pathways and increased CAV1 expression by 10% and FLOT1 by 1% 
(p<0.05). Overall gene expression was reduced by 0.55%. In Calu-1 cells 37 cancer pathways 
were up-regulated and 57 were down-regulated.  MβCD treatment, in contrast, caused 6 
cancer pathways in MDA-MB231 cells to be down-regulated and CAV1 expression to be up-
regulated by 25%. Overall gene expression in this experiment was increased by 8.64% 
(p<0.05). However, in Calu-1 cells 37 cancer pathways were up-regulated and 57 were 
down-regulated by statin treatment and mirrored the result of MβCD treatment (50 up-
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regulated and 73 down-regulated). When the two treatments in MDA-MB-231 cells are 
compared [Table 2] 2 genes specifically related to cancer are significantly affected by statin 
but not MβCD: PTGS2 (Log FC -1.73; p = 6.50E-06) and IL8 (Log FC -1.01; p=0.017). In Calu-1 
cells 7 cancer related genes have low p values but the fold-change is minimal. These include 
IL-6, CCND1 and SMAD3. The data from the MβCD relative to Pravastatin treatments 
suggests that removing cholesterol from the bilayer is not biologically equivalent to 
inhibition of the mevalonate pathway. 
MDA-MB-231 was analysed for differences in the densities of cholesterol-rich rafts and 
caveolae following treatment with Pravastatin and MβCD as determined by immuno-
fluorescence [Figure 7-8]. The results indicate that both treatments cause a reduction of 
available Cav-1 at the membrane – despite the observed up-regulation of CAV1, with 
Pravastatin causing a significantly greater reduction. This difference in response to the 
treatments was not seen in Flot-1 availability suggesting that Pravastatin causes a specific 
reduction in caveolae but not rafts per se.  Caveolae have unique signalling functionality in 
cancer that can vary by cell type and stage of disease progression38 and caveolae require 
cholesterol for their formation. Pravastatin causes depletion of available sterol to perform 
this function but also causes significant reduction in membrane Cav-1 (as assayed by 
immunofluorescence) favouring the formation of rafts rather than caveolae with any 
available cholesterol. This is despite an up-regulation in CAV1 gene expression.  Indeed, rafts 
containing other sterol intermediates are likely to be viable signalling platforms whereas 
caveolae may have a specific requirement for cholesterol so that the Cav-1 protein can 
oligomerize and coordinate with the other lipids correctly.  However, the statin is able to 
significantly reduce membrane Cav-1 at higher doses. Neither treatment caused any change 
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to the amount of flotillin actually being transcribed by RNA so it seems likely that the 
changes in membrane flotillin and caveolin are not driven by transcription events but rather 
they are a down-stream result of the reduction of cholesterol. Statins are known to induce 
COX-2 gene expression in a manner consistent with farnesyl transferase inhibitors, 
geranylgeranyltransferase inhibition and impairment of G-protein prenylation39 but this 
does not explain the breadth of response at the mRNA level.  It has been suggested that 
statins specifically antagonise a set of genes modulated by L-NAME induced hypertension in 
vivo40 but the results presented here reveal that 35 genes are modulated >2-fold by 
pravastatin in breast cancer cells and more than 300 are affected >2-fold in lung cancer 
cells. 
Statins are among the most prescribed pharmaceuticals and have undoubted health 
benefits not limited to lipid lowering indications. However, membrane repair genes are 
activated during statin treatment irrespective of clinical myopathy and this could be due to 
cholesterol deprived membranes becoming more permeable to ion leakage as the bilayer 
becomes fluidised without sufficient sterol re-enforcement. Calcium leakage is associated 
with myopathy. It has been reported that 5% of patients using statins suffer from toxic 
muscle damage41. Common side-effects of statin treatment include peripheral myopathy 
and mood disturbance42, but multiple others can be expected given the profound 
alterations that statins cause to both membrane microdomains and gene expression.  
While the anti-inflammatory and anti-oncogenic characteristics of some statin treatments 
are unexpected but welcome it is possible that rebound effects on gene expression 
following termination of long-term statin use – similar to those seen in inflammatory 
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response43 - might result in reduced or reversed biochemical impact in cancer patients 
benefiting from statin treatment.   
The overall effect on cancer of statin treatment may be either deleterious or beneficial 
depending on the cell type, cancer phenotypes and tissue environment. Cholesterol is, after 
all, primarily a structural component of the plasma membrane and it seems reasonable to 
assume that its effects can be measured by the density of those microdomains that are rich 
in this sterol - be they predominantly cholesterol-lipid or cholesterol-protein in nature. 
Many of the anti-cancer and anti-inflammatory effects noted by other researchers could be 
explained by a diminution of either raft or caveolae based canonical pathways leading to 
mRNA dysregulation or abortive non-canonical signalling. 
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Figures 
MDA-MB-231 Volcano Plots 
 
 
FIGURE 1-2 PRAVASTATIN CAUSES MANY MORE AND GREATER INTENSITY DOWN-REGULATIONS COMPARED TO MΒCD. THE DIFFERENT 
RESPONSE IN TERMS OF GENE EXPRESSION COULD BE A RESULT OF THE TYPE OF MEMBRANE DOMAIN AFFECTED BY THE TWO 
TREATMENTS 
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FIGURE 3 VOLCANO PLOT OF PRAVASTATIN RELATIVE TO MΒCD. THE TREATMENTS DO NOT HAVE EQUIVALENT EFFECTS ON MRNA 
EXPRESSION 
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Calu-1 Volcano Plots 
 
 
 
 
FIGURE 4-6  VOLCANO PLOTS OF FOLD CHANGES AND SIGNIFICANCE IN CALU-1 LUNG CELLS. 
 
233 
 
 
FIGURE 7 THE EFFECTS OF PRAVASTATIN AND MΒCD ON CAVEOLIN-1 PROTEIN DETECTION BY IMMUNOFLUORESCENCE ASSAY. 
MβCD caused a reduction in Caveolin-1 concentrations at both doses tested. The statin did not reduce cav-1 at 8µM but at 
much higher concentrations did reduce levels of the protein with a clear dose response. * indicates statistical significant 
difference p<0.05 between treatment and control data by Annova Two-tailed test, n=3. 
 
 
FIGURE 8  THE EFFECT OF PRAVASTATIN AND MΒCD ON FLOTILLIN-1 PROTEIN DETECTION BY IMMUNOFLUORESCENCE ASSAY. 
Pravastatin did not reduce Flotillin concentrations indicating that statins may not reduce prevalence 
of cholesterol-rich rafts in MB231. MβCD did reduce raft density. * indicates statistical significant 
difference p<0.05 between treatment and control data by Annova Two-tailed test, n=3. 
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Tables 
Table 1 Changes to array features by treatment with Pravastatin and MβCD 
Cell Type Comparison Significant array 
features at p<0.001 
(corrected using 
Benjamini and 
Hochberg method for 
multiple testing 
Features >2 fold change 
MDA-MB-231 Pravastatin relative to 
Control  
101  35  
MDA-MB-231 MβCD relative to 
Control  
79  34 
MDA-MB-231 Pravastatin relative to 
MβCD  
27  8 
Calu-1 Pravastatin relative to 
Control  
2013 393 
Calu-1 MβCD relative to 
Control  
3149 742 
Calu-1 Pravastatin relative to 
MβCD  
30 4 
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Table 2 Most significantly affected genes 
Treatment Cell Type Gene Identifier Log Fold Change Adjusted Significance 
Pravastatin-Control MDA-MB-231 PTGS21 -2.10 1.62E-11 
MβCD-Control MDA-MB-231 Lipocalin-22 -0.96 6.19E-10 
Pravastatin-MβCD MDA-MB-231 PTGS2 -1.73 6.50E-06 
Pravastatin-Control Calu-1 ASNS3 2.63 5.43E-18 
MβCD-Control Calu-1 ASNS 2.87 1.18E-18 
Pravastatin-MβCD Calu-1 RNU1-54 1.42 1.75E-06 
 
When the 50 genes with the highest fold-change are ranked according to adjusted statistical 
significance these four genes are most impacted.  
  
                                                          
1 Prostaglandin-endoperoxide synthase-2 is a component of the Pathways in Cancer and Small Cell Lung Cancer 
pathways 
2 Steroid transport protein 
3 Asparagine synthase 
4 snRNA component of the spliceosome 
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Abstract 
Cancer related morbidity is negatively correlated to the use of statins but the processes 
underlying this epidemiological observation are poorly understood. Direct anti-neoplastic 
effects are thought to involve isoprenoid intermediates that permit post-translational 
modification of the Rho family of GTPases. The role of statins as anti-metastatic agents 
appears more complex, involving a balance of mesenchymal and epithelial traits. 
In breast cancer MB231 and lung adenocarcinoma CaLu-1 treated with either a statin or a Δ-
24 oxidoreductase inhibitor we found the statin had the greater effect on mRNA metastatic 
markers and that lung cancer cells are more vulnerable to this intervention. Overlaps with a 
hESC marker gene-set revealed that exposure of cells to statins causes changes in gene 
expression that indicate a partial shift of cellular identity towards mesenchymal status. 
Wider analysis of the genome revealed that cytoskeleton genes and matrix 
metalloproteinases, but not growth-related genes, are antagonised by statins. Genes 
controlling the formation of invadapodia, a characteristic features of motile cancer cells, are 
down-regulated.  
It is hypothesized that chemotaxis local to these protrusions is necessarily diminished. The 
cellular response to paracrine signals, normally triggering adaptation of the cancer cell to its 
new environment, is therefore truncated.  We conclude that inhibition of the isoprenoid 
pathway, but not cholesterol per se, promotes quiescence of disseminated cancer cells by 
reducing transduction of extrinsic factors to the nucleus.  Thus, farnesyl pyrophosphate 
(FPP) and geranyl pyrophosphate (GPP) mediate cognition signals that move gene 
expression in the direction towards pluripotency. 
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Introduction 
The dissemination of solid tumour cell clones often precedes the detection of the primary 
growth. The metastatic cascade is a multistep process beginning with infiltration through 
the organ of the primary cancer and into the blood stream1. This stage has often occurred 
prior to treatment (for example, 40% of newly diagnosed patients with non-small lung 
cancer already have metastases2) and it is therefore later steps of the cascade that 
represent opportunities for useful chemotherapeutic intervention: specifically suppression 
of existing disseminated cells at a pre-aggressive stage3. Typical oncology drugs target 
replication and promote apoptosis but these are ineffective strategies to kill latent clones 
and progress has been impeded by a lack of validated predictive biomarkers of metastatic 
potential4. Angiogenesis has been successfully targeted5 by drugs such as Bevacizumab but 
newer therapies targeting other phenotypic changes or intrinsic genetic or epigenetic 
markers are sought to combat metastasis6. Statins as incidental inhibitors of isoprenoid 
pathway have been studied in the context of cell cycle arrest and apoptosis7 but their 
putative effects on metastasis per se have not been fully explained.  
 
Paget’s ‘seed and soil’ theory 8 indicates that disseminated cancer cells only fulfil their 
potential for invasion and proliferation when they are able to adapt to their new 
environment. It is likely that MET enables the cell to re-acquire the signal processing 
apparatus that allows cognition of the microenvironment 9 and we hypothesize that MET is 
restricted by statins. Distal metastases are under stress by their new microenvironment and 
by any systemic drug regimen - the response being either adaptive10 or quiescent11. 
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Quiescent cells, including micro-metastases, can remain dormant for years yet changes to 
the microenvironment can then trigger unrestrained proliferation and the re-emergence of 
disease 12,13. 
EMT (epithelial to mesenchymal transition) can be induced by extrinsic factors such as 
hepatocyte growth factor, VEGF, platelet derived factor and others 14. EMT cells are not only 
motile but also non-senescing and refractory to apoptosis inducing treatments. Van Zijl calls 
this amoeboid phenotype “the ultimate exit strategy of cancer cells” 15.  A switch into MET is 
needed for the cell to undergo differentiation into the distal organ identity and lose the 
plasticity needed for invasion. We propose that only those hESC genes that map to invasion 
characteristics in MET cells are central to the pathology of metastatic cancer – specifically 
those genes that mediate response to extrinsic recognition factors.  The absence of 
extracellular matrix (ECM) recognition at this stage can cause the micrometastases to 
become dormant and that this cognition is inhibited by statins, making their mode of action 
as antimetastatic agents very useful to study.  
 
Invadapodia and lamellipodia were first observed in MDA-MB-231 cells and these 
protrusions permit motility and are primary sites of proteolysis16,17. They are the structures 
that allow the cell to sense its environment by chemotaxis18. Bravo-Cordero et al have 
described how the micro-environment directs the nature of motility behaviour19. This being 
the case, it is reasonable to suppose that inhibition of the formation of invadapodia will 
likewise prevent the transduction of extrinsic factors that would normally permit successful 
MET.   
244 
 
Β-catenin, N-cadherin and vimentin are regarded as mesenchymal signature marker 
proteins contributing to the formation of lamellopodia and increased motility. However, 
EMT and MET are likely to be characterised by wide scale changes of protein production and 
require full genomic analysis to measure qualitatively. For this reason, while some cancer 
markers, cytoskeleton and invadapodia markers and some of the enzymes involved in the 
mevalonate pathway are extracted for detailed analysis, perhaps more meaningful is the 
overlap of data of statin-treated groups with a hESC identity and the move of the treated 
groups towards a quasi-mesenchymal genetic status.  
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Materials and Methods 
Sources: MDA-MB-231 and CaLu-1 cells were obtained from Cell Lines Service, Eppenheim, 
Germany. Illumina HumanHT12_V4_0_R2_15002873_B human expression microarrays were 
purchased from Gen-Probe Ltd, UK. RNeasy Maxi Kit was purchased from Qiagen Ltd. All 
other reagents were sourced from Sigma Aldrich Ltd, UK except where noted.  
Treatments: The final concentrations of Pravastatin and Proadifen (N,N-diethylaminoethyl 2, 
2-diphenylethanoate hydrochloride)  in culture flasks were 8.0µM and 0.00085% (w/v) 
respectively, dissolved in DMEM plus 10% v/v serum. Pravastatin, a lipophilic statin has 
previously been shown to have pro-apoptotic properties that are dependent upon inhibition 
of HM-CoA reductase20. The dose of Pravastatin was chosen because low millimolar serum 
levels are attainable in vivo at high doses of other statins (Lovastatin)21.  Treatment 
exposure was for 24 hours beginning after cells reached 80% confluence.  
Gene Expression Assay 
All treatments and controls were conducted in quadruplicate and the microarray was 
performed using these biological replicates. There were no technical replicates except 
where noted.  Cells were treated in 174ml culture flasks (Nunc) containing the agent 
dissolved in 40ml of Dulbeco’s DMEM with 10% (v/v) FBS per treatment. Negative control 
flasks contained only the FBS supplemented media.  Treatments were 24 hours and 
treatment start time was 24 hours after sub-culture. Incubation was at 37oC with 5.0% CO2.  
Cells from each treatment were harvested with 0.5g/L porcine trypsin w/v and 0.2g/L w/v 
EDTA in Dulbecco phosphate buffer and immediately spun down to a cell pellet. The cells 
were then re-suspended in PBS containing 0.1% of Sigma Protease inhibitor cocktail and 
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then re-centrifuged. The resultant cell pellet was then stored in LN2 prior to RNA extraction. 
Array analysis was performed in accordance with the manufacturer’s guidance.   
Statistical Treatment 
Raw array data were assessed for quality, and outliers removed. 47,319 features were 
transformed using a variance stabilizing transformation (VST) method prior to normalisation 
across all arrays using the robust spline normalisation (RSN) method. p values were 
adjusted, using Benjamini & Hochberg method for multiple testing, to 0.001 for the 
comparison of significant array features. Expression measures (summarised intensities) are 
in log base 2. Assou et a 22 published a meta-analysis of stem cells that provided a core set 
of pluripotency markers. These up and down regulated genes map to 91 and 55 probes on 
the Illumina HT-12 microarray respectively. This set of 146 markers was contrasted with the 
drug induced genes in both the treated and control MDA-MB-231 and CaLu-1 experiments. 
To assess convergence with hESC data the experimental and public datasets were merged 
(see table 1) and 79 probes that overlapped all groups were retained.  An adjusted p value 
threshold was set to <0.05 and then further reduced to the largest 15 up- and down logFC 
measurements. 
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Results 
Tables 2 and 3 show the 15 most significant values of the convergence sets of hESC gene expression 
and the two treatments in both cell lines. These have been further re-ordered by log 2 fold change 
(logFC) data so that the magnitude and the directionality of the changes can be seen.  The table 
shows that the largest effects within these top 15 results have mainly the same directionality as the 
hESCs and favour EMT. Both treatments caused some markers associated with EMT to be up-
regulated with growth factors the most significant group of convergent and up-regulated genes that 
are affected by the treatments. The top 15 affected genes (by p value) in the statin treatment 
include 5 genes appearing in both cell lines but Proadifen treatments had no common genes 
between the two lines. 
Table 4 shows that Proadifen (but not Pravastatin) causes a significant up-regulation of the enzymes 
in the mevalonate pathway in MDA-MB-231. This suggests a feedback loop from the cholesterol 
pathway to the mevalonate pathway under mRNA control. Both treatments have less impact on 
mevalonate intermediates in CaLu-1 line in this analysis despite this cell type being more responsive 
to the treatments overall. Both Proadifen and Pravastatin caused a rise in the level of FDFT1` in 
CaLu-1. 
Table 5 compares the effects of the treatment and cell type on four classic metastasis markers, each 
of which has an impact on the formation and behaviour of invadapodia. Here, Pravastatin down-
regulates the cancer promoters PLAUR/CD87 by a small amount (LogFC  -0.089) in MDA-MB-231 but 
increases the expression of promoter S100A by logFC 0.54. However, this table reveals an 
asymmetry between the cell types with the statin causing down-regulation of the cancer suppressor 
NDRG1 in MDA-MB-231 (LogFC -1.4) and (LogFC +0.96) in CaLu-1. Proadifen had a negligible effect 
274 
 
on the expression of both NDRG1 and CDH1. In MDA-MB-231 cells Proadifen effects were all down-
regulatory while in CaLu-1 they were all positive. 
Table 6 highlights only those genes most active at the membrane of the invadapodia: matrix 
metalloproteinases (MMPs 1,2, 3,7, 24 and 28) and Rho associated mediators of cytoskeleton 
rearrangement: Ena VASP23, ROCK and its regulator PDK124, Rac25  and RhoC26 . 
Only those genes with significant up/down regulation are shown. This analysis shows that on this 
gene subset, Pravastatin on CaLu-1 cells has the most consistent effects, notably down-regulating 
CDC42, MMP1, MMP3 and RhoC but surprisingly, up-regulating EGFR.  Across both cell lines there 
are six genes (p<0.05) that have opposite directionality following exposure to Proadifen and 
Pravastatin: of these, ANGPLTL2, a paracrine signal and member of VEGF family is up-regulated by 
the statin (0.16 in MDA-MB-231 and 0.19 in CaLu-1) and down-regulated by Proadifen (-0.057 and -
0.29 respectively). ID1, a transcription factor restricting gene expression is affected in the same way 
(up-regulated by the statin + 0.98 and +0.67 and down-regulated by Proadifen -0.44 and -2.3 in 
MDA-MB-231 and CaLu-1 respectively).  
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Discussion and Conclusions 
Much research effort has been focussed on the reduction of cancer related morbidity and mortality 
in long term statin users and we have previously reported that gene expression of cells treated with 
statins in vitro is profoundly altered27. The mevalonate pathway intermediates geranylgeranyl 
pyrophosphate (GGPP) and farnesylpyrophosphate (FPP) are responsible for the isoprenylation of 
numerous GTP-ase signal proteins. Here, we present evidence that these post-translational 
modifications may condition mRNA transcription and reduce phenotypes associated with 
invadapodia, invasion and motility. Certainly statins appear to reduce these behaviours in vitro  
particularly in combination with farnesyl transferase inhibitors.  
Statins competitively inhibit the HMG-CoA reductase enzyme found at the beginning of the 
mevalonate pathway. They have been implicated in pleiotropic effects such as inflammation, 
immune modulation and autophagy of cancer cells while epidemiological studies suggest a 
beneficial role in cancer recurrence.  Proadifen is a Δ-24 oxidoreductase inhibitor and truncates the 
pathway at the desmosterol and lanosterol intermediates. Proadifen prevents conversion of 4,4-
Dimethylcholesta-8,[9], 24-dien-3β-ol to 4,4-Dimethylcholesta-8[9},24-en-3β-ol, zymosterol into 7-
Dihydroxyzymesterol, 7,24-cholestadien-3β-ol into 7-cholesten-3β-ol and 5,7,24-cholestatrien-3β-ol 
into 5,7-cholestadi en-3β-ol. It is thus able to prevent the synthesis of cholesterol without an impact 
on mevalonate or squalene intermediates such as farnesylpyrophosphate or geranylpyrophosphate. 
It is included in the experiments to identify the involvement, if any, of the distal sterol pathways in 
EMT-MET transitions. 
The results suggest that inhibitors of the mevalonate pathway have considerable impacts on gene 
expression and that the response varies by cell type: CaLu-1 is much more vulnerable to the effects 
of statins. The response to Proadifen is significantly less than the response to Pravastatin and this is 
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unsurprising since its target of Δ-24 reductase features in the cholesterol pathway downstream of 
the production of farnesyl pyrophosphate and geranylpyrophosphate. Intriguingly however, 
Proadifen does have notable effects on gene expression and this suggests enzyme inhibition outside 
of the cholesterol pathway. It may be significant that Proadifen inhibits several of the cytochrome 
p450 mono-oxygenase reactions in a non-specific manner28.  
A number of nitrogenous bisphosphonates are currently used clinically to reduce bone re-sorption 
in osteoporosis and bone cancer. They inhibit farnesyl diphosphate synthase29  probably because 
bisphosphonic acid is competitively binding in place of pyrophosphonic acid 30,31: the result is GGPP 
depletion. Weimer and Hohl32  have generated bisphosphonate analogues with greater specificity 
against GGDPS and these are clinically relevant to metastasis. Additional specificity against GGDPS 
has been added by other researchers using phosphonacetamidooxy- and organoboronfunctional 
groups33,34. The signal transduction of the farnesylated Ras35 and Rho is blocked by farnesyl 
transferase inhibitors that have anti-cancer effects36. However, Proadifen and Pravastatin caused a 
small rise in the expression of farnesyl diphosphate farnesyl transferase suggesting a feedback 
system is employed by the cell.  
An inability to process extrinsic factors in the ECM due to inadequate prenylation or 
phosphorylation appears to truncate the transduction cascade connecting the extrinsic signalling to 
RNA transcription.  Gene expression is thus unchanged and the cells remain quiescent. Likewise, 
cells forced to maintain a more epithelial identity maybe unable to re-acquire malignant 
proliferation 37,38. 
Inhibitors of the mevalonate pathway weakly blockade farnesylation and geranylation yet this study 
suggests that statins are able to restrict cytoskeleton rearrangement required for invadapodia 
function and as a consequence the cell is unable to properly process extrinsic signals that would 
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normally permit full transition to epithelial identity. Other indicators of pluripotency are affected by 
the treatments and the response is cell-type specific, with CaLu-1 displaying more sensitivity to the 
statin compared to MDA-MB-2312.  It is proposed that limited decreases in isoprenylation of signal 
proteins taking place in invadapodia cause an arrest of the MET and could induce cancer cell 
latency. More targeted inhibition of FFDP and GGDP synthesis using specific and irreversible 
inhibitors, rather than competitively binding inhibitors, could further impede MET signalling. The 
indication of such a drug would most usefully be the forced dormancy of disseminated tumour cells 
and suppression of metastatic disease. Both the statin and Δ-24 reductase inhibitor reduce the 
formation of invadapodia; in the case of the statin, it is theorized that this attenuates signal 
transduction from the ECM to the nucleus and could arrest the cells transition towards adaptation. 
Proadifen treatment does not have the same effect on gene regulation despite the gross changes to 
the cell morphology. The photomicrographs reveal that both the statin and Proadifen impact the 
formation of lamellae and invadapodia, yet the statin reduces the metastatic markers and the Δ-24 
reductase inhibitor has the only statistically significant effect on the mevalonate pathway enzymes 
(See table 4).  
 
One explanation for this could be that the statin utilizes a feedback control system for HMG-CoA 
that involves the sterol element binding proteins (SREBPs) via the isoprenoid pathway while the 
Proadifen utilises a secondary feedback regulation of reductase mediated by cholesterol and 
reduces squalene synthase in a manner proposed by Brown et al39.  
 
Suppression of squalene synthase in such a multivalent feedback would leave the isoprenoid 
pathway and the SREBPs unaffected. This explains why the statins affect isoprenoid mediated 
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transduction of ECM signals with consequent down-regulation of affected metastatic genes and 
why Proadifen does not. 
 
For the first time a link between the mevalonate pathway and a metastatic phenotype is 
established. Inhibition of prenylation of paracrine signals is one possible mechanism for this and 
provides an explanation of the anti-cancer effects of statins observed in epidemiological studies. 
Further work is needed to follow gene expression and protein levels in vivo during the metastasis of 
cancer cells into their ultimate host organ and the cell-type dependant effects of Proadifen deserve 
additional investigation.  
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TABLE 1  SAMPLE NUMBERS FOR THE TREATMENTS INDICATE BIOLOGICAL REPLICATES. HESC DATA WERE TAKEN FROM THE PUBLIC GEO DATASETS 
GSE42956, GSE35027 AND GSE37077  (WWW://WWW.NCBI.NLM.NIH.GOV/GEO/) 
 MB231 
 
Calu-1 hESCs Fibroblasts 
Pravastatin 4  
GSE47461 
3  
GSE47458 
  
Proadifen 4 
 GSE47461 
3  
GSE47458 
  
Control 4 
 GSE47461 
3  
GSE47458 
3 
GSM1053949, GSM1053950 
GSM1053951, GSM860961 
GSM860962, GSM860963 
GSM910308, GSM910309 
6 
GSM1053955, 
GSM1053956, 
GSM1053957, 
GSM1053961, 
GSM1053962, 
GSM1053963 
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TABLE 2 HESC MARKER SET FILTERED TO THE 15 LOWEST P VALUE AND ORDERED BY LOGFC 
MB-231 Pravastatin P-Factor Up/Down 
Actual 
direction 
   
Symbol Description 
Regulated in 
hESCs of FC 
Log2 Fold 
Change 
 
P-Factor 
IGFBP3 insulin-like growth factor binding protein 3   -2.70 
 
5.70E-14 
IGFBP3 insulin-like growth factor binding protein 3   -2.20 
 
9.70E-14 
NDRG1 N-myc downstream regulated 1   -1.40 
 
5.70E-10 
PIM2 pim-2 oncogene   -0.38 
 
1.00E-03 
NASP 
 
nuclear autoantigenic sperm protein (histone-
binding)   -0.17 
 
3.30E-02 
UGP2 UDP-glucose pyrophosphorylase 2   -0.06 
 
3.80E-02 
DCN decorin   -0.01 
 
1.90E-02 
SNRPN small nuclear ribonucleoprotein polypeptide N   0.01 
 
4.00E-02 
BMP4 bone morphogenetic protein 4   0.03 
 
9.70E-03 
HSPA4 heat shock 70kDa protein 4   0.10 
 
2.90E-03 
KRT18 keratin 18   0.14 
 
1.00E-02 
PHF17 PHD finger protein 17   0.14 
 
2.70E-02 
M6PR 
mannose-6-phosphate receptor (cation 
dependent)   0.24 
 
2.60E-02 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)   0.31 
 
5.10E-02 
COL5A1 collagen, type V, alpha 1   0.43 
 
2.00E-05 
      
MB-231 Proadifen P-Factor Up/Down 
Actual 
direction 
   
Symbol Description 
Regulated in 
hESCs of FC 
Log2 Fold 
Change 
 
P-Factor 
IGFBP3 insulin-like growth factor binding protein 3   -0.59 
 
2.10E-04 
DLGAP5 
 
discs, large (Drosophila) homolog-associated 
protein 5   -0.47 
 
2.30E-03 
UGP2 UDP-glucose pyrophosphorylase 2   -0.44 
 
1.90E-03 
CD47 CD47 molecule   -0.41 
 
8.30E-05 
IGFBP3 insulin-like growth factor binding protein 3   -0.36 
 
4.00E-03 
SEPHS1 selenophosphate synthetase 1   -0.30 
 
1.60E-03 
PSIP1 PC4 and SFRS1 interacting protein 1   -0.28 
 
6.00E-04 
HELLS helicase, lymphoid-specific   -0.18 
 
4.30E-03 
CD47 CD47 molecule   -0.11 
 
1.50E-02 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta   -0.01 
 
7.30E-03 
GABRB3 
gamma-aminobutyric acid (GABA) A receptor, 
beta 3   0.01 
 
1.20E-02 
POU5F1 POU class 5 homeobox 1   0.01 
 
8.20E-03 
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta   0.12 
 
9.60E-03 
M6PR 
mannose-6-phosphate receptor (cation 
dependent)   0.39 
 
1.10E-03 
PLA2G16 phospholipase A2, group XVI   0.44 
 
6.70E-04 
OVERALL MOVEMENT TOWARDS MET AS A PERCENTAGE OF STATISTICALLY SIGNIFICANT (P<0.05) FOLD CHANGES IN ENTIRE DATA SET IN MDA-
MB-231 PRAVASTATIN: 50% AND PROADIFEN : 50%  BASED ONLY ON DIRECTIONALITY  NOT FOLD CHANGE. 
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TABLE 3 
CALU-1 Pravastatin P-Factor Up/Down Actual direction 
   
Symbol Description 
Regulated in 
hESCs of FC 
Log2 Fold 
Change 
 
P-Factor 
NASP nuclear autoantigenic sperm protein (histone-binding)   -1.10 
 
3.70E-10 
UNG uracil-DNA glycosylase   -1.00 
 
1.20E-07 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5   -0.93 
 
4.30E-07 
COL1A1 collagen, type I, alpha 1   -0.80 
 
7.50E-07 
BMP4 bone morphogenetic protein 4   -0.73 
 
7.50E-06 
BUB1 
 
budding uninhibited by benzimidazoles 1 homolog 
(yeast)   -0.67 
 
1.80E-07 
MSH2 
 
mutS homolog 2, colon cancer, nonpolyposis type 1 (E. 
coli)   -0.64 
 
1.50E-07 
LUM lumican   -0.55 
 
8.60E-07 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5   -0.52 
 
2.20E-06 
AASS aminoadipate-semialdehyde synthase   0.43 
 
7.30E-06 
KRT7 keratin 7   0.66 
 
3.10E-06 
PHF17 PHD finger protein 17   0.72 
 
1.20E-06 
TERF1 telomeric repeat binding factor (NIMA-interacting) 1   0.72 
 
4.50E-06 
SNRPN small nuclear ribonucleoprotein polypeptide N   0.83 
 
1.50E-08 
NDRG1 N-myc downstream regulated 1   0.96 
 
9.20E-08 
       
       CALU-1 Proadifen P-Factor Up/Down Actual direction 
   
Symbol Description 
Regulated in 
hESCs of FC 
Log2 Fold 
Change 
 
P-Factor 
COL1A1 collagen, type I, alpha 1   -4.20 
 
1.30E-18 
BMP4 bone morphogenetic protein 4   -2.60 
 
2.70E-14 
COL1A2 collagen, type I, alpha 2   -1.80 
 
1.10E-11 
UNG uracil-DNA glycosylase   -1.80 
 
1.40E-11 
ANGEL2 angel homolog 2 (Drosophila)   -1.40 
 
7.70E-13 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5   -1.30 
 
1.70E-09 
NASP nuclear autoantigenic sperm protein (histone-binding)   -1.10 
 
2.10E-10 
COL5A1 collagen, type V, alpha 1   -1.10 
 
1.20E-09 
SEPHS1 selenophosphate synthetase 1   -0.86 
 
8.90E-10 
LUM lumican   -0.80 
 
3.80E-09 
SNRPN small nuclear ribonucleoprotein polypeptide N   1.10 
 
3.30E-10 
TERF1 telomeric repeat binding factor (NIMA-interacting) 1   1.10 
 
1.20E-08 
PHF17 PHD finger protein 17   1.70 
 
1.70E-12 
PHF17 PHD finger protein 17   1.80 
 
1.70E-13 
NDRG1 N-myc downstream regulated 1   1.80 
 
4.50E-12 
 
OVERALL MOVEMENT TOWARDS MET AS A PERCENTAGE OF STATISTICALLY SIGNIFICANT (P<0.05) FOLD CHANGES IN ENTIRE DATA SET IN CALU-1 
PRAVASTATIN: 60.3% AND PROADIFEN:54% BASED ONLY ON DIRECTIONALITY NOT FOLD CHANGE. 
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TABLE 4   CHANGES IN GENE EXPRESSION OF ENZYMES INVOLVED IN THE MEVALONATE PATHWAY 
   
Cell Line 
 
ID 
 
MDA-MB-231 Calu-1 
Treatment Mevalonate pathway enzymes LOG FC Adj. p LOG FC Adj. p 
Proadifen DHCR7 Δ-7 reductase 1.5 7.7 E-08 1.5 3.1E-09 
 
FDFT1 Farnesyl diphosphate farnesyl transferase 1.3 4.10 E-07 1.1 8.4E-12 
 
LSS Lanosterolsynthase 1.3 1.70 E-06 -0.012 >0.05 
 
DHCR24 Δ-24 reductase 1.1 3.2 E-05 0.61 0.0029 
 
SQLE Squalene epoxidase 0.87 0.00086 0.89 0.000013 
       
Pravastatin DHCR7 Δ-7 reductase -0.25 >0.05 1.6 2.4E-09 
 
FDFT1 Farnesyl diphosphate farnesyl transferase 0.15 >0.05 1.3 1E-12 
 
LSS Lanosterolsynthase -0.0078 >0.05 -0.099 >0.05 
 
DHCR24 Δ-24 reductase 0.097 >0.05 0.046 >0.05 
 
SQLE Squalene epoxidase 0.15 >0.05 0.033 >0.05 
 
 
ALL STATISTICALLY SIGNIFICANT CHANGES IN LOGFC ARE POSITIVE SUGGESTING THE CELLS’ HOMEOSTASIS RESPONSE TO REDUCED PATHWAY INTERMEDIATE FEEDSTOCK IS UP-REGULATION OF THE RELEVANT 
ENZYMES. BOTH DRUGS CAUSED Δ7 REDUCTASE AND FDFT1 EXPRESSION TO BE DRASTICALLY INCREASED. 
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TABLE  5  DIFFERENCES IN RESPONSE BY TREATMENT AND CELL TYPE ON CANCER MARKERS 
 
Cell line 
  
MDA-MB-231 Calu-1 
   
Pravastatin v control Proadifen v control Pravastatin v control Proadifen v control 
   
logFC P.Value adj.P.Val logFC P.Value adj.P.Val logFC P.Value adj.P.Val logFC P.Value adj.P.Val 
Cancer 
Promoters 
 
PLAUR 
 
 
Plasminogen 
activator, urokinase 
receptor -0.089 p>0.05 n/a -0.64 0.00068 0.043 -0.87 0.000026 0.00067 0.19 0.24 >0.05 
 
S100A4 
 
S100 calcium 
binding protein A4 0.54 1.60E-08 2.00E-05 -0.4 1.00E-06 0.00036 0.88 4.70E-06 1.70E-04 0.43 5.80E-03 0.03 
Cancer 
Suppressors 
NDRG1 
 
N-myc downstream 
regulated 1 -1.4 5.70E-10 1.10E-06 -0.023 0.84 0.98 0.96 9.20E-08 7.50E-06 1.8 4.5E-12 4.8E-10 
 
CDH1 
 
Cell adhesion 
molecule 0.00025 p>0.05 n/a -0.012 0.0015 0.069 0.67 7.6E-09 1.1E-06 0.36 0.00003 0.0003 
 
 
S100A ACTIVATES SIGNALLING LEADING TO THE RE-MODELLING OF THE CYTOSKELETON AND ACTIVATES SIGNALLING PATHWAYS40(20).PLAUR /CD87 IS OVER-EXPRESSED IN MANY METASTATIC TUMOURS AND 
IS INVOLVED IN SEVERAL CANCER PHENOTYPES41(21).  NDRG1 AND CDH1 ARE METASTASIS SUPPRESSORS42(22). 
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TABLE 6 DIFFERENCES IN RESPONSE BY TREATMENT AND CELL TYPE ON INVASION MARKERS 
  Fold Change  P-Factor 
 
  MB-231 CALU-1  MB-231 CALU-1 
Symbol Description Pravastatin Proadifen Pravastatin Proadifen  Pravastatin Proadifen Pravastatin Proadifen 
           
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 0.13 0.15 -0.41 0.13  - - 9.20E-04 - 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 -0.014 -0.19 -0.61 -0.014  - 8.30E-03 3.70E-05 - 
EGFR epidermal growth factor receptor -0.1 0.038 0.77 -0.1  - - 7.00E-08 - 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) -1.5 0.37 -0.86 -1.5  1.30E-11 1.90E-03 4.40E-06 1.30E-11 
MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) -0.014 0.36 -2.3 -0.014  - 8.70E-07 4.70E-13 - 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) -0.0037 -0.0044 -0.36 -0.0037  - - 6.30E-04 - 
 
Regulators of cell motility mediated by actomyosin include ROCK and its regulator PDK1, Rho family GTP-ases especially RhoC and CDC42 control cytoskeleton modifying 
proteins. The largest changes were observed following treatment with Pravastatin on the lung cell Calu-1 with many large down-regulations that are statistically significant. 
Calu-1 appears to be very responsive to both of these agents. Notable exceptions are seen in MDA-MB-231 cells where CDC42EP3 was up-regulated on treatment with the 
statin and MMP3 and PDK3 were both up-regulated on treatment with Proadifen. 
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          Untreated control cells   Cells treated with Proadifen  Cells treated with Pravastatin  
 
THESE IMAGES SHOW REPRESENTATIVE CELLS FROM STATIN AND 24-DHCR TREATMENTS. THERE IS A SIGNIFICANT ALTERATION TO THE CELL MORPHOLOGY ASSOCIATED WITH FEWER AND SMALLER 
INVADAPODIA AND CILIA. 
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APPENDIX 3 
 
Detailed results from the gene expression assays. 
 
 
PROADIFEN RELATIVE TO CONTROL: 
361 array features were statistically significant (196 up-regulated, 165 down-regulated). 
Within the significant features, ABL2, ACACA, ACAT2, ACSS2, ACTR5, AHNAK2, AKR1C3, 
AP1M2, APBB1IP and ARHGEF18 were up-regulated. Within the significant features, ABCA1, 
ACOX2, AFAP1L2, AGR2, ALDH1A3, ARSJ, ASF1A, ATP2B1, B3GALNT1 and BCL3 were down-
regulated. 
 
The predominant up-regulated pathways include Metabolic pathways (36), Lysosome (13), 
Steroid biosynthesis (11), terpenoid backbone biosynthesis (7), phagosome (5), Oxidative 
phosphorylation (4), Pyruvate metabolism (4), Collecting duct acid secretion (4), Vibrio 
cholerae infection (4), Epithelial cell signalling in Helicobacter pylori infection (4), Amino 
sugar and nucleotide sugar metabolism (3), propanoate metabolism (3), MAPK signalling 
pathway (3), Protein processing in endoplasmic reticulum (3), Insulin signalling pathway (3), 
Synthesis and degradation of ketone bodies (2), Steroid hormone biosynthesis (2), valine, 
leucine and isoleucine degradation (2), Other glycan degradation (2) and Glycosaminoglycan 
degradation (2). 
 
The predominant down-regulated pathways include Cytokine-cytokine receptor interaction 
(12), Metabolic pathways (10), amoebiasis (7), Pathways in cancer (7), Hematopoietic cell 
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lineage (6), Chemokine signalling pathway (5), NOD-like receptor signalling pathway (5), 
MAPK signalling pathway (4), Leishmaniasis (4), Graft-versus-host disease (4), ErbB signalling 
pathway (3), Cell cycle (3), p53 signalling pathway (3), Cell adhesion molecules (CAMs) (3), 
Tight junction (3), Toll-like receptor signalling pathway (3), Jak-STAT signalling pathway (3), 
Type I diabetes mellitus (3), Salivary secretion (3) and Prion diseases (3). 
 
In terms of observed fold change (independent of statistical threshold), 33 features 
exhibited >2-fold up-regulation, while 16 features exhibited >2-fold down-regulation. Fold 
changes ranged from 20.3-fold up to 4.7-fold down. Within the biggest change loci, 
MIR1978, MIR1974, HMGCS1, SC4MOL, ACSS2, DHCR7, TMEM97, ACAT2, NSMAF and 
HMGCR were up-regulated. Within the biggest change loci, IL8, IL1B, CXCL1, IL6, ACTG1, 
C15orf48, IL11, RASD1, CD24 and THBS1 were down-regulated. 
 
29 KEGG pathways were statistically enriched. Members of Steroid biosynthesis, Terpenoid 
backbone biosynthesis and Lysosome pathways were amongst those enriched in up-
regulated loci. Members of cytokine-cytokine receptor interaction, Amoebiasis and 
Hematopoietic cell lineage pathways were amongst those enriched in down-regulated loci. 
 
 174 GO terms were statistically enriched. Members annotated with sterol biosynthetic 
process, sterol metabolic process and cholesterol biosynthetic process GO terms were 
amongst those enriched in up-regulated loci. Members annotated with extracellular space, 
extracellular region part and cytokine activity GO terms were amongst those enriched in 
down-regulated loci. 
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PRAVASTATIN RELATIVE TO CONTROL: 
101 array features were statistically significant (27 up-regulated, 74 down-regulated). 
Within the significant features, ANGPTL2, COL5A1, COPS2, DST, FOS, GAS2L1, GPR56, 
GPRC5C, ID1 and ID2 were up-regulated. Within the significant features, ABCA1, ADM, 
ANGPTL4, C10orf10, C13orf15, C15orf48, C7orf68, CCL20, CCL26 and CDCP1 were down-
regulated. 
 
The predominant up-regulated pathways include TGF-beta signalling pathway (3), focal 
adhesion (2) and ECM-receptor interaction (2). 
 
The predominant down-regulated pathways include cytokine-cytokine receptor interaction 
(9), chemokine signalling pathway (5), NOD-like receptor signalling pathway (5), 
hematopoietic cell lineage (4), prion diseases (4), amoebiasis (4), pathways in cancer (4), 
MAPK signalling pathway (3), toll-like receptor signalling pathway (3), Leishmaniasis (3), 
Chagas disease (3), Malaria (3), Graft-versus-host disease (3), PPAR signalling pathway (2), 
protein processing in endoplasmic reticulum (2), apoptosis (2), complement and coagulation 
cascades (2), cytosolic DNA-sensing pathway (2), Jak-STAT signalling pathway (2) and Type I 
diabetes mellitus (2). 
 
In terms of observed fold change (independent of statistical threshold), 0 features exhibited 
>2-fold up-regulation, while 24 features exhibited >2-fold down-regulation. Fold changes 
ranged from 2-fold up to 10.4-fold down. Within the biggest change loci, ID1, NQO1, THBS1, 
TUBB3, ID3, IGFBP4, PKM2, TRNP1, GPRC5C and VIM were up-regulated. Within the biggest 
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change loci, PTGS2, IGFBP3, IL8, LOX, IL1B, IL6, MMP1, CXCL1, NDRG1 and CDCP1 were 
down-regulated. 
 
20 KEGG pathways were statistically enriched. Members of TGF-beta signalling pathway, 
ECM-receptor interaction and NA pathways were amongst those enriched in up-regulated 
loci. Members of cytokine-cytokine receptor interaction, NOD-like receptor signalling 
pathway and Prion diseases pathways were amongst those enriched in down-regulated loci. 
 
170 GO terms were statistically enriched. The R-SMAD binding GO term was enriched in up-
regulated loci. Members annotated with extracellular region, extracellular region part and 
extracellular space GO terms were amongst those enriched in down-regulated loci. 
  
MBCD RELATIVE TO CONTROL: 
79 array features were statistically significant (3 up-regulated, 76 down-regulated). Within 
the significant features, MARCH4, NQO1 and SNX6 were up-regulated. Within the significant 
features, ABCA1, ADAM8, ADM, AGR2, ANGPTL4, C10orf10, C13orf15, C15orf48, C7orf68 
and CCL20 were down-regulated. 
 
The predominant down-regulated pathways include cytokine-cytokine receptor interaction 
(9), pathways in cancer (6), chemokine signalling pathway (5), NOD-like receptor signalling 
pathway (5), amoebiasis (5), prion diseases (4), Graft-versus-host disease (4), PPAR signalling 
pathway (3), MAPK signalling pathway (3), toll-like receptor signalling pathway (3), 
hematopoietic cell lineage (3), Type I diabetes mellitus (3), Leishmaniasis (3), Chagas disease 
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(3), malaria (3), bladder cancer (3), metabolic pathways (2), mTOR signalling pathway (2), 
apoptosis (2) and VEGF signalling pathway (2). 
 
 In terms of observed fold change (independent of statistical threshold), 0 features exhibited 
>2-fold up-regulation, while 13 features exhibited >2-fold down-regulation. Fold changes 
ranged from 1.6-fold up to 3.2-fold down. Within the biggest change loci, THBS1, AMY1C, 
FTLP2, NQO1, ID3, FLNC, CAV1, RPL35, SLC7A5 and PSMC1 were up-regulated. Within the 
biggest change loci, PTGS2, IL8, IGFBP3, IL1B, LOX, NDRG1, CDCP1, IL6, STC1 and C15orf48 
were down-regulated. 
 
17 KEGG pathways were statistically enriched. Members of cytokine-cytokine receptor 
interaction, NOD-like receptor signalling pathway and Prion diseases pathways were 
amongst those enriched in down-regulated loci. 
 
145 GO terms were statistically enriched. Members annotated with NAD(P)H 
dehydrogenase (quinone) activity, negative regulation of catalytic activity and NA GO terms 
were amongst those enriched in up-regulated loci. Members annotated with extracellular 
pathways and cytokine activity GO terms were amongst those enriched in down-regulated 
loci. 
 LPC relative to Control: 
5708 array features were statistically significant (2999 up-regulated, 2709 down-regulated). 
Within the significant features, A1BG, AAMP, AARS2, AARSD1, AATF, ABCB6, ABCB9, 
ABCC10, ABCC5 and ABCF1 were up-regulated. Within the significant features, AASDHPPT, 
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ABCA1, ABCB10, ABCC4, ABCF2, ABHD3, EPHX4, ABLIM1, ACAD8 and ACADM were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (178), pathways in 
cancer (41), endocytosis (39), MAPK signalling pathway (38), lysosome (30), focal adhesion 
(30), Huntington's disease (30), purine metabolism (29), spliceosome (28), protein 
processing in endoplasmic reticulum (28), oxidative phosphorylation (26), pyrimidine 
metabolism (26), regulation of actin cytoskeleton (24), cell cycle (23), neurotrophin 
signalling pathway (23), ubiquitin mediated proteolysis (22), phagosome (21), Insulin 
signalling pathway (20), Alzheimer's disease (20) and Parkinson's disease (20). 
 
The predominant down-regulated pathways include metabolic pathways (164), pathways in 
cancer (52), protein processing in endoplasmic reticulum (39), ribosome (37), focal adhesion 
(37), Huntington's disease (35), cell cycle (33), purine metabolism (32), regulation of actin 
cytoskeleton (31), endocytosis (30), cytokine-cytokine receptor interaction (29), Alzheimer's 
disease (28), MAPK signalling pathway (27), spliceosome (26), Wnt signalling pathway (26), 
ubiquitin mediated proteolysis (25), Parkinson's disease (24), phagosome (23), oxidative 
phosphorylation (22) and oocyte meiosis (21). 
 
 In terms of observed fold change (independent of statistical threshold), 260 features 
exhibited >2-fold up-regulation, while 569 features exhibited >2-fold down-regulation. Fold 
changes ranged from 3.3-fold up to 15.9-fold down. Within the biggest change loci, 
C19orf33, ISG15, NUCKS1, SNRNP70, GPR1, FLNC, ATF5, ACTN4, MRPL2 and PVR were up-
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regulated. Within the biggest change loci, IL8, IL1B, ACTG1, RPLP0, ALDOA, SRGN, UBB, 
PTGS2, ACTB and EIF4A1P4 were down-regulated. 
 
63 KEGG pathways were statistically enriched. Members of metabolic pathways, pyrimidine 
metabolism and lysosome pathways were amongst those enriched in up-regulated loci. 
Members of ribosome, Shigellosis and cell cycle pathways were amongst those enriched in 
down-regulated loci. 
 
393 GO terms were statistically enriched. Members annotated with intracellular, 
intracellular part and membrane-bounded organelle GO terms were amongst those 
enriched in up-regulated loci. Members annotated with intracellular pathway and cytoplasm 
pathway GO terms were amongst those enriched in down-regulated loci. 
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FLUPHENAZINE RELATIVE TO CONTROL: 
6808 array features were statistically significant (3428 up-regulated, 3380 down-regulated). 
Within the significant features, A4GALT, AAGAB, AAMP, AARS2, AARSD1, AATF, AATK, 
ABCA7, ABCA8 and ABCB6 were up-regulated. Within the significant features, NCEH1, 
AASDHPPT, ABCA1, ABCB10, ABCC4, ABCC5, ABCD3, ABCE1, ABCF2 and ABHD12 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (184), pathways in 
cancer (60), endocytosis (48), focal adhesion (39), Huntington's disease (37), MAPK 
signalling pathway (36), regulation of actin cytoskeleton (36), protein processing in 
endoplasmic reticulum (35), lysosome (35), purine metabolism (33), cell cycle (30), 
phagosome (30), oxidative phosphorylation (29), chemokine signalling pathway (29), 
pyrimidine metabolism (28), spliceosome (26), Alzheimer's disease (26), ubiquitin mediated 
proteolysis (24), Parkinson's disease (24) and neurotrophin signalling pathway (23). 
 
The predominant down-regulated pathways include metabolic pathways (202), pathways in 
cancer (68), protein processing in endoplasmic reticulum (50), ribosome (47), focal adhesion 
(44), endocytosis (43), regulation of actin cytoskeleton (40), purine metabolism (39), MAPK 
signalling pathway (39), cell cycle (38), Huntington's disease (37), spliceosome (35), 
Alzheimer's disease (33), cytokine-cytokine receptor interaction (31), Wnt signalling 
pathway (31), ubiquitin mediated proteolysis (30), oocyte meiosis (27), neurotrophin 
signalling pathway (27), chemokine signalling pathway (26) and Parkinson's disease (26). 
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In terms of observed fold change (independent of statistical threshold), 421 features 
exhibited >2-fold up-regulation, while 661 features exhibited >2-fold down-regulation. Fold 
changes ranged from 3.6-fold up to 11.9-fold down. Within the biggest change loci, NUCKS1, 
NLRP8, C19orf33, C5orf28, GPR1, NUBPL, PNPT1, ALPP, SNRNP70 and ARFGAP1 were up-
regulated. Within the biggest change loci, IL8, ACTG1, RPLP0, IL1B, ALDOA, SRGN, ACTB, 
UBB, PGAM1 and LOX were down-regulated. 
 
 67 KEGG pathways were statistically enriched. Members of lysosome, pyrimidine 
metabolism and endocytosis pathways were amongst those enriched in up-regulated loci. 
Members of ribosome, protein processing in endoplasmic reticulum and Shigellosis 
pathways were amongst those enriched in down-regulated loci. 
 
450 GO terms were statistically enriched. Members annotated with intracellular pathways 
and intracellular organelle GO terms were amongst those enriched in up-regulated loci. 
Members annotated with intracellular pathways and cytoplasm GO terms were amongst 
those enriched in down-regulated loci. 
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PROADIFEN RELATIVE TO PRAVASTATIN: 
 663 array features were statistically significant (342 up-regulated, 321 down-regulated). 
Within the significant features, ABL2, ACACA, ACAT2, ACLY, ACO1, ACSS2, ADARB1, ADM, 
AHNAK2 and ALDOC were up-regulated. Within the significant features, ABCA1, ACOX2, 
ACTG2, ADAM19, ADNP, AEBP2, AFAP1L2, AIM1, ANGPTL2 and ANXA8L2 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (47), lysosome (20), 
steroid biosynthesis (11), pathways in cancer (11), phagosome (8), terpenoid backbone 
biosynthesis (7), oxidative phosphorylation (5), MAPK signalling pathway (5), protein 
processing in endoplasmic reticulum (5), endocytosis (5), insulin signalling pathway (5), 
Vibrio cholerae infection (5), epithelial cell signalling in Helicobacter pylori infection (5), 
PPAR signalling pathway (4), cytokine-cytokine receptor interaction (4), Jak-STAT signalling 
pathway (4), collecting duct acid secretion (4), amino sugar and nucleotide sugar 
metabolism (3), glycerophospholipid metabolism (3) and pyruvate metabolism (3). 
 
The predominant down-regulated pathways include metabolic pathways (22), focal 
adhesion (8), p53 signalling pathway (7), pathways in cancer (7), purine metabolism (5), cell 
cycle (5), axon guidance (5), pyrimidine metabolism (4), nicotinate and nicotinamide 
metabolism (4), MAPK signalling pathway (4), endocytosis (4), ECM-receptor interaction (4), 
Fc gamma R-mediated phagocytosis (4), Type II diabetes mellitus (4), citrate cycle (TCA 
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cycle) (3), spliceosome (3), protein processing in endoplasmic reticulum (3), phagosome (3), 
TGF-beta signalling pathway (3) and Jak-STAT signalling pathway (3). 
 
In terms of observed fold change (independent of statistical threshold), 74 features 
exhibited >2-fold up-regulation, while 26 features exhibited >2-fold down-regulation. Fold 
changes ranged from 23.7-fold up to 3.6-fold down. Within the biggest change loci, 
MIR1978, MIR1974, PTGS2, ACSS2, HMGCS1, SC4MOL, IGFBP3, NSMAF, MMP1 and DHCR7 
were up-regulated. Within the biggest change loci, THBS1, ACTG1, ID1, RASD1, TUBB, ACTB, 
IGFBP4, TUBB3, LOC148430 and TUBA1A were down-regulated. 
 
23 KEGG pathways were statistically enriched. Members of steroid biosynthesis, lysosome 
and terpenoid backbone biosynthesis pathways were amongst those enriched in up-
regulated loci. Members of p53 signalling pathway, nicotinate and nicotinamide metabolism 
and Type II diabetes mellitus pathways were amongst those enriched in down-regulated 
loci. 
 
143 GO terms were statistically enriched. Members annotated with sterol biosynthetic 
process, vacuole and sterol metabolic process GO terms were amongst those enriched in 
up-regulated loci. Members annotated with cytoplasm, non-membrane-bounded organelle 
and intracellular non-membrane-bounded organelle GO terms were amongst those 
enriched in down-regulated loci. 
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PROADIFEN RELATIVE TO MBCD: 
564 array features were statistically significant (342 up-regulated, 222 down-regulated). 
Within the significant features, ABL2, ACACA, ACAT2, ACLY, ACSS2, ADAM8, ADM, AGAP8, 
AHNAK2 and AKR1C3 were up-regulated. Within the significant features, ABCA1, ACTG2, 
ADAM19, AFAP1L2, ALDH1A3, ANKRD50, ANP32B, ARSJ, ASF1A and ATL3 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (47), lysosome (17), 
steroid biosynthesis (11), terpenoid backbone biosynthesis (8), phagosome (8), oxidative 
phosphorylation (5), endocytosis (5), Vibrio cholerae infection (5), epithelial cell signalling in 
Helicobacter pylori infection (5), pathways in cancer (5), pyruvate metabolism (4), protein 
processing in endoplasmic reticulum (4), cell adhesion molecules (CAMs) (4), insulin 
signalling pathway (4), collecting duct acid secretion (4), glycolysis / gluconeogenesis (3), 
other glycan degradation (3), amino sugar and nucleotide sugar metabolism (3), 
glycerophospholipid metabolism (3) and propanoate metabolism (3). 
 
The predominant down-regulated pathways include metabolic pathways (11), oocyte 
meiosis (9), cell cycle (8), p53 signalling pathway (8), ribosome (5), progesterone-mediated 
oocyte maturation (5), axon guidance (4), tight junction (4), neurotrophin signalling pathway 
(4), pyrimidine metabolism (3), MAPK signalling pathway (3), endocytosis (3), Wnt signalling 
pathway (3), TGF-beta signalling pathway (3), focal adhesion (3), Jak-STAT signalling 
pathway (3), leukocyte transendothelial migration (3), Insulin signalling pathway (3), GnRH 
signalling pathway (3) and Huntington's disease (3). 
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In terms of observed fold change (independent of statistical threshold), 44 features 
exhibited >2-fold up-regulation, while 16 features exhibited >2-fold down-regulation. Fold 
changes ranged from 26.6-fold up to 3.2-fold down. Within the biggest change loci, 
MIR1978, MIR1974, HMGCS1, ACSS2, SC4MOL, DHCR7, NSMAF, HMGCR, IDI1 and INSIG1 
were up-regulated. Within the biggest change loci, THBS1, ACTG1, LOC148430, DUSP1, 
ACTB, CAV1, TUBA1A, EIF4A1P4, TRMT5 and LOC642817 were down-regulated. 
 
19 KEGG pathways were statistically enriched. Members of steroid biosynthesis, terpenoid 
backbone biosynthesis and lysosome pathways were amongst those enriched in up-
regulated loci. Members of p53 signalling pathway, oocyte meiosis and cell cycle pathways 
were amongst those enriched in down-regulated loci. 
 
240 GO terms were statistically enriched. Members annotated with sterol biosynthetic 
process, cholesterol biosynthetic process and sterol metabolic process GO terms were 
amongst those enriched in up-regulated loci. Members annotated with protein binding, cell 
cycle process and cell division GO terms were amongst those enriched in down-regulated 
loci. 
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PROADIFEN RELATIVE TO LPC: 
3460 array features were statistically significant (1505 up-regulated, 1955 down-regulated). 
Within the significant features, A3GALT2, ABCC4, EPHX4, ABL2, ABLIM1, ACAD8, ACADM, 
ACAT2, ACLY and ACOT1 were up-regulated. Within the significant features, AATF, ABCA1, 
ABCB6, ABCC10, ABCF1, ABCF2, ABCG1, ABHD10, ABHD14A and ABHD14B were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (110), pathways in 
cancer (30), protein processing in endoplasmic reticulum (25), focal adhesion (21), 
endocytosis (20), MAPK signalling pathway (18), cytokine-cytokine receptor interaction (18), 
cell cycle (18), regulation of actin cytoskeleton (18), purine metabolism (17), ribosome (16), 
lysosome (16), Wnt signalling pathway (16), oocyte meiosis (14), ubiquitin mediated 
proteolysis (14), phagosome (14), spliceosome (13), glycolysis / gluconeogenesis (12), tight 
junction (12) and insulin signalling pathway (12). 
 
The predominant down-regulated pathways include metabolic pathways (104), endocytosis 
(31), pathways in cancer (29), focal adhesion (28), purine metabolism (21), spliceosome (20), 
MAPK signalling pathway (20), cell cycle (20), regulation of actin cytoskeleton (20), 
Huntington's disease (20), pyrimidine metabolism (17), ubiquitin mediated proteolysis (16), 
tight junction (16), Alzheimer's disease (15), oxidative phosphorylation (14), chemokine 
signalling pathway (14), protein processing in endoplasmic reticulum (14), oocyte meiosis 
(13), Fc gamma R-mediated phagocytosis (13) and insulin signalling pathway (13). 
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 In terms of observed fold change (independent of statistical threshold), 303 features 
exhibited >2-fold up-regulation, while 65 features exhibited >2-fold down-regulation. Fold 
changes ranged from 11.8-fold up to 4.8-fold down. Within the biggest change loci, 
MIR1978, MIR1974, SRGN, INSIG1, NSMAF, SC4MOL, RPLP0, ACAT2, ALDOA and UBB were 
up-regulated. Within the biggest change loci, ISG15, ACTN4, NEK2, BCYRN1, C19orf33, 
GAMT, NUCKS1, MRPL2, KLF2 and C19orf48 were down-regulated. 
 
44 KEGG pathways were statistically enriched. Members of steroid biosynthesis, terpenoid 
backbone biosynthesis and biosynthesis of unsaturated fatty acids pathways were amongst 
those enriched in up-regulated loci. Members of base excision repair, endocytosis and 
aminoacyl-tRNA biosynthesis pathways were amongst those enriched in down-regulated 
loci. 
 
282 GO terms were statistically enriched. Members annotated with cytoplasm and 
intracellular pathway GO terms were amongst those enriched in up-regulated loci. Members 
annotated with intracellular pathway and intracellular organelle GO terms were amongst 
those enriched in down-regulated loci. 
  
PROADIFEN RELATIVE TO FLUPHENAZINE: 
4461 array features were statistically significant (2153 up-regulated, 2308 down-regulated). 
Within the significant features, ABCC4, ABHD3, ABHD5, EPHX4, ABL2, ABLIM1, ACACA, 
ACAD8, ACADM and ACAT2 were up-regulated. Within the significant features, A4GALT, 
AARS2, ABCA1, ABCA7, ABCB6, ABCC10, ABCC3, ABCF2, ABCG1 and ABHD10 were down-
regulated. 
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The predominant up-regulated pathways include metabolic pathways (160), pathways in 
cancer (40), protein processing in endoplasmic reticulum (32), endocytosis (29), ribosome 
(26), focal adhesion (26), purine metabolism (25), MAPK signalling pathway (25), lysosome 
(25), regulation of actin cytoskeleton (24), cell cycle (22), spliceosome (21), ubiquitin 
mediated proteolysis (21), Huntington's disease (21), Alzheimer's disease (20), cytokine-
cytokine receptor interaction (19), oocyte meiosis (18), phagosome (18), Wnt signalling 
pathway (18) and neurotrophin signalling pathway (18). 
 
The predominant down-regulated pathways include metabolic pathways (127), endocytosis 
(40), pathways in cancer (37), focal adhesion (30), MAPK signalling pathway (29), regulation 
of actin cytoskeleton (27), Huntington's disease (26), protein processing in endoplasmic 
reticulum (24), cell cycle (23), purine metabolism (22), spliceosome (21), tight junction (21), 
chemokine signalling pathway (20), Alzheimer's disease (20), ubiquitin mediated proteolysis 
(19), oxidative phosphorylation (18), pyrimidine metabolism (18), oocyte meiosis (18), 
insulin signalling pathway (18) and Parkinson's disease (18). 
 
In terms of observed fold change (independent of statistical threshold), 381 features 
exhibited >2-fold up-regulation, while 101 features exhibited >2-fold down-regulation. Fold 
changes ranged from 14.9-fold up to 4.8-fold down. Within the biggest change loci, 
MIR1978, MIR1974, SC4MOL, SRGN, NSMAF, ACAT2, INSIG1, CYR61, ALDOA and B2M were 
up-regulated. Within the biggest change loci, NEK2, NUCKS1, ISG15, BCYRN1, LOC388564, 
LFNG, KLF2, ACTN4, THOC2 and C19orf33 were down-regulated. 
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49 KEGG pathways were statistically enriched. Members of steroid biosynthesis, Ribosome 
and terpenoid backbone biosynthesis pathways were amongst those enriched in up-
regulated loci. Members of endocytosis, Aminoacyl-tRNA biosynthesis and NA pathways 
were amongst those enriched in down-regulated loci. 
 
371 GO terms were statistically enriched. Members annotated with cytoplasm, and 
intracellular pathway GO terms were amongst those enriched in up-regulated loci. Members 
annotated with intracellular pathway and intracellular organelle GO terms were amongst 
those enriched in down-regulated loci. 
  
PRAVASTATIN RELATIVE TO MBCD: 
27 array features were statistically significant (16 up-regulated, 11 down-regulated). Within 
the significant features, ANGPTL2, GAS2L1, GPR56, GPRC5C, ID1, ID2, IGFBP6, ITGB4, MALL 
and MXD4 were up-regulated. Within the significant features, ABCA1, CRY1, FST, IGFBP3, 
IL11, LOX, MMP1, PTGER4 and PTGS2 were down-regulated. 
 
 The predominant up-regulated pathways include TGF-beta signalling pathway (2). The 
predominant down-regulated pathways include Pathways in cancer (2).  
 
In terms of observed fold change (independent of statistical threshold), 0 features exhibited 
>2-fold up-regulation, while 3 features exhibited >2-fold down-regulation. Fold changes 
ranged from 1.8-fold up to 3.3-fold down. Within the biggest change loci, GPRC5C, S100A4, 
KRT19, AHNAK2, MXD4, ID1, SLC20A1, SH2B3, LAMA5 and NRP1 were up-regulated. Within 
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the biggest change loci, PTGS2, IGFBP3, IL8, LOX, IL11, MMP1, HIST1H4C, BCYRN1, DUSP1 
and FST were down-regulated. 
 
6 KEGG pathways were statistically enriched. The TGF-beta signalling pathway was enriched 
in up-regulated loci. 21 GO terms were statistically enriched. Members annotated with 
regulation of localization, negative regulation of transport and negative regulation of 
hormone secretion GO terms were amongst those enriched in down-regulated loci. 
  
PRAVASTATIN RELATIVE TO LPC: 
6581 array features were statistically significant (3049 up-regulated, 3532 down-regulated). 
Within the significant features, AASDHPPT, ABCB10, ABCC4, ABCD3, ABCF2, ABHD3, EPHX4, 
ABLIM1, ACAD8 and ACADM were up-regulated. Within the significant features, A1BG, 
AAGAB, AAMP, AARS2, AARSD1, AATF, ABCA7, ABCB6, ABCB9 and ABCC10 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (191), pathways in 
cancer (60), protein processing in endoplasmic reticulum (44), focal adhesion (41), 
regulation of actin cytoskeleton (39), Alzheimer's disease (38), ribosome (37), cell cycle (37), 
Huntington's disease (37), purine metabolism (35), Wnt signalling pathway (34), 
spliceosome (32), oocyte meiosis (31), endocytosis (31), ubiquitin mediated proteolysis (30), 
MAPK signalling pathway (29), Parkinson's disease (29), oxidative phosphorylation (26), 
neurotrophin signalling pathway (26) and insulin signalling pathway (25). 
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The predominant down-regulated pathways include metabolic pathways (197), pathways in 
cancer (49), endocytosis (45), MAPK signalling pathway (40), lysosome (38), protein 
processing in endoplasmic reticulum (34), Huntington's disease (33), spliceosome (31), focal 
adhesion (31), oxidative phosphorylation (30), phagosome (29), regulation of actin 
cytoskeleton (28), purine metabolism (27), pyrimidine metabolism (25), cell cycle (23), 
ubiquitin mediated proteolysis (23), neurotrophin signalling pathway (23), Alzheimer's 
disease (21), Parkinson's disease (21) and insulin signalling pathway (20). 
 
 In terms of observed fold change (independent of statistical threshold), 625 features 
exhibited >2-fold up-regulation, while 359 features exhibited >2-fold down-regulation. Fold 
changes ranged from 13.6-fold up to 3.8-fold down. Within the biggest change loci, ACTG1, 
UBB, RPLP0, ALDOA, SRGN, ACTB, EIF4A1P4, ITGB1, B2M and PRDX3 were up-regulated. 
Within the biggest change loci, NUCKS1, BCYRN1, TDP1, DMC1, PVR, ALPP, SNRNP70, 
HCG2P7, SEMA3E and GPR1 were down-regulated. 
 
61 KEGG pathways were statistically enriched. Members of ribosome, cell cycle and protein 
processing in endoplasmic reticulum pathways were amongst those enriched in up-
regulated loci. Members of lysosome, metabolic pathways and base excision repair 
pathways were amongst those enriched in down-regulated loci. 
 
414 GO terms were statistically enriched. Members annotated with intracellular pathway 
and cytoplasm GO terms were amongst those enriched in up-regulated loci. Members 
annotated with intracellular pathway and membrane-bounded organelle GO terms were 
amongst those enriched in down-regulated loci. 
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PRAVASTATIN RELATIVE TO FLUPHENAZINE: 
7510 array features were statistically significant (3643 up-regulated, 3867 down-regulated). 
Within the significant features, NCEH1, AASDH, AASDHPPT, ABCB10, ABCC4, ABCD3, ABCE1, 
ABCF2, ABHD11 and ABHD12 were up-regulated. Within the significant features, A4GALT, 
AAGAB, AAMP, AARS2, AARSD1, AATF, ABCA7, ABCA8, ABCB6 and ABCB9 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (218), pathways in 
cancer (71), protein processing in endoplasmic reticulum (50), spliceosome (46), focal 
adhesion (46), ribosome (45), cell cycle (44), endocytosis (43), regulation of actin 
cytoskeleton (43), Huntington's disease (43), Alzheimer's disease (42), Wnt signalling 
pathway (38), purine metabolism (37), MAPK signalling pathway (37), ubiquitin mediated 
proteolysis (32), Parkinson's disease (32), oocyte meiosis (31), oxidative phosphorylation 
(30), neurotrophin signalling pathway (28) and tight junction (27). 
 
The predominant down-regulated pathways include metabolic pathways (212), pathways in 
cancer (67), endocytosis (50), MAPK signalling pathway (42), protein processing in 
endoplasmic reticulum (40), lysosome (40), focal adhesion (38), Huntington's disease (36), 
oxidative phosphorylation (31), regulation of actin cytoskeleton (31), insulin signalling 
pathway (31), purine metabolism (30), ubiquitin mediated proteolysis (30), neurotrophin 
signalling pathway (30), spliceosome (29), Cell cycle (29), pyrimidine metabolism (28), 
phagosome (28), Alzheimer's disease (28) and chemokine signalling pathway (27). 
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 In terms of observed fold change (independent of statistical threshold), 705 features 
exhibited >2-fold up-regulation, while 471 features exhibited >2-fold down-regulation. Fold 
changes ranged from 11.6-fold up to 4.6-fold down. Within the biggest change loci, ACTG1, 
UBB, ACTB, ALDOA, SRGN, B2M, RPLP0, PGAM1, EIF4A1P4 and PRDX3 were up-regulated. 
Within the biggest change loci, TDP1, NUCKS1, BCYRN1, ALPP, DMC1, NLRP8, USP49, FCAR, 
MARCH6 and LOC401098 were down-regulated. 
 
 81 KEGG pathways were statistically enriched. Members of ribosome, spliceosome and Cell 
cycle pathways were amongst those enriched in up-regulated loci. Members of lysosome, 
base excision repair and metabolic pathways pathways were amongst those enriched in 
down-regulated loci. 
 
497 GO terms were statistically enriched. Members annotated with intracellular pathway 
and cytoplasm GO terms were amongst those enriched in up-regulated loci. Members 
annotated with intracellular pathway and intracellular membrane-bounded organelle GO 
terms were amongst those enriched in down-regulated loci. 
  
MBCD RELATIVE TO LPC: 
6196 array features were statistically significant (2635 up-regulated, 3561 down-regulated). 
Within the significant features, NCEH1, AASDHPPT, ABCA1, ABCB10, ABCC4, ABCD3, ABCF2, 
EPHX4, ABLIM1 and ACAD8 were up-regulated. Within the significant features, A1BG, 
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AAGAB, AAMP, AARSD1, AATF, ABCA7, ABCB6, ABCB9, ABCC10 and ABCC5 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (156), pathways in 
cancer (48), ribosome (41), focal adhesion (36), cell cycle (35), regulation of actin 
cytoskeleton (35), protein processing in endoplasmic reticulum (34), spliceosome (31), 
purine metabolism (30), Huntington's disease (30), ubiquitin mediated proteolysis (29), 
Alzheimer's disease (27), Wnt signalling pathway (26), oocyte meiosis (25), MAPK signalling 
pathway (24), endocytosis (24), neurotrophin signalling pathway (23), insulin signalling 
pathway (23), Parkinson's disease (23) and phagosome (21). 
 
 The predominant down-regulated pathways include metabolic pathways (200), endocytosis 
(50), pathways in cancer (45), MAPK signalling pathway (42), focal adhesion (38), lysosome 
(35), protein processing in endoplasmic reticulum (33), Huntington's disease (29), regulation 
of actin cytoskeleton (28), oxidative phosphorylation (26), purine metabolism (25), 
chemokine signalling pathway (25), neurotrophin signalling pathway (25), ubiquitin 
mediated proteolysis (24), phagosome (24), insulin signalling pathway (24), Alzheimer's 
disease (24), spliceosome (23), pyrimidine metabolism (21) and cell cycle (21). In terms of 
observed fold change (independent of statistical threshold), 557 features exhibited >2-fold 
up-regulation, while 203 features exhibited >2-fold down-regulation. Fold changes ranged 
from 11.5-fold up to 3.3-fold down. Within the biggest change loci, ACTG1, SRGN, RPLP0, 
ALDOA, EIF4A1P4, ACTB, UBB, PRDX3, IL8 and SUMO2 were up-regulated. Within the 
biggest change loci, C19orf33, NUCKS1, PVR, ISG15, LAMB2, SFN, SNRNP70, CHD8, ALPP and 
TDP1 were down-regulated. 
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61 KEGG pathways were statistically enriched. members of ribosome, cell cycle and 
Shigellosis pathways were amongst those enriched in up-regulated loci. Members of 
metabolic pathways, lysosome and endocytosis pathways were amongst those enriched in 
down-regulated loci. 
 
357 GO terms were statistically enriched. Members annotated with intracellular pathway 
and cytoplasm GO terms were amongst those enriched in up-regulated loci. Members 
annotated with intracellular pathway and membrane-bounded organelle GO terms were 
amongst those enriched in down-regulated loci. 
  
MBCD RELATIVE TO FLUPHENAZINE: 
7399 array features were statistically significant (3328 up-regulated, 4071 down-regulated). 
Within the significant features, NCEH1, AASDHPPT, ABCA1, ABCB10, ABCC4, ABCD3, ABCE1, 
ABCF2, ABCG1 and ABHD11 were up-regulated. Within the significant features, MACC1, 
A2BP1, A4GALT, AAGAB, AAMP, AARS2, AARSD1, AATF, ABCA3 and ABCA7 were down-
regulated. 
 
The predominant up-regulated pathways include metabolic pathways (192), pathways in 
cancer (64), ribosome (50), protein processing in endoplasmic reticulum (46), endocytosis 
(45), spliceosome (40), regulation of actin cytoskeleton (40), focal adhesion (39), cell cycle 
(38), Huntington's disease (37), purine metabolism (36), Alzheimer's disease (34), ubiquitin 
mediated proteolysis (33), MAPK signalling pathway (32), oocyte meiosis (29), Wnt signalling 
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pathway (29), Parkinson's disease (27), neurotrophin signalling pathway (25), insulin 
signalling pathway (25) and oxidative phosphorylation (24). 
 
The predominant down-regulated pathways include metabolic pathways (217), pathways in 
cancer (61), endocytosis (50), MAPK signalling pathway (43), focal adhesion (42), lysosome 
(39), protein processing in endoplasmic reticulum (38), regulation of actin cytoskeleton (33), 
insulin signalling pathway (33), Huntington's disease (33), ubiquitin mediated proteolysis 
(31), neurotrophin signalling pathway (31), purine metabolism (30), chemokine signalling 
pathway (30), oxidative phosphorylation (29), phagosome (28), Alzheimer's disease (28), 
pyrimidine metabolism (24), spliceosome (24) and axon guidance (24). 
 
In terms of observed fold change (independent of statistical threshold), 653 features 
exhibited >2-fold up-regulation, while 381 features exhibited >2-fold down-regulation. Fold 
changes ranged from 9.8-fold up to 3.7-fold down. Within the biggest change loci, ACTG1, 
SRGN, ACTB, RPLP0, ALDOA, EIF4A1P4, UBB, CKS1B, PRDX3 and CYR61 were up-regulated. 
Within the biggest change loci, NUCKS1, C19orf33, ALPP, TDP1, NLRP8, ARFGAP1, C21orf58, 
LAMB2, LOC202781 and LRRC37BP1 were down-regulated. 
72 KEGG pathways were statistically enriched. Members of ribosome, spliceosome and 
Protein processing in endoplasmic reticulum pathways were amongst those enriched in up-
regulated loci. Members of lysosome, metabolic pathways and base excision repair 
pathways were amongst those enriched in down-regulated loci. 
 
 418 GO terms were statistically enriched. Members annotated with intracellular part, 
intracellular and cytoplasm GO terms were amongst those enriched in up-regulated loci. 
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Members annotated with intracellular pathway and intracellular membrane-bounded 
organelle GO terms were amongst those enriched in down-regulated loci. 
  
LPC RELATIVE TO FLUPHENAZINE: 
61 array features were statistically significant (33 up-regulated, 28 down-regulated). Within 
the significant features, ABL2, FAM26D, CCDC54, CD3EAP, CYP2F1, CCDC93, FST, 
LOC401093, KIR2DS5 and LDLRAP1 were up-regulated. Within the significant features, 
ABCC3, ACSS1, ATOH8, PYROXD2, C17orf58, C9orf169, CEBPD, COL8A1, FCGBP and GAA 
were down-regulated. 
 
 The predominant up-regulated pathways include ErbB signalling pathway (2), TGF-beta 
signalling pathway (2) and natural killer cell mediated cytotoxicity (2). 
The predominant down-regulated pathways include metabolic pathways (2) and pathways 
in cancer (2). 
 
In terms of observed fold change (independent of statistical threshold), 0 features exhibited 
>2-fold up-regulation, while 4 features exhibited >2-fold down-regulation. Fold changes 
ranged from 1.6-fold up to 2.4-fold down. Within the biggest change loci, DKK1, ODC1, 
FLNC, CTGF, EXOSC8, FTL, SC4MOL, CYR61, RND3 and GNPDA1 were up-regulated. Within 
the biggest change loci, TFPI, RN18S1, PTGS2, COL8A1, FCGBP, WBP5, PTGES, IL1B, VEZT and 
TDG were down-regulated. 
 
6 KEGG pathways were statistically enriched. 7 GO terms were statistically enriched. 
Members annotated with phosphotyrosine binding, protein phosphorylated amino acid 
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binding and phosphoprotein binding GO terms were amongst those enriched in up-
regulated loci. 
  
In the figure below, the enrichment analyses are shown graphically, with comparisons along 
the X axis, and KEGG pathways along the Y axis. Note that only comparisons with enriched 
pathways are shown; up- and down- regulated enrichments are shown separately, as 
different components of a given pathway could be up- and down- regulated within a single 
comparison. Colour (red for up-regulated pathways, blue for down-regulated pathways) is 
assigned on a 20 point scale based on the -log10 (enrichment p value), with white being 
least statistically robust. 
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CALU-1 CELLS GENE EXPRESSION  
 
A total of 24 Illumina HumanHT12_V4_0_R2_15002873_B arrays were QC analysed using 
the array Quality Metrics Bioconductor package to identify sub-standard and/or outlier 
arrays. No arrays were identified as outliers. None of the arrays failed QC.  
 
At the QC stage, it is clear that there is good correlation between replicates particularly for 
the Controls (13-15), LPE (10-12), Pravastatin (16-18), Proadifen (19-21) and MβCD (22-24) 
(Q.1.7 Sample Relations). Raw data were transformed using a variance stabilizing 
transformation (VST) method prior to normalisation across all arrays using the robust spline 
normalisation (RSN) method. Expression measures (summarised intensities) are in log base 
2. 
 
LPC RELATIVE TO CONTROL 
181 array features were statistically significant (44 up-regulated, 137 down-regulated). 
Within the significant features, ALCAM, ANGPTL4, APITD1, C11orf41, CAMK2N1, CRIP1, 
DUSP6, E2F5, EGR1 and ESAM were up-regulated. Within the significant features, ABCA1, 
ADAMTS9, ALDH1A1, ALOX5AP, ALPK2, ANKRD33, ANXA8L2, APOE, ART1 and BACE2 were 
down-regulated. The predominant up-regulated pathways include MAPK signalling pathway 
(2), cell cycle (2), apoptosis (2) and cell adhesion molecules (CAMs) (2). The predominant 
down-regulated pathways include cytokine-cytokine receptor interaction (9), metabolic 
pathways (8), phagosome (6), chemokine signalling pathway (5), amoebiasis (5), pathways in 
cancer (5), systemic lupus erythematosus (5), lysosome (4), complement and coagulation 
cascades (4), toll-like receptor signalling pathway (4), NOD-like receptor signalling pathway 
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(4), hematopoietic cell lineage (4), Leishmaniasis (4), Chagas disease (4), malaria (4), graft-
versus-host disease (4), Other glycan degradation (3), MAPK signalling pathway (3), 
apoptosis (3) and TGF-beta signalling pathway (3). 
 
 In terms of observed fold change (independent of statistical threshold), 5 features exhibited 
>2-fold up-regulation, while 17 features exhibited >2-fold down-regulation. Fold changes 
ranged from 3.3-fold up to 4.7-fold down. Within the biggest change loci, FOS, EGR1, 
RN28S1, ANGPTL4, RN18S1, SFN, KHDRBS3, TAOK1, MGLL and GPR126 were up-regulated. 
Within the biggest change loci, CHI3L1, SAA1, CXCL1, PDZK1IP1, CXCL6, CFB, IL8, APOE, SAA2 
and GPNMB were down-regulated.  
 
23 KEGG pathways were statistically enriched. Members of other glycan degradation, 
cytokine-cytokine receptor interaction and Graft-versus-host disease pathways were 
amongst those enriched in down-regulated loci. 135 GO terms were statistically enriched. 
The activation of NF-kappaB-inducing kinase activity GO term was enriched in up-regulated 
loci. Members annotated with defense response, inflammatory response and response to 
wounding GO terms were amongst those enriched in down-regulated loci. 
 
MΒCD RELATIVE TO CONTROL 
6868 array features were statistically significant (3417 up-regulated, 3451 down-regulated). 
Within the significant features, A4GALT, AARS, AASS, ABCA1, ABCB6, ABCB9, ABCG1, ABHD3, 
ABHD4 and ABHD8 were up-regulated. Within the significant features, NCEH1, ABCB10, 
ABCC4, ABCC5, ABCD3, ABCE1, ABCF2, ABHD12, ABHD5 and ABI3 were down-regulated. The 
predominant up-regulated pathways include metabolic pathways (173), pathways in cancer 
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(50), endocytosis (39), MAPK signalling pathway (37), insulin signalling pathway (34), 
lysosome (30), cytokine-cytokine receptor interaction (29), Jak-STAT signalling pathway (26), 
phagosome (23), regulation of actin cytoskeleton (23), protein processing in endoplasmic 
reticulum (22), neurotrophin signalling pathway (22), ribosome (21), ubiquitin mediated 
proteolysis (21), purine metabolism (20), Cell cycle (20), Wnt signalling pathway (19), 
Huntington's disease (19), ErbB signalling pathway (18) and axon guidance (18). The 
predominant down-regulated pathways include metabolic pathways (174), pathways in 
cancer (73), spliceosome (61), cell cycle (53), purine metabolism (49), ubiquitin mediated 
proteolysis (40), protein processing in endoplasmic reticulum (40), MAPK signalling pathway 
(38), Huntington's disease (37), pyrimidine metabolism (36), oocyte meiosis (36), focal 
adhesion (36), Wnt signalling pathway (34), Alzheimer's disease (32), endocytosis (30), 
regulation of actin cytoskeleton (29), neurotrophin signalling pathway (28), cytokine-
cytokine receptor interaction (26), oxidative phosphorylation (25) and Parkinson's disease 
(25). 
 
 In terms of observed fold change (independent of statistical threshold), 393 features 
exhibited >2-fold up-regulation, while 349 features exhibited >2-fold down-regulation. Fold 
changes ranged from 16.4-fold up to 8.1-fold down. Within the biggest change loci, GDF15, 
NUPR1, TRIB3, DDIT3, RNF165, ASNS, PDE5A, CTH, DDIT4 and FBXO32 were up-regulated. 
Within the biggest change loci, CTGF, STC1, NPPB, BMPER, CYP24A1, GLIPR1, TXNIP, MMP3, 
EDN1 and MARCH4 were down-regulated. 66 KEGG pathways were statistically enriched. 
Members of steroid biosynthesis, valine, leucine and isoleucine degradation and insulin 
signalling pathways were amongst those enriched in up-regulated loci. Members of 
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spliceosome, cell cycle and DNA replication pathways were amongst those enriched in 
down-regulated loci.  
 
500 GO terms were statistically enriched. Members annotated with intracellular pathway 
and membrane-bounded organelle GO terms were amongst those enriched in up-regulated 
loci. Members annotated with intracellular organelle pathway GO terms were amongst 
those enriched in down-regulated loci.  
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PRAVASTATIN RELATIVE TO CONTROL 
5107 array features were statistically significant (2535 up-regulated, 2572 down-regulated). 
Within the significant features, A4GALT, AARS, AASS, ABCA1, ABCB6, ABCB9, ABCC3, ABCC6, 
ABHD4 and ABHD8 were up-regulated. Within the significant features, NCEH1, ABCB10, 
ABCC5, ABCD3, ABCE1, ABCF2, ABHD11, ABHD12, ABHD5 and ABR were down-regulated. 
The predominant up-regulated pathways include metabolic pathways (154), pathways in 
cancer (37), endocytosis (35), insulin signalling pathway (29), MAPK signalling pathway (28), 
lysosome (26), cytokine-cytokine receptor interaction (22), Jak-STAT signalling pathway (21), 
neurotrophin signalling pathway (19), regulation of actin cytoskeleton (19), focal adhesion 
(18), cell adhesion molecules (CAMs) (18), cell cycle (17), axon guidance (17), purine 
metabolism (16), ErbB signalling pathway (16), calcium signalling pathway (16), protein 
processing in endoplasmic reticulum (16), phagosome (16) and peroxisome (16). The 
predominant down-regulated pathways include metabolic pathways (126), pathways in 
cancer (57), spliceosome (49), cell cycle (44), protein processing in endoplasmic reticulum 
(37), purine metabolism (35), oocyte meiosis (31), ubiquitin mediated proteolysis (30), 
Huntington's disease (27), pyrimidine metabolism (26), Wnt signalling pathway (26), focal 
adhesion (26), Alzheimer's disease (25), MAPK signalling pathway (24), cytokine-cytokine 
receptor interaction (23), regulation of actin cytoskeleton (22), DNA replication (21), 
endocytosis (21), Jak-STAT signalling pathway (19) and Parkinson's disease (19).  
 
In terms of observed fold change (independent of statistical threshold), 219 features 
exhibited >2-fold up-regulation, while 174 features exhibited >2-fold down-regulation. Fold 
changes ranged from 11.1-fold up to 5.1-fold down. Within the biggest change loci, NUPR1, 
GDF15, TRIB3, RNF165, DDIT3, ASNS, DDIT4, PDE5A, CTH and PCK2 were up-regulated. 
298 
 
Within the biggest change loci, TXNIP, MMP3, STC1, CTGF, GLIPR1, NPPB, BMPER, EDN1, 
MAP2K3 and CYP24A1 were down-regulated.  
 
59 KEGG pathways were statistically enriched. Members of steroid biosynthesis, valine, 
leucine and isoleucine degradation and terpenoid backbone biosynthesis pathways were 
amongst those enriched in up-regulated loci. Members of spliceosome, Cell cycle and DNA 
replication pathways were amongst those enriched in down-regulated loci.  
 
408 GO terms were statistically enriched. Members annotated with intracellular pathway 
and cytoplasm GO terms were amongst those enriched in up-regulated loci. Members 
annotated with nuclear pathway, organelle pathway and intracellular pathway GO terms 
were amongst those enriched in down-regulated loci.  
 
PROADIFEN RELATIVE TO CONTROL 
9839 array features were statistically significant (4938 up-regulated, 4901 down-regulated). 
Within the significant features, A4GALT, AARS, AARSD1, AASS, AATF, AATK, ABCB7, ABCB9, 
ABCF3 and ABHD14B were up-regulated. Within the significant features, NCEH1, AAK1, 
AARS2, AASDHPPT, ABCA6, ABCB10, ABCC4, ABCC5, ABCC9 and ABCD3 were down-
regulated. The predominant up-regulated pathways include metabolic pathways (225), 
pathways in cancer (66), MAPK signalling pathway (60), endocytosis (55), protein processing 
in endoplasmic reticulum (48), cytokine-cytokine receptor interaction (42), lysosome (37), 
Jak-STAT signalling pathway (36), purine metabolism (34), phagosome (33), regulation of 
actin cytoskeleton (33), insulin signalling pathway (33), Huntington's disease (33), 
chemokine signalling pathway (31), cell cycle (30), axon guidance (29), neurotrophin 
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signalling pathway (29), natural killer cell mediated cytotoxicity (28), focal adhesion (27) and 
cell adhesion molecules (CAMs) (26). The predominant down-regulated pathways include 
metabolic pathways (249), pathways in cancer (87), focal adhesion (61), spliceosome (59), 
Huntington's disease (59), cell cycle (55), regulation of actin cytoskeleton (54), purine 
metabolism (53), Alzheimer's disease (51), ubiquitin mediated proteolysis (47), protein 
processing in endoplasmic reticulum (43), MAPK signalling pathway (40), endocytosis (40), 
oocyte meiosis (39), Parkinson's disease (39), oxidative phosphorylation (38), pyrimidine 
metabolism (37), Wnt signalling pathway (36), phagosome (35) and calcium signalling 
pathway (31).  
 
In terms of observed fold change (independent of statistical threshold), 830 features 
exhibited >2-fold up-regulation, while 971 features exhibited >2-fold down-regulation. Fold 
changes ranged from 29.9-fold up to 31.7-fold down. Within the biggest change loci, GDF15, 
NUPR1, ATF3, RNU1-3, RN18S1, RNU1-9, RNU1-5, RN5S9, TRIB3 and RNU1-1 were up-
regulated. Within the biggest change loci, CTGF, COL1A1, THBS1, MAT2A, NPPB, RGS4, F3, 
SRSF1, CYR61 and BMPER were down-regulated.  
 
81 KEGG pathways were statistically enriched. Members of Protein processing in 
endoplasmic reticulum, Lysosome and Amino sugar and nucleotide sugar metabolism 
pathways were amongst those enriched in up-regulated loci. Members of spliceosome, DNA 
replication and Cell cycle pathways were amongst those enriched in down-regulated loci.  
 
522 GO terms were statistically enriched. Members annotated with intracellular, 
intracellular part and intracellular membrane-bounded organelle GO terms were amongst 
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those enriched in up-regulated loci. Members annotated with intracellular part, intracellular 
organelle part and organelle part GO terms were amongst those enriched in down-regulated 
loci.  
 
LPC RELATIVE TO MΒCD 
7302 array features were statistically significant (3669 up-regulated, 3633 down-regulated). 
Within the significant features, NCEH1, AAGAB, ABCB10, ABCC4, ABCC5, ABCD3, ABCE1, 
ABCF1, ABCF2 and ABCG2 were up-regulated. Within the significant features, A4GALT, AARS, 
AASS, ABCA1, ABCB9, ABCC3, ABCG1, ABHD14B, ABHD4 and ABHD8 were down-regulated. 
The predominant up-regulated pathways include metabolic pathways (178), pathways in 
cancer (73), spliceosome (60), cell cycle (54), purine metabolism (49), protein processing in 
endoplasmic reticulum (46), ubiquitin mediated proteolysis (42), MAPK signalling pathway 
(41), focal adhesion (41), oocyte meiosis (38), endocytosis (38), Huntington's disease (38), 
pyrimidine metabolism (37), regulation of actin cytoskeleton (34), Wnt signalling pathway 
(31), neurotrophin signalling pathway (31), Alzheimer's disease (29), DNA replication (26), 
Parkinson's disease (26) and small cell lung cancer (25). The predominant down-regulated 
pathways include metabolic pathways (169), pathways in cancer (52), lysosome (43), 
endocytosis (41), MAPK signalling pathway (37), phagosome (36), cytokine-cytokine 
receptor interaction (31), Jak-STAT signalling pathway (30), protein processing in 
endoplasmic reticulum (26), cell adhesion molecules (CAMs) (26), insulin signalling pathway 
(26), Huntington's disease (25), antigen processing and presentation (24), regulation of actin 
cytoskeleton (24), ribosome (23), calcium signalling pathway (22), ubiquitin mediated 
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proteolysis (22), focal adhesion (22), Leishmaniasis (22) and neurotrophin signalling pathway 
(21). 
 
In terms of observed fold change (independent of statistical threshold), 421 features 
exhibited >2-fold up-regulation, while 473 features exhibited >2-fold down-regulation. Fold 
changes ranged from 8.9-fold up to 34.9-fold down. Within the biggest change loci, CTGF, 
EGR1, STC1, HBEGF, BMPER, TXNIP, CYP24A1, ANGPTL4, MARCH4 and UHRF1 were up-
regulated. Within the biggest change loci, GDF15, NUPR1, TRIB3, DDIT3, FBXO32, DDIT4, 
PDE5A, ASNS, ATF3 and CCNG2 were down-regulated.  
 
62 KEGG pathways were statistically enriched. Members of spliceosome, DNA replication 
and Cell cycle pathways were amongst those enriched in up-regulated loci. Members of 
lysosome, other glycan degradation and glycosaminoglycan degradation pathways were 
amongst those enriched in down-regulated loci.  
 
521 GO terms were statistically enriched. Members annotated with organelle part, 
intracellular organelle part and intracellular part GO terms were amongst those enriched in 
up-regulated loci. Members annotated with intracellular, intracellular part and cytoplasm 
GO terms were amongst those enriched in down-regulated loci.  
 
LPC RELATIVE TO PRAVASTATIN 
5757 array features were statistically significant (2912 up-regulated, 2845 down-regulated). 
Within the significant features, NCEH1, ABCB10, ABCC4, ABCC5, ABCD3, ABCE1, ABCF2, 
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ABCG2, ABHD12 and ABHD15 were up-regulated. Within the significant features, A4GALT, 
AARS, AASS, ABCA1, ABCB6, ABCB9, ABCC3, ABHD14B, ABHD4 and ABHD8 were down-
regulated. The predominant up-regulated pathways include metabolic pathways (138), 
pathways in cancer (63), spliceosome (52), cell cycle (50), Protein processing in endoplasmic 
reticulum (41), MAPK signalling pathway (36), purine metabolism (35), oocyte meiosis (34), 
focal adhesion (34), pyrimidine metabolism (32), Huntington's disease (32), ubiquitin 
mediated proteolysis (31), regulation of actin cytoskeleton (30), Wnt signalling pathway 
(28), Alzheimer's disease (27), endocytosis (26), p53 signalling pathway (22), neurotrophin 
signalling pathway (21), small cell lung cancer (21) and DNA replication (20). 
 
The predominant down-regulated pathways include metabolic pathways (173), pathways in 
cancer (46), lysosome (40), phagosome (36), MAPK signalling pathway (35), endocytosis 
(34), cell adhesion molecules (CAMs) (25), insulin signalling pathway (25), cytokine-cytokine 
receptor interaction (24), focal adhesion (22), antigen processing and presentation (22), 
neurotrophin signalling pathway (22), regulation of actin cytoskeleton (22), calcium 
signalling pathway (21), Leishmaniasis (21), Jak-STAT signalling pathway (20), cell cycle (19), 
valine, leucine and isoleucine degradation (18), ubiquitin mediated proteolysis (18) and 
protein processing in endoplasmic reticulum (18). 
 
In terms of observed fold change (independent of statistical threshold), 199 features 
exhibited >2-fold up-regulation, while 283 features exhibited >2-fold down-regulation. Fold 
changes ranged from 6.4-fold up to 23.1-fold down. Within the biggest change loci, EGR1, 
CTGF, TXNIP, ANGPTL4, STC1, HBEGF, BMPER, GLIPR1, FOS and CYP24A1 were up-regulated. 
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Within the biggest change loci, GDF15, NUPR1, TRIB3, DDIT3, DDIT4, PDE5A, ASNS, RNF165, 
SCD and FBXO32 were down-regulated.  
 
70 KEGG pathways were statistically enriched. Members of spliceosome, cell cycle and DNA 
replication pathways were amongst those enriched in up-regulated loci. Members of 
lysosome, valine, leucine and isoleucine degradation and Steroid biosynthesis pathways 
were amongst those enriched in down-regulated loci.  
 
489 GO terms were statistically enriched. Members annotated with nuclear part, 
intracellular organelle part and organelle part GO terms were amongst those enriched in up-
regulated loci. Members annotated with cytoplasm and intracellular pathway GO terms 
were amongst those enriched in down-regulated loci.  
 
 
 
 
LPC RELATIVE TO PROADIFEN 
10096 array features were statistically significant (5010 up-regulated, 5086 down-
regulated). Within the significant features, NCEH1, AAK1, AARS2, AASDH, AASDHPPT, 
ABCB10, ABCB6, ABCC4, ABCC5 and ABCD1 were up-regulated. Within the significant 
features, A4GALT, AARS, AARSD1, AATF, AATK, ABCA1, ABCB9, ABCC3, ABCF3 and ABHD12 
were down-regulated.  
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The predominant up-regulated pathways include metabolic pathways (249), pathways in 
cancer (82), spliceosome (62), cell cycle (60), focal adhesion (60), purine metabolism (58), 
Huntington's disease (56), regulation of actin cytoskeleton (52), ubiquitin mediated 
proteolysis (48), oocyte meiosis (47), protein processing in endoplasmic reticulum (47), 
Alzheimer's disease (47), MAPK signalling pathway (45), endocytosis (45), pyrimidine 
metabolism (42), Wnt signalling pathway (40), Parkinson's disease (39), oxidative 
phosphorylation (36), tight junction (32) and calcium signalling pathway (31).  
 
The predominant down-regulated pathways include metabolic pathways (252), pathways in 
cancer (71), MAPK signalling pathway (59), endocytosis (57), protein processing in 
endoplasmic reticulum (52), lysosome (51), phagosome (47), cytokine-cytokine receptor 
interaction (44), Huntington's disease (41), purine metabolism (35), Jak-STAT signalling 
pathway (35), Alzheimer's disease (33), chemokine signalling pathway (32), cell adhesion 
molecules (CAMs) (32), oxidative phosphorylation (31), antigen processing and presentation 
(30), neurotrophin signalling pathway (30), ubiquitin mediated proteolysis (29), regulation of 
actin cytoskeleton (29) and insulin signalling pathway (29). In terms of observed fold change 
(independent of statistical threshold), 1068 features exhibited >2-fold up-regulation, while 
930 features exhibited >2-fold down-regulation. Fold changes ranged from 30.6-fold up to 
63.7-fold down. Within the biggest change loci, CTGF, THBS1, COL1A1, MAT2A, RGS4, F3, 
SRSF1, CYR61, BMPER and CSTF3 were up-regulated. Within the biggest change loci, GDF15, 
NUPR1, RNU1-9, ATF3, RNU1-3, RNU1-5, TRIB3, DDIT3, MIR1974 and RN5S9 were down-
regulated.  
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81 KEGG pathways were statistically enriched. Members of spliceosome, cell cycle and DNA 
replication pathways were amongst those enriched in up-regulated loci. Members of 
lysosome, antigen processing and presentation and protein processing in endoplasmic 
reticulum pathways were amongst those enriched in down-regulated loci.  
 
534 GO terms were statistically enriched. Members annotated with intracellular organelle 
pathway GO terms were amongst those enriched in up-regulated loci. Members annotated 
with intracellular pathway and membrane-bounded organelle GO terms were amongst 
those enriched in down-regulated loci.  
 
MΒCD RELATIVE TO PRAVASTATIN 
382 array features were statistically significant (210 up-regulated, 172 down-regulated). 
Within the significant features, AARS, ABCA1, ADM, ARHGAP24, ARRDC3, ASNS, ATF3, 
ATP6V1C1, ATXN3 and BEND7 were up-regulated. Within the significant features, ACAA2, 
ACOX2, ADAMTS5, ADCY9, AGL, AKR1B10, ALPK2, ANGEL2, ANKRD1 and ANXA8L2 were 
down-regulated. The predominant up-regulated pathways include metabolic pathways (8), 
cytokine-cytokine receptor interaction (7), protein processing in endoplasmic reticulum (6), 
MAPK signalling pathway (4), apoptosis (4), prion diseases (4), pathways in cancer (4), p53 
signalling pathway (3), NOD-like receptor signalling pathway (3), hematopoietic cell lineage 
(3), neurotrophin signalling pathway (3), renal cell carcinoma (3), graft-versus-host disease 
(3), purine metabolism (2), pyrimidine metabolism (2), lysine degradation (2), inositol 
phosphate metabolism (2), ErbB signalling pathway (2), calcium signalling pathway (2) and 
phosphatidylinositol signalling system (2).  
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The predominant down-regulated pathways include metabolic pathways (17), cell cycle (8), 
pathways in cancer (7), DNA replication (6), Wnt signalling pathway (5), TGF-beta signalling 
pathway (5), pancreatic cancer (5), purine metabolism (4), pyrimidine metabolism (4), p53 
signalling pathway (4), focal adhesion (4), Jak-STAT signalling pathway (4), prostate cancer 
(4), chronic myeloid Leukaemia (4), small cell lung cancer (4), MAPK signalling pathway (3), 
cytokine-cytokine receptor interaction (3), chemokine signalling pathway (3), oocyte meiosis 
(3) and endocytosis (3). 
 
 In terms of observed fold change (independent of statistical threshold), 4 features exhibited 
>2-fold up-regulation, while 0 features exhibited >2-fold down-regulation. Fold changes 
ranged from 2.8-fold up to 1.9-fold down. Within the biggest change loci, RNU1-9, RNU1-5, 
RNU1-3, LOC730167, IL24, IGFBP3, HRK, IL6, RNU1-1 and LOC400750 were up-regulated. 
Within the biggest change loci, CTGF, MCM3, DUSP6, RGS4, DHCR24, TPI1, FOSL1, NUCKS1, 
NEDD4L and FAM20C were down-regulated. 
 
23 KEGG pathways were statistically enriched. Members of prion diseases, protein 
processing in endoplasmic reticulum and NA pathways were amongst those enriched in up-
regulated loci. Members of DNA replication, cell cycle and pancreatic cancer pathways were 
amongst those enriched in down-regulated loci.  
 
113 GO terms were statistically enriched. Members annotated with cellular response to 
stress and response to stimulus GO terms were amongst those enriched in up-regulated loci. 
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Members annotated with cell division, DNA replication and organelle fission GO terms were 
amongst those enriched in down-regulated loci.  
 
MΒCD RELATIVE TO PROADIFEN 
4955 array features were statistically significant (2575 up-regulated, 2380 down-regulated). 
Within the significant features, NCEH1, AAK1, AARS2, AASDH, AASDHPPT, ABCA1, ABCA5, 
ABCB10, ABCB6 and ABCC4 were up-regulated. Within the significant features, A4GALT, 
AAGAB, AARSD1, AATF, ABCB9, ABCF1, ABHD12, ABHD14A, ABHD14B and ABHD2 were 
down-regulated. The predominant up-regulated pathways include metabolic pathways 
(158), pathways in cancer (56), focal adhesion (42), insulin signalling pathway (29), cell cycle 
(28), endocytosis (28), regulation of actin cytoskeleton (28), MAPK signalling pathway (27), 
TGF-beta signalling pathway (27), phagosome (25), Wnt signalling pathway (25), purine 
metabolism (23), Alzheimer's disease (22), pathogenic Escherichia coli infection (22), 
calcium signalling pathway (21), ubiquitin mediated proteolysis (21), axon guidance (21), 
neurotrophin signalling pathway (21), small cell lung cancer (21) and oocyte meiosis (20). 
The predominant down-regulated pathways include metabolic pathways (106), pathways in 
cancer (44), MAPK signalling pathway (35), protein processing in endoplasmic reticulum 
(35), cytokine-cytokine receptor interaction (30), endocytosis (27), chemokine signalling 
pathway (24), spliceosome (23), purine metabolism (22), Cell cycle (21), Huntington's 
disease (20), Jak-STAT signalling pathway (19), Chagas disease (19), neurotrophin signalling 
pathway (18), lysosome (17), pyrimidine metabolism (16), phagosome (16), axon guidance 
(16), RIG-I-like receptor signalling pathway (16) and natural killer cell mediated cytotoxicity 
(16).  
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In terms of observed fold change (independent of statistical threshold), 179 features 
exhibited >2-fold up-regulation, while 152 features exhibited >2-fold down-regulation. Fold 
changes ranged from 6.8-fold up to 16.6-fold down. Within the biggest change loci, COL1A1, 
ID1, THBS1, HEG1, F3, MAT2A, CYR61, CTGF, CDH11 and COL1A2 were up-regulated. Within 
the biggest change loci, HSPA1A, RN5S9, MIR1974, HSPA6, CSF2, HSPA1B, RNU1-9, RN18S1, 
IL8 and RNU1-5 were down-regulated.  
 
59 KEGG pathways were statistically enriched. Members of pathogenic Escherichia coli 
infection, TGF-beta signalling pathway and valine, leucine and isoleucine degradation 
pathways were amongst those enriched in up-regulated loci. Members of protein processing 
in endoplasmic reticulum, Amino sugar and nucleotide sugar metabolism and bladder 
cancer pathways were amongst those enriched in down-regulated loci.  
 
353 GO terms were statistically enriched. Members annotated with intracellular pathway 
and intracellular organelle GO terms were amongst those enriched in up-regulated loci. 
Members annotated with intracellular pathway and membrane-bounded organelle GO 
terms were amongst those enriched in down-regulated loci.  
 
PRAVASTATIN RELATIVE TO PROADIFEN 
6172 array features were statistically significant (3166 up-regulated, 3006 down-regulated). 
Within the significant features, NCEH1, AAK1, AARS2, AASDH, AASDHPPT, ABCA1, ABCA2, 
ABCB10, ABCB6 and ABCC4 were up-regulated. Within the significant features, A4GALT, 
AAGAB, AARS, AARSD1, AATF, AATK, ABCB9, ABCF1, ABCF3 and ABHD12 were down-
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regulated. The predominant up-regulated pathways include metabolic pathways (207), 
pathways in cancer (62), focal adhesion (55), cell cycle (39), regulation of actin cytoskeleton 
(38), MAPK signalling pathway (37), insulin signalling pathway (37), ubiquitin mediated 
proteolysis (36), Wnt signalling pathway (34), purine metabolism (31), endocytosis (31), 
axon guidance (31), oocyte meiosis (29), TGF-beta signalling pathway (29), Alzheimer's 
disease (29), Huntington's disease (29), calcium signalling pathway (28), phagosome (28), 
bacterial invasion of epithelial cells (25) and spliceosome (24). The predominant down-
regulated pathways include metabolic pathways (118), pathways in cancer (46), protein 
processing in endoplasmic reticulum (44), MAPK signalling pathway (41), endocytosis (35), 
cytokine-cytokine receptor interaction (32), chemokine signalling pathway (28), spliceosome 
(27), purine metabolism (25), lysosome (24), Huntington's disease (23), phagosome (22), 
neurotrophin signalling pathway (21), Jak-STAT signalling pathway (20), cell cycle (19), axon 
guidance (19), pyrimidine metabolism (18), natural killer cell mediated cytotoxicity (18), 
ubiquitin mediated proteolysis (17) and Alzheimer's disease (17).  
 
In terms of observed fold change (independent of statistical threshold), 334 features 
exhibited >2-fold up-regulation, while 263 features exhibited >2-fold down-regulation. Fold 
changes ranged from 10.7-fold up to 20.7-fold down. Within the biggest change loci, 
COL1A1, ID1, THBS1, CTGF, HEG1, F3, CYR61, MAT2A, CDH11 and RGS4 were up-regulated. 
Within the biggest change loci, RNU1-9, RN5S9, HSPA1A, RNU1-5, RNU1-3, MIR1974, HSPA6, 
RNU1-1, RNU1-8 and CSF2 were down-regulated. 69 KEGG pathways were statistically 
enriched. Members of valine, leucine and isoleucine degradation, focal adhesion and cell 
cycle pathways were amongst those enriched in up-regulated loci. Members of protein 
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processing in endoplasmic reticulum, protein export and Vibrio cholerae infection pathways 
were amongst those enriched in down-regulated loci.  
 
384 GO terms were statistically enriched. Members annotated with intracellular pathway 
and organelle pathway GO terms were amongst those enriched in up-regulated loci. 
Members annotated with intracellular pathway and membrane-bounded organelle GO 
terms were amongst those enriched in down-regulated loci. 
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APPENDIX 4 
Heatmaps 
 
 
Heatmaps were used in this study as a quick way of checking the quality of the data. In the gene 
expression experiments the treatments and controls were either in triplicate or quadruplicate. For 
this reason the data appears in bands that have clusters of significance. These indicate that the 
replicates are all similar. No technical replicates were used in this study.  
 
Significant genes (adjusted p<0.01) from each contrast were analysed for enrichment of KEGG 
pathway membership using a hypergeometric test. Enrichment (p < 0.05) was assessed for up-
regulated and down-regulated genes separately. In the figures below, the enrichment analyses are 
shown graphically, with comparisons along the X axis, and KEGG pathways along the Y axis. Note 
that only comparisons with enriched pathways are shown; up- and down- regulated enrichments are 
shown separately, as different components of a given pathway could be up- and down- regulated 
within a single comparison. Colour (red for up-regulated pathways, blue for down-regulated 
pathways) is assigned on a 20 point scale based on the -log10(enrichment p value), with white being 
least statistically robust. 
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HEATMAP OF DOWN REGULATED KEGG PATHWAYS (MDA-MB-231) 
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HEATMAP OF UPREGULATED KEGG PATHWAYS (MDA-MB-231) 
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HEATMAP OF DOWN REGULATED GO TERMS (MDA-MB-231) 
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HEATMAP OF UP REGULATED GO TERMS (MDA-MB-231) 
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COMBINED HEATMAP DOWN REGULATED GO TERMS (CALU-1) 
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COMBINED HEATMAP UP REGULATED GO TERMS (CALU-1) 
 
In the figures below, the enrichment analyses are shown graphically, with comparisons along the X axis, and GO terms 
along the Y axis. Note that only comparisons with enriched GO terms are shown; up- and down- regulated enrichments 
are shown separately, as different markers with the same GO term could be up- and down- regulated within a single 
comparison. Colour (red for up-regulated pathways, blue for down-regulated pathways) is assigned on a 20 point scale 
based on the -log10(enrichment p value), with white being least statistically robust. 
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COMBINED HEATMAP DOWN REGULATED KEGG PATHWAYS (CALU-1) 
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 COMBINED HEATMAP UP REGULATED KEGG PATHWAYS (CALU-1) 
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APPENDIX 5 
 
Proton nuclear magnetic resonance spectra of the key analogues of Proadifen synthesized for the 
study. 
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